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Frequently used abbreviations 
 
AMR = antimicrobial resistance 
AMT =  antibiotic management team  
ASP =  antimicrobial stewardship program 
ATC = Anatomical Therapeutic Chemical classification   
BAPCOC = Belgian Antibiotic Policy Coordination Committee  
CDC = Centers for Disease Control and Prevention of the United States  
DDD = defined daily doses  
ECDC = European Centre for Disease Prevention and Control  
EARS = European Antimicrobial Resistance Surveillance Network 
ED = emergency department  
EPOC = Cochrane Effective Practice and Organisation of Care   
ESAC = European Surveillance of Antimicrobial Consumption 
MIT = multidisciplinary infectious diseases team  
PK/PD= pharmacokinetic/pharmacodynamic  
TATFAR = Transatlantic Task Force on Antimicrobial Resistance  
TFAD = time to first antibiotic dose  
WHO =  World Health Organization    
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CHAPTER 1: INTRODUCTION 
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1. General introduction  
The discovery of penicillin by Alexander Fleming in 1929 triggered the development of different 
antimicrobials during the following decennia (1). Antimicrobials have contributed to the control of 
infectious diseases that seven decades ago represented the leading cause of human morbidity and 
mortality. Effective antimicrobial therapy rendered many fields of modern medicine feasible, such as 
major surgery, the care of premature infants, cancer chemotherapy, care of the critically ill, and 
transplantation medicine (2).  
At present however health care is challenged by the emergence of antimicrobial resistance and the low 
number of truly new antimicrobials  against multi-resistant bacteria (3,4) (Figure 1). From the 1940s 
up to the 1970s the pharmaceutical industry developed several antimicrobials with new mechanisms to 
treat problems caused by bacterial resistance. Since then, only three systemically-administered 
antibiotics (quinupristindalfopristin, linezolid and daptomycin), including two from new classes 
(oxazolidinones and lipopeptides,) have been marketed in the EU to treat infections caused by 
multidrug-resistant Gram-positive bacteria. The other systemic antimicrobials that have reached the 
EU market during this period belong to existing classes of antimicrobials and had no superior activity 
against the majority of organisms already resistant to other agents in the same class (4). There may be 
some new treatments, such as ceftazidim/avibactam against a range of resistant Gram negatives. With 
this paucity of options, the field has been pushed into the reintroduction of old, often poorly 
documented antimicrobials, such as colistin.  
 
Figure 1. Discovery of new classes of antibiotics  
 
(Source: ECDC/EMEA joint technical report. The bacterial challenge: time to react. A call to narrow the gap between multidrug-resistant bacteria in the EU and 
the development of new antibacterial agents September 2009 ISBN 978-92-9193-193-4) 
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Recently a new cell wall inhibitor, teixobactin, was discovered in a screen of uncultured bacteria. 
Hopefully the methodology used can lead in the future to the discovery of other uncultured bacteria 
that are likely to harbour new antimicrobials (5).   
 
The World Health Organization (WHO) has recognized antimicrobial resistance (AMR) as a growing 
global health threat, and has called upon Member States and the international community to take 
measures to curtail the emergence and spread of antimicrobial resistance (6). The most important 
cause of AMR has been a massive overuse of antimicrobials worldwide across all ecosystems over the 
past decades, including humans, animals, aquaculture, and agriculture (7). 
  
The Centers for Disease Control and Prevention of the United States (CDC) prioritized bacteria into 
one of three categories: urgent, serious, and concerning (7) (Table 1). Bacteria within the category 
“urgent” are immediate public health threats that require urgent and aggressive action. Bacteria 
defined as “serious threat” require prompt and sustained action to ensure the problem does not grow. 
Careful monitoring and prevention action are needed for bacteria within the “concerning” category.  
 
Table 1. CDC’s prioritized list (categories: urgent, serious, and concerning) with bacteria regarding level 
of concern  
Urgent Threats 
Clostridium difficile 
Carbapenem-resistant Enterobacteriaceae 
(CRE) 
Drug-resistant Neisseria gonorrhoeae 
Serious Threats 
Multidrug-resistant Acinetobacter 
Drug-resistant Campylobacter 
Fluconazole-resistant Candida (a fungus) 
Extended spectrum β-lactamase producing 
Enterobacteriaceae (ESBLs) 
Vancomycin-resistant Enterococcus (VRE) 
Multidrug-resistant Pseudomonas 
aeruginosa 
Drug-resistant Non-typhoidal Salmonella 
Drug-resistant Salmonella Typhi 
Drug-resistant Shigella 
Methicillin-resistant Staphylococcus aureus 
(MRSA) 
Drug-resistant Streptococcus pneumoniae 
Drug-resistant tuberculosis 
Concerning Threats 
Vancomycin-resistant Staphylococcus 
aureus (VRSA) 
Erythromycin-resistant Group A 
Streptococcus 
Clindamycin-resistant Group B 
Streptococcus 
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CDC defines four core actions that will help fight deadly infections (7): 
• preventing infections and preventing the spread of resistance (immunization, safe 
food preparation, handwashing, and using antimicrobials according guidelines and only when 
necessary) 
• tracking resistant bacteria 
• improving the use of current antimicrobials 
• promoting the development of new antimicrobials and developing new diagnostic tests for 
resistant bacteria 
 
On a European level, the European Parliament adopted a non-legislative resolution on antimicrobial 
resistance in which it stresses that AMR has become a huge issue (8). EU surveillance systems have 
been developed to monitor AMR (European Antimicrobial Resistance Surveillance Network-EARS) 
and the consumption of antimicrobials (European Surveillance of Antimicrobial Consumption, 
ESAC). These systems provide key information and data in support of prevention and control of 
AMR. Although the levels of resistance in  Gram-positive pathogens (Streptococcus pneumoniae, 
Staphylococcus aureus, Enterococcus faecium and Enterococcus faecalis) tend to  stabilize, or even 
decrease -in some countries-, there is a general increase across Europe of antimicrobial resistance in 
the Gram-negative pathogens (Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa) 
(9).  
 
2. Resistance impacts on clinical outcome 
Antimicrobial resistance is associated with increased patient mortality, longer hospital stays, and 
increased healthcare costs (10). Increasing resistance compromises effective treatment. This may result 
in failure of initial therapy if an ineffective agent is chosen, and effective therapy may be delayed by 
several days until the culture and sensitivity results for a resistant organism are available (11). If the 
organism is resistant to multiple antimicrobial drugs, the cure may be severely limited and in a few 
cases there may be no effective therapy. Due to increased emergence of bacterial resistance and 
declining development of new antimicrobials, ‘older’ compounds, previously banned because of 
efficacy/toxicity considerations (colistin, fosfomycin, fusidic acid) are being reintroduced into the 
clinic for multidrug resistant bacteria (12). As these antimicrobials have never been subjected to the 
contemporary drug development process, their redevelopment using contemporary analytical and 
pharmacokinetic/pharmacodynamic methods are critical in order to optimize therapy. Colistin is an 
example of successful redevelopment in which the use of new state-of-the-art bioanalytical, 
microbiological and pharmacokinetic/pharmacodynamic approaches has generated an improved 
understanding of its clinical pharmacology, and has enabled rational optimization of patient therapy 
(12). 
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In a recent systematic review the health  impact of infections caused by third generation cephalosporin 
resistant (including ESBL) E. Coli, fluoroquinolone resistant E. Coli, third generation cephalosporine 
resistant K. pneumonia , carbapenem resistant K. pneumonia and MRSA was assessed . For all type of 
infections there was a significant increase of all cause mortality. Bacterium-attributable mortality was 
significant increased except for infections with fluoroquinolone resistant E. Coli and carbapenem 
resistant K. pneumonia. Hospital LOS was significant increased for MRSA infections. Admission to an 
ICU was significant increased for fluoroquinolone resistant E. Coli and third generation cephalosporin 
resistant K. pneumonia (13).  
 
Roberts et al. reported that twice as many patients with antimicrobial-resistant infections died than 
patients infected with nonresistant organisms. When multiresistant pathogens are prevalent, clinicians 
are forced to use broader spectrum and usually more expensive agents to treat seriously ill patients. All 
of these effects contribute to increasing healthcare and societal costs (14).  
 
An estimation of the yearly human burden of infections due to selected antimicrobial-resistant bacteria 
in EU Member States, Iceland and Norway in 2007 showed 386.100 cases of infection, 25.100 extra 
deaths and 2.536.000 extra hospital days (9). This resulted in an overall cost of 1.534.100.000 euro 
(927.800.00 EUR extra in hospital costs, 10.000.000 EUR extra outpatient costs, 150.400.000 EUR 
productivity losses due to absence from work and 445.900.000 EUR productivity losses due to patients 
who died from their infection. 
 
Smith et al published recently a report on the economic burden of antimicrobial resistance. They 
concluded that the current estimates of antimicrobial resistance show a low economic impact (15). 
They add that all of the published studies do not consider a world which there are no effective 
antimicrobial available and concluded that we may not ever be able to make an accurate forecast of 
costs. They suggest that rather than see expenditure on antimicrobial policies as costs, we should think 
of it as an insurance policy against a catastrophe (15). 
 
3. The Antimicrobial Stewardship balance 
The yearly report on “Surveillance of antimicrobial consumption in Europe 2012”of the European 
Centre for Disease Prevention and Control (ECDC) demonstrated that the consumption in the 
community varied by a factor of 2.8 between the highest consumption (31.9 defined daily doses 
(DDD) per 1 000 inhabitants and per day in Greece) and the lowest (11.3 DDD per 1 000 inhabitants 
and per day in the Netherlands) (16) (Figure 2). With a consumption of 29.8 DDD per 1 000 
inhabitants, Belgium has a high consumption of antibiotics in the community comparable with Greece, 
Romania, Cyprus and France. The ECDC report concludes that a significant increasing trend in the 
consumption during 2008–2012 was observed in Belgian community. However a recent study by 
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Coenen et al showed that the number of package is a more appropriate measure than the number of 
DDDs when assessing outpatient antibiotic use (17). Doing so consumption figures demonstrate no 
increase of antibiotic consumption expressed in number of packages during 2008–2012 in Belgium. 
Increasing numbers of DDDs per package (more items per package and higher doses per unit for 
amoxicillin and co-amoxiclav) explain these discrepancies. The authors observed less frequent 
treatments of fewer individuals with higher amounts of active substance (more DDDs) and higher 
proportions of recommended antibiotics (more amoxicillin) since the start of the national public 
antibiotic awareness campaigns in Belgium. 
 
Figure 2. Consumption of antibacterials for systemic use (ATC group J01) in the community 
sector in EU/EEA countries, 2012, expressed as DDD per 1 000 inhabitants and per day  
 
 
In 2012, the consumption of antibacterials for systemic use (Anatomical Therapeutic Chemical (ATC) 
classification system group J01) in the hospital sector varied from 1.00 (the Netherlands) to 2.8 DDD 
per 1 000 inhabitants and per day (Finland) with a median of 2.0 DDD per 1 000 inhabitants and per 
day (16) (Figure 3). With 1.71 DDD per 1000 inhabitants and per day, Belgian hospitals have a 
moderate consumption of antibacterials for systemic use (ATC group J01) compared with other 
European countries (16). In Belgium 10% of the total consumption (DDD) of antibacterials for 
systemic use is used in hospitals.  
  
14 
 
Figure 3. Consumption of antibacterials for systemic use (ATC group J01) in the hospital sector 
in EU/EEA countries, 2012, expressed as DDD per 1 000 inhabitants and per day  
 
For several antimicrobial–pathogen combinations, e.g. fluoroquinolone-resistance in E. coli, K. 
pneumoniae, P. aeruginosa and for MRSA, a north-to-south gradient is evident in Europe. In general, 
lower resistance percentages are reported in the north and higher percentages in the south of Europe. 
These geographical differences may reflect differences in infection control practices and antimicrobial 
use in the reporting countries (9). A recent systematic review of the effects of antibiotic consumption 
on antibiotic resistance in Europe confirmed that studies conducted in southern Europe were more 
likely to find a strong positive relationship between antibiotic consumption and resistance whereas 
studies that examined B-lactam consumption or MRSA tended to find a weaker relationship between 
consumption and resistance (18).  
 
Recent data from the Belgian Scientific Institute of Public Health show an antibiotic consumption of 
548.2 DDD (median) per 1000 beddays ( p25 = 541.6; p 75= 603.2) in 2013 (Table 2).     
 
Table 2. Evolution antibiotic use (J01) in Belgian hospitals for non-paediatric departments 
(DDD/1000 patient days). (Source:Anne INGENBLEEK. Scientific Institute of Public Health, Brussels,Belgium) 
Non- Paediatric Departements 
(including Intensive Care & Haemato-oncology) 
Antibiotics (J01) 2007 2008 2009 2010 2011 2012 2013* 
Frequency 54 95 98 96 96 92 70 
Mean 534.1 528.6 537.5 541.9 557.9 567.6 541.6 
P25 453.8 459.7 465.9 477.9 474.8 484.9 472.4 
Median 518.9 523.3 530.6 535.4 553.5 555.0 548.2 
P75 620.7 580.2 601.8 605.3 620.8 631.9 603.2 
2013*: Provisional (but representative) data 
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Antimicrobials account up for an important part of the hospital pharmacy budgets while literature 
shows that up to 50% of antimicrobial use is inappropriate, adding considerable cost to patient care 
(19). 
 
The European Surveillance of Antimicrobial Consumption (ESAC) has established a method for point 
prevalence of antimicrobial prescribing interventions to improve antimicrobial prescribing practices 
for hospital inpatients. Results of the “2009 survey” show that the indication for treatment was not 
compliant with local or national guidelines in 38% of patients (20). 
 
Appropriate use of antimicrobials is necessary to extend their useful lifetime. This means that a 
prospective, formalized, strategy is needed to ensure that antimicrobials are used appropriately. 
Programs developed from this strategy are called antimicrobial stewardship programs (ASPs) (21).  
The ultimate objective is to achieve a balance between an effective antimicrobial treatment and the 
risk for collateral damage through the selection of resistant pathogens (Figure 4). 
 
Figure 4. The Antimicrobial Stewardship balance 
 
 
 
 
In 2007, the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology 
of America (SHEA) jointly published guidelines for the development of programs to enhance 
antimicrobial stewardship in the institutional setting (19). The primary goal of antimicrobial 
stewardship is to optimize clinical outcomes while minimizing unintended consequences of 
antimicrobial use, including toxicity, the selection of pathogenic organisms, and the emergence of 
resistance. A secondary goal of antimicrobial stewardship is to reduce health care costs without 
adversely impacting quality of care (19,22,23,24). 
 
Unnecessary use of broad-spectrum 
antimicrobials resulting in the selection 
of resistant pathogens 
An effective antimicrobial treatment for 
patients 
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4. Belgian Antibiotic Policy Coordination Committee 
In 1999, the Belgian Ministry of Health established by Royal Decree the Belgian Antibiotic Policy 
Coordination Committee (BAPCOC) (25,26,27). The objectives of BAPCOC are to promote judicious 
use of antimicrobials in humans and animals and enhance infection control and hospital hygiene, with 
the overall aim of reducing antimicrobial resistance. To address these specific tasks BAPCOC founded 
five multidisciplinary working groups: ambulatory care, hospital care, awareness campaigns, infection 
control and veterinary medicine. The BAPCOC working Group Hospital Care  was able to secure 
federal funding, provide technical guidance and offer advanced specialist training for the formal 
establishment and follow-up of antibiotic management teams (AMTs) for all Belgian hospitals. The 
minimum composition, mandate and tasks of hospital AMTs have been consolidated in legislation 
through publication of the Royal Decree of 12 February 2008 on the norms for AMTs as dedicated 
subgroups of the hospital Drugs and Therapeutic Committee (25,26). AMTs are responsible for the 
development of an antibiotic formulary and clinical practice guidelines on antimicrobial therapy and 
prophylaxis, active initiatives to limit the inappropriate use of antimicrobials, education of healthcare 
workers, audit with feedback to prescribers and surveillance of local antibiotic consumption and 
microbial resistance. The AMTs must provide yearly activity reports and consumption figures 
(25,26,27). Each AMT receives a yearly compiled report from the BAPCOC working Group Hospital 
Care. The Belgian Scientific Institute of Public Health provides an online tool where each hospital can 
compare their own consumption figures with national figures.     
 
Antimicrobial stewardship by itself is not the only solution for the problem of antimicrobial resistance. 
It is a necessary part of a global approach including regulatory policies, interventions to control 
antibiotic use in livestock, educational measures and triggering incentives to the research and 
development of new classes of safe and effective antimicrobials (28).  
 
5. Complexity of anti-infective management 
An infectious disease is explored by determining the site of infection, defining the host 
(immunocompromised, diabetic, of advanced age), and establishing, when possible, the 
microbiological cause (29) (Figure 5). A successful anti-infective management depends on the 
immunity of the host, the management of the infection site and on the choice of an appropriate 
antimicrobial agent (30). The initiation of the therapy should be guided by the urgency of the situation. 
In critically ill patients, such as those in septic shock, and patients with bacterial meningitis, empiric 
therapy should be initiated immediately after or concurrently with collection of diagnostic specimens 
(31). The optimal dose of an antimicrobial agent depends on the pharmacokinetic/pharmacodynamic 
properties of the agent and the pathophysiology (distribution, clearance, ..) of the patient.      
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Figure 5. Complexity of anti-infective management (Blot S, 2008 - all rights reserved (with 
permission) 
 
 
6. A closer look at the antimicrobial stewardship program in current literature 
The Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America 
describe two proactive strategies as foundation of an antimicrobial stewardship program (19).  
An effective program should include a prospective audit with direct intervention and feedback to the 
provider and/or preauthorization requirements for antimicrobial use (19) (Figure 6). Other elements 
with  good evidence in literature are education, multidisciplinary development of evidence-based 
practice guidelines, streamlining or de-escalation of therapy, optimization of antimicrobial dosing 
(based on individual patient characteristics, causative organism and pharmacokinetic/ 
pharmacodynamic characteristics of the drug) and a systematic plan for parenteral to oral conversion 
of antimicrobials with excellent bioavailability. Moderate evidence exists for antimicrobial order 
forms and poor evidence for antimicrobial cycling and combination therapy.  
Core members of an optimal multidisciplinary antimicrobial stewardship team include an infectious 
diseases physician, a clinical microbiologist, a clinical pharmacist with infectious diseases training, an 
information system specialist and infection control professional.  
Effective audit with intervention and feedback can be facilitated through computer assisted 
surveillance of antimicrobial use, allowing the screening of specific services or units where problems 
exist, as well as identification of patients receiving particular agents or combinations of agents that 
might benefit from intervention (19). 
 
18 
 
Figure 6. Type of antimicrobial stewardship interventions according to the Infectious Diseases 
Society of America and the Society for Healthcare Epidemiology of America 
 
 
 
Structure, process and outcome indicators can be used to evaluate the grade of implementation and the 
results of antimicrobial stewardship programs (32, 33, 34). 
 
The Cochrane Collaboration recently updated a systematic review “Interventions to improve antibiotic 
prescribing practices for hospital inpatients” (35). This review showed that of all literature published, 
only one fifth or 89 studies could be included. In other words, literature is still dominated by 
inadequate interrupted time series (ITS) or uncontrolled before-after (CBA) studies that do not provide 
interpretable or conclusive data.  
 
In the Cochrane Collaboration review outcome measures were antibiotic prescribing process measures 
(decision to treat, choice of drug, dose, route or duration of treatment), clinical outcome measures 
(mortality, length of hospital stay) and microbial outcome measure (colonization or infection with 
Clostridium difficile or antibiotic-resistant bacteria). Interventions were categorized based on the  
Cochrane Effective Practice and Organisation of Care (EPOC) criteria. We can distinguish restrictive, 
persuasive and structural interventions (figure 7).  
 
 
 
Antimicrobial order 
forms
Antimicrobial cycling
Combination therapy
Education
Guidelines and 
clinical pathways
Streamlining or 
de-escalation of 
therapy
Dose optimization
Parenteral to oral 
conversion
Prospective audit 
with intervention 
and feedback.
Formulary 
restriction and 
preauthorization
Degree of evidence 
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Figure 7 Interventions to improve antibiotic prescribing practices for hospital inpatients 
according The Cochrane Collaboration 
 
 
Restrictive interventions were implemented through restriction of the freedom of prescribers to select 
some antibiotics using compulsory order forms, preliminary expert approval, restriction by removal 
(for example by removing restricted antibiotics from wards) and review and make change (here the 
reviewer changes the prescription rather than giving health professionals either a verbal or written 
recommendation).  Persuasive interventions used one or more of the following methods for changing 
professional behavior: dissemination of educational resources, reminders, audit and feedback, or 
educational outreach.  Structural interventions described the rapid reporting of laboratory results and 
on the introduction of tests of inflammatory markers (35). 
 
In the Cochrane Collaboration review several clinical outcomes were analysed (35,36) (Table 3). 
Interventions intended to increase effective prescribing did not significantly affect mortality (RR=0.92 
[95% CI 0.69, 1.22]; n=3). Interventions intended to increase effective prescribing by increasing 
guideline compliance in patients with pneumonia reduced mortality (RR=0.89 [95% CI 0.82, 0.97]; 
n=4). Based on meta-analysis of 10 RCTs and 1 CCT, interventions intended to decrease excessive 
prescribing did not affect mortality (RR=0.92 [95% CI 0.81, 1.06]). Six of the studies reported length 
of stay and found no significant difference (mean difference -0.04 [95% CI -0.34, 0.25] days). Five 
studies reported readmission. The combined result was a significant increase in overall readmissions 
(RR=1.26 [95% CI 1.02, 1.57]). 
 
 
Restrictive 
interventions
•Compulsory order form
•Expert approval
•Restriction by removal
•Review and make 
change
Persuasive 
interventions
•Dissemination of 
educational materials 
•Reminders
•Audit and feedback
•Educational outreach 
Structural 
interventions
•New technology for 
laboratory testing
•Computerized decision 
support
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Table 3. Clinical outcome by Intervention Aim (from Davey et al 2013) 
Intervention aim Outcome 
Risk Ratio [95% 
Confidence 
Interval] 
I2 
Study designs, 
number of 
participants (n) 
Increase effective prescribing Mortality 0.92 [0.69, 1.22] 72% 
2 RCTs, 1 CCT, 
n=1,484 
Increase guideline compliance (CAP) Mortality 0.89 [0.82, 0.97] 0% 
1 RCT, 3 CBAs; 
n=22,526 
Decrease excessive prescribing Mortality 0.92 [0.81, 1.06] 0% 
7 RCTs, 3 cluster 
RCTs, 1 cluster 
CCT; n=9,817 
Decrease excessive prescribing Length of stay 
Mean difference 
(days) -0.04 [-
0.34, 0.25] 
63% 
4 RCTs, 2 cluster 
RCTs; n=8,071 
Decrease excessive prescribing 
Readmission (all 
cause or infection 
related) 
1.26 [1.02, 1.57] 9% 
4 RCTs, 1 cluster 
RCT; n=5,856 
I2 = test for heterogeneity; RCT = randomized controlled trial; CBA = controlled before and after trial; CCT = controlled 
clinical trial 
 
The impact on prescribing outcome for persuasive, restrictive and structural  interventions is 
mentioned in Table 4 (36). For the persuasive interventions, the median (interquartile range) change in 
antibiotic prescribing was 42.3% for the interrupted interrupted time series studies (ITSs), 31.6% for 
the controlled interrupted time series studies (CITSs), 17.7% for the controlled before-after studies 
(CBAs), 3.5% for the cluster-randomized controlled trials (CRCTs) and 24.7% for the randomized 
controlled trials (RCTs). The restrictive interventions had a median effect size of 34.7% for the 
interrupted time series designs, 17.1% for the controlled before-after designs and 40.5% for the 
randomized controlled trials. The structural interventions had a median effect of 13.3% for the RCTs 
and 23.6% for the cluster-RCTs.  
 
The Cochrane update provides evidence that increase in effective treatment can be associated with 
reduced mortality and that decrease in excessive antibiotic use can be associated with improvement in 
microbial outcome without compromising clinical outcomes. It provides also stronger evidence about 
clinical outcomes and lists 11 interventions that aimed to decrease exposure to antibiotics by reducing 
the percentage of patients that received treatment or by shortening duration of a treatment or 
prophylaxis.  
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Table 4 Median Change* in Antimicrobial Prescribing by Intervention Type and Study Design 
(from Davey et al., 2013) 
Intervention type RCT CRCT CBA ITS CITS 
Persuasive 24.7% 3.5% 17.7% 42.3% 31.6% 
Dissemination of educational materials  -3.1% 
(n=1) 
16.1% 
(n=2) 
10.6% 
(n=2) 
42.5% 
(n=1) 
Reminders 27.4% 
(n=3) 
  20.0% 
(n=5) 
 
Audit and feedback  3.5% 
(n=1) 
7.5% 
(n=2) 
32.7% 
(n=4) 
24.3% 
(n=2) 
Educational outreach 25.0% 
(n=10) 
 20% 
(n=1) 
46.3% 
(n=10) 
 
Restrictive 40.5%  17.1% 34.7%  
Compulsory order forms    7.3% 
(n=5) 
 
Expert approval   - 2.8% 
(n=1) 
24.1% 
(n=7) 
 
Removal by restriction   37.0% 
(n=1) 
60.7% 
(n=7) 
 
Review and make change 40.5% 
(n=2) 
  94.3% 
(n=2) 
 
Structural 13.3% 
(n=6) 
23.6% 
(n=2) 
   
RCT = randomized controlled trial; CRCT = cluster randomized controlled trial; CCT = controlled clinical trial; CBA = controlled before 
and after study; ITS = interrupted time series; CITS = controlled interrupted time series; n = number of studies  
*Positive change is a change in the direction of the intended change  
 
Interventions intended to decrease excessive prescribing were associated with reduction in Clostridium 
difficile infections and colonization or infection with aminoglycoside- or cephalosporin-resistant gram-
negative bacteria, methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus 
faecalis. Meta-analysis of clinical outcomes showed that four interventions intended to increase 
effective prescribing for pneumonia were associated with significant reduction in mortality (risk ratio 
0.89, 95% CI 0.82 to 0.97), whereas nine interventions intended to decrease excessive prescribing 
were not associated with significant increase in mortality (risk ratio 0.92, 95% CI 0.81 to 1.06). 
 
Interventions to reduce excessive antibiotic prescribing to hospital inpatients can reduce antimicrobial 
resistance or hospital-acquired infections, and interventions to increase effective prescribing can 
improve clinical outcome. The meta-analysis supports the use of restrictive interventions when the 
need is urgent (such as in an outbreak situation), but suggests that persuasive and restrictive 
interventions are equally effective after six months.   
 
The objective evaluation of outcomes poses a particularly difficult problem for studies of 
antimicrobial stewardship interventions. Multiple factors - not just appropriate antimicrobial 
prescription - determine antimicrobial resistance rates and clinical outcomes. Controlling of the 
confounding factors is difficult as the great majority of published antimicrobial stewardship studies 
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have been of quasi-experimental design, typically before- and after-implementation studies, where 
“treatment” allocation and other potential confounding factors are not controlled (28). 
 
The result of the Cochrane review demonstrates that changing hospital antibiotic use is a challenge of 
paramount complexity. Many determinants as cultural, contextual, and behavioral aspects, can affect 
antibiotic use in hospitals (33,34). To improve physicians' antimicrobial practice, it is important to 
identify barriers to and facilitators of guideline adherence (39). Cortoos et al demonstrated that staff 
members are influenced by previous routine and habits, while residents are guided by external 
influences such as how much control they experience. For both groups of physicians different 
approaches to improving antimicrobial use may be necessary.  
It seems obvious that education on antimicrobial stewardship is likely to be more successful when 
started at the time knowledge; attitude and behavior of professionals are being shaped (40). That is the 
reason why education on prudent antibiotic prescribing should also be an important part of 
undergraduate medical/professional curriculum (40). 
 
Successful antimicrobial stewardship programs include all the elements of successful quality 
improvement programs and measuring the effectiveness of program activities is a key component. In 
an ASP, this usually includes measuring antimicrobial use, auditing the quality of prescribing, and 
monitoring process and outcome indicators. This information can then be used to provide feedback to 
prescribers, and inform the AMT and drug and therapeutics committee of the effect of stewardship 
initiatives on antimicrobial use and resistance patterns (41). 
 
Controlling for confounding can be a special problem for studies of antimicrobial stewardship because 
while antimicrobial use is a major factor that determines antimicrobial resistance, it is not the only 
factor. Other factors can be changes in patient demographic profile, changes in patient case mix or 
changes in infection control measures or their intensity (33).  
 
In general, hospitals need to make choices and to focus on a limited bundle of measures that are 
feasible and likely to be implemented rather than to elaborate an expanded set of measures.  
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7. Research aims and overview of the different chapters 
The first aim of this research was to develop indicators for evaluating antimicrobial stewardship 
programs in a hospital setting (Chapter 2 and 3). The second aim was to evaluate components of an 
antimicrobial stewardship program in a hospital setting (Chapter 3,4,5,7). 
 
Indicators for evaluating antimicrobial stewardship programs in a hospital setting 
After a general introduction in Chapter 1, we describe the development of quality of care indicators 
towards antimicrobial stewardship programs (Chapter 2 and 3).  
 
In chapter 2, a prospective multicenter feasibility study of a quality of care indicator for intravenous to 
oral switch therapy with highly bioavailable antibiotics was performed in five university hospitals in 
Austria, Belgium and Germany.   
 Research  question: 
• Is it feasible to implement a quality of care indicator for intravenous to oral switch therapy with 
highly bioavailable antibiotics? 
• Is there heterogeneity of the performance gap considering intravenous to oral switch therapy in 
five European hospitals? 
 
Chapter 3 describes the development and validation of potential structure indicators for evaluating 
antimicrobial stewardship programmes in European hospitals.  
 Research question: 
• Which structure indicators for hospital antimicrobial stewardship programmes could be used 
according different professionals (infectious disease specialists, clinical microbiologists, hospital 
pharmacists, and quality and health care scientists) from four countries? 
• Is it feasible to implement the selected indicators in eleven European hospitals? 
• Is there a heterogeneity among participating centers with regard to their score for structural 
components?  
 
Components of an antimicrobial stewardship program in a hospital setting 
In chapter 4, the results of a survey of beta-lactam antibiotics and vancomycin dosing strategies on 
intensive care units and general wards in Belgian hospitals are described. Optimization of 
antimicrobial dosing based on pharmacokinetic and pharmacodynamic characteristics of the drug is a 
part of an antimicrobial stewardship program. This survey not only describes the implementation of 
prolonged and continuous infusions in Belgian hospitals but also reveals the pitfalls in implementing 
such dosing regimens. 
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Research question: 
• Which beta-lactam antibiotics and vancomycin dosing strategies are recommended in intensive 
care units and general wards in Belgian hospitals. 
• What are the pitfalls to consider by implementing extended or continuous antibiotic infusions? 
 
In chapter 5, the time to the first antibiotic administration for adult patients admitted to the emergency 
department was assessed before and after the implementation of corrective interventions. The time to 
first antibiotic dose was evaluated as it can be considered as a marker of optimal care in patients 
treated with antimicrobials for an infection. Factors predicting delays in time to first antibiotic dose 
were evaluated. 
Research question: 
• What is the time to first antibiotic dose (TFAD) for adult patients admitted to the emergency 
department in a tertiary hospital? 
• What is the impact of an intervention to optimize the TFAD?   
 
Chapter 6, presents the implementation of guidelines for sequential therapy with fluoroquinolones in a 
Belgian hospital. One can presume that one of the simplest cost-savings stewardship initiatives is the 
recommendation to switch select antimicrobials from intravenous-to-oral therapy. This study describes 
the results of three different interventions on patient outcome and on fluoroquinolone consumption.  
 Research question: 
• Which interventions can be used to promote intravenous-to-oral therapy switch with 
fluoroquinolones in a tertiary hospital? 
• What is the impact on the antibiotic treatment and consumption? 
 
Chapter 7, describes the type and acceptance rate of interventions provided by a multidisciplinary 
infectious diseases team (MIT) in a tertiary hospital. Prospective audit with persuasive intervention, 
i.e.  intervention and feedback, is considered as a core antimicrobial stewardship strategy.  
 Research question: 
• Which recommendations are made by a multidisciplinary infection team in a tertiary hospital? 
• What is the acceptance rate of the interventions? 
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Abstract 
 
Background 
Enhanced oral (po) bioavailability of antimicrobial drugs allows conversion to po therapy once 
a patient meets defined clinical criteria. This can reduce length of hospital stay, healthcare costs and 
risk of complications related to intravenous (iv) access. We developed a quality indicator for assessing 
the appropriate iv-to- po switch of bioavailable antibiotics and evaluated its feasibility and clinical 
relevance across acute healthcare systems. 
 
Methods 
The study was designed as a multicenter, multinational observational audit. The indicator was 
the proportion of inappropriate iv treatments at any point in time in adult patients treated with 
fluoroquinolones, clindamycin, linezolid or metronidazole. Treatments were prospectively evaluated 
by a trained physician or clinical pharmacist using predefined clinical criteria. The feasibility of the 
indicator was evaluated by measuring data availability, data collection workload and sensitivity to 
improvement 
 
Results 
Data were collected over a 3 month period in five university hospitals in Austria, Belgium and 
Germany and iv treatment was assessed in 211 patients. The indicator was measurable in 99.1% of 
cases. By intention to- treat analysis, 37.0% (95% CI 30.5–43.9) of treatments were inappropriate, 
ranging from 17.5% to 53.8% across hospitals. The median time needed for case assessment and 
documentation was 29 min. 
 
Conclusions 
This quality indicator was found to be generally feasible in hospitals across three European 
countries, and informative about the local need for clinical quality improvement. 
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Introduction 
The project ‘ABS International—Implementing antibiotic strategies for appropriate use of antibiotics 
in hospitals in member states of the European Union’ (co-financed by the European Commission) 
started in September 2006. The objectives were to develop and evaluate the feasibility of quality 
indicators for hospital antibiotic use. 
 
Quality indicators can be defined as ‘a measurable aspect of care provided for which there is evidence 
and/or consensus that it represents quality on the grounds of scientific research or consensus among 
experts’(1). As part of the ABS project, quality indicators of antimicrobial therapy were developed by 
expert consensus and evaluated in an international sample of acute care hospitals. 
 
Antimicrobial stewardship programmes promote the appropriate use of antimicrobials by selecting the 
appropriate drug, dose, duration and route of administration (2). High oral (po) bioavailability of 
antimicrobial drugs, like fluoroquinolones, linezolid, metronidazole, clindamycin, fluconazole and 
voriconazole, allows conversion to po therapy once a patient meets defined clinical criteria. This can 
result in reduced length of hospital stay, healthcare costs, potential complications due to 
intravenous (iv) access and a lower work burden for nursing staff. Many studies show a significant 
delay in switching from iv to po antibiotic therapy after criteria for the po route are met (3–9). 
 
By considering the evidence relating to iv-to-po switch, an indicator for measuring the performance of 
hospitals was tested. 
 
Methods 
The objective of this multicentre, multinational prospective observational audit was to evaluate the 
feasibility and clinical relevance of measuring an indicator of appropriate iv use of highly bioavailable 
antibiotics in acute care hospitals across European countries. The indicator rate (%) was calculated 
using the following formula: the number of patients with inappropriate fluoroquinolone, clindamycin, 
linezolid or metronidazole treatment by iv route divided by the number of patients treated with iv 
fluoroquinolones, clindamycin, linezolid or metronidazole multiplied by 100. 
 
Data were collected from 1 February 2008 to 30 April 2008 in five university hospitals: two in 
Austria, two in Belgium and one in Germany. Treatments in inpatients (>18 years) were identified 
based on daily review of prescriptions. The appropriateness of the iv administration route was 
evaluated by a physician or pharmacist trained in infectious diseases and antibiotic stewardship. The 
following criteria were used to define the inappropriate iv route: body temperature <38°C during 
the previous 24h, decreasing or normal blood leucocyte count, absence of unexplained tachycardia, 
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functional gastrointestinal tract (patient is able to eat or has a functional gastric feeding tube), no 
vomiting, no diarrhea and no severe sepsis. 
 
Consecutive cases were audited until 40 treatment courses were included or the study completion date 
was reached. Data collected were patient’s age and gender, infection type, antimicrobial 
treatment, indication and type of care (medical, surgical or intensive care) using a standardized case 
record paper form (CRF). The feasibility of the indicator was evaluated by measuring data availability 
(%), data collection workload (min/case) and baseline rate of the indicator (% inappropriate care). The 
minimum value of 80% cases with available data was predefined as the threshold of general 
feasibility. The average time spent by the data assessor per assessed case for collecting and reviewing 
the data, and filling the CRF was used as the workload parameter. The baseline indicator rate, 
expressed as the proportion of cases with nonadherence to recommended practice, reflects the 
‘performance gap’ or sensitivity to improvement in the process of care by antimicrobial 
stewardship interventions. No pre-set value was assigned to this endpoint as the performance level 
achieved was expected to vary by hospital according to previous or ongoing local quality intervention 
programmes. 
 
Case-mix stability of the indicator was explored by comparing indicator rates by type of care, 
infection, age group, antibiotic used, gender and availability of an iv-to-po switch improvement 
programme in the previous 2 years. 
 
The protocol was approved by the Ethics Committees of Ghent University Hospital and Erasme 
University Hospital. Ethics Committee approval in the participating German hospital was available for 
general hospital wide antibiotic prescription point prevalence surveys covering the present 
investigation. The Austrian Ethics Committee did not see the necessity for an ethics review as actual 
patient treatment was not part of the project and we only dealt with retrospective and anonymous 
data collection. 
 
Each investigator completed a questionnaire including the implementation of an improvement 
programme for iv-to-po switch in the previous 2 years. 
 
Data were analysed using the PASW.v18 software package (SPSS Inc., Chicago, IL, USA). The 2 test 
was used to assess differences in inappropriateness of prescribing and was performed with two-sided 
probability of type 1 error at a significance level of P=0.05. A logistic regression model was built to 
identify factors associated with the inappropriateness of prescribing. 
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Results 
The size of the five participating hospitals ranged from 835 to 1600 beds. Infectious disease specialists 
(n=4), microbiologists (n=3) and pharmacists (n=3) were involved in data collection. Two hundred 
and eleven patients with an iv treatment with fluoroquinolones, clindamycin, linezolid or 
metronidazole were included in the study (Table 1). Four hospitals collected data on 40 treatment 
courses and one on 51 courses. The mean age of the patients was 59 years and 56% were female. 
Respectively, 45.9%, 31.2% and 20.8% of the patients were admitted to a surgical, medical and 
intensive care ward. The most frequent site of infection was the respiratory tract (24.6%), followed by 
skin, soft tissue, bone or joint (22.7%), urinary or genital tract (18.0%) and intra-abdominal cavity 
(17.0%). Fluoroquinolones were the most frequently administered drug class. 
 
Table 1. Percentage inappropriate IV antibiotic treatments by indication, type of care,  
antibiotics used, participating center and the availability of an iv-po improvement program.  
 
 
 
a 4 not documented; b 3 not documented; c 1 not documented; d 1 not documented; e 2 not documented 
 
In two hospitals one treatment could not be evaluated because of missing data, resulting in availability 
for this indicator of 99.1%. The median time needed to assess the case and fill in the CRF was 29 min 
(range 20–37 min). 
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The intention-to-treat analysis showed that 37.0% (95% CI 30.5–43.9) of the patients were 
inappropriately treated with iv antibiotics. 
 
The reasons for inappropriate iv administration were the ability to eat (90%) and the availability of a 
functioning gastric feeding tube (10%). Among patients who were appropriately receiving iv therapy, 
a non-functioning gastrointestinal tract (24.6%), inability to swallow (23.7%), vomiting (17.5%), 
diarrhoea (13.2%) or severe sepsis (5.3%) rendered parenteral administration necessary. Appropriate 
iv therapy was given to 15.8% of the patients based on a written medical order to switch to po therapy 
the next day. 
 
Comparing inappropriateness by indication, the indicator rate ranged from 11.1% inappropriate 
treatments 1 day before a planned operation to 68.8% for skin, soft tissue, bone or joint infection (P< 
0.001). The highest proportion of inappropriate iv therapy was found in the medical wards (48.5%), 
followed by surgical (37.1%) and intensive care (18.2%) wards (P=0.007). 
 
The percentage of inappropriate iv treatments by centre ranged from 17.5% to 53.8% (P=0.001). The 
average proportion of inappropriate iv administration was 20.9% in the hospitals (C and D) with an 
improvement programme versus 50.0% in the other hospitals (P=0.001). 
 
After adjusting for type of care and type of infection, absence of an iv-to-po switch programme was 
associated with more inappropriate prescribing (OR 6.78; 95% CI 3.02–15.23; P<0.001). Age group 
(P=0.442) and gender (P=0.131) were not significantly related to inappropriateness of prescribing. 
 
Discussion 
This study evaluated the feasibility and clinical usefulness of an iv-to-po switch indicator in five acute 
care hospitals from three European countries. Importantly, two participants reported that, in the 2 years 
preceding the study, local quality improvement programmes were in place to improve the process 
of care under study. Therefore, the results observed do not reflect ‘baseline’ practice. 
 
More than 99% of the required data proved available, which is higher than the pre-set threshold value 
of 80%. On average, the workload required for collecting, reviewing the data and filling the CRF was 
29 min per assessed case. Significant inter-hospital variation suggests that the efficiency of data 
extraction depends on the quality and accessibility of clinical and pharmacy data sources. 
Opportunities for automated data extraction from computerized patient records should enhance the 
efficiency of monitoring such indicators (10). 
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The indicator revealed a substantial heterogeneity of the performance gap, with a range of 17.5%–
53.8% of antibiotic iv administrations considered avoidable. Hospitals with an iv-to-po switch 
improvement programme scored significantly better for this indicator, although this study did not aim 
to test this hypothesis. This indicator suggests substantial sensitivity to improvement in this sample of 
hospitals and may be selected as the target for local quality improvement efforts. The iv-to-po switch 
improvement programme in the two hospitals consisted of yearly educational letters, poster campaigns 
and support by clinical pharmacists and infectious disease physicians. 
 
For this indicator, results can preferably be reported by type of care and type of infection, as these 
characteristics were associated with significant differences in the rate of appropriate use. Medical 
patients were more often inappropriately treated iv compared with surgical patients. Skin, soft tissue, 
bone or joint infection had the highest proportion of inappropriate iv treatments, which could reflect 
physicians’ reluctance to treat this type of infection po. For bone and joint infection it is important to 
emphasize that in the acute phase of the illness iv therapy is the standard administration route. The 
high proportion of inappropriate iv treatments can be explained by the limited evidence that suggests 
that the route of administration does not affect the rate of disease remission in the treatment of 
acute osteomyelitis (11,12). Each center used a standardized CRF to collect the data. As skin, soft 
tissue, bone or joint infections were grouped as one type of infection it was not possible to specify 
retrospectively which patients were treated for a bone or joint infection, which is a limitation of this 
study. 
 
It is important to mention that fluoroquinolones and voriconazole administered by a gastric feeding 
tube should not be given simultaneously with enteral feeding. A common practice is to withhold 
enteral feeding for at least 1 h before and 2 h after fluoroquinolone and voriconazole dosing (13). 
 
In conclusion, the results of this study indicate that the ABS iv-to-po quality indicator is widely 
applicable to acute care hospitals. Hospital antibiotic management teams can consider adopting it as a 
tool to evaluate compliance with iv-to-po switch guidelines. 
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Abstract 
This study describes the development of structure indicators for hospital antimicrobial stewardship 
programmes and pilot validation across European hospitals. 
 
A multidisciplinary panel from four European countries developed structure indicators in three steps: 
identification and listing of indicators, remote ranking of indicators using multi-criteria scoring, 
selection of indicators in a face-to-face consensus meeting. Additionally, the top-ten indicators were 
identified as a minimal set of key indicators. A survey was sent to the directors of antimicrobial 
stewardship programmes in European hospitals. The yes/no answers for the indicators were 
transformed into numbers in order to calculate the total scores.  
 
A list of 58 indicators was selected and categorised into the following topics: antimicrobial 
stewardship services (12 items), tools (16 items), human resources and mandate (6 items), health care 
personnel development (4 items), basic diagnostic capabilities (6 items), microbiological rapid tests (2 
items), evaluation of microbiological drug resistance data (3 items), antibiotic consumption control (5 
items) and drug use monitoring (4 items). 
 
The indicator scores, reported by 11 pilot hospitals from five European countries, ranged from 32 to 
50 (maximum score=58) and from 5 to 10 points (maximum score= 10) for, respectively, the complete 
and the top-ten list. An international panel selected 58 potential structure indicators, among which was 
a minimal set of ten key structure indicators, that could be useful for assessment of the 
comprehensiveness and resource-intensity of antimicrobial stewardship programmes. 
 
There was significant heterogeneity among participating centres with regard to their score for 
structural components of effective antimicrobial stewardship. 
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Background 
The increasing incidence of antibiotic resistance represents a serious worldwide problem. In 
November 2001, the European Council adopted a recommendation on the prudent use of antimicrobial 
agents in human medicine (2002/77/EC), with a focus on the surveillance of antimicrobial 
resistance, surveillance of antimicrobial use, control and preventive measures, education and training, 
and research [1]. 
 
The project proposal “Implementing antibiotic strategies (ABS) for appropriate use of antibiotics in 
hospitals in member states of the European Union—ABS International” was presented to the EU 
Commission in 2005. The project started in September 2006 and was implemented in nine 
Member States of the EU: Austria, Germany, Belgium, Italy, Poland, Hungary, Czech Republic, 
Slovenia and Slovakia [2, 3]. 
 
As part of the project, structure and process indicators for evaluating activities of antimicrobial 
stewardship committees were developed in order to provide antimicrobial stewardship committees or 
antimicrobial management teams (AMTs) with quality assessment tools for evaluating their activities 
[4]. Structural indicators describe the organisation and resources as well as communication and 
evaluation tools available at the hospital level for implementing a multi-modal, multi-disciplinary 
antibiotic stewardship programme [5–7]. These indicators should focus on the appropriateness of 
antimicrobial drug prescribing and administration in hospital care, with reference to national standards 
and international, national or local practice guidelines. In addition to optimising individual patient care 
outcome, the quality objective for antibiotic use is also an important ecological dimension, namely, to 
minimise the risk of antibacterial resistance selection and spread associated with individual and 
population antibiotic exposure. 
 
Finally, in a general setting of budgetary limitations, the efficient use of financial and human resources 
should also be considered in recommending any interventions to modify or monitor antimicrobial drug 
use. Antibacterial drugs are among the most frequently administered drugs in hospital care and a 
significant driver of drug acquisition, administration and bio-monitoring costs. 
 
This study describes the development of structure indicators for antimicrobial stewardship and 
antibiotic use in a hospital setting by a multi-national expert panel. Furthermore, it reports on the 
results of a validation survey based on the selected indicators across a pilot sample of 
European hospitals. 
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Methodology 
 
Development of structure indicators 
A multi-disciplinary team composed of five infectious disease specialists, two clinical microbiologists, 
three hospital pharmacists and three quality of health care experts from four countries (Austria, 
Germany, Belgium, USA) developed and selected structure indicators on hospital organisation and 
resources, as well as drug use. This team was composed on an ad hoc basis with experts participating 
in the ABS International project. The development of structure indicators was achieved in three steps. 
In the first step, candidate quality indicators were identified based on the scientific literature and a 
structured list was compiled by all team members. The second step was to score and rank the listed 
quality indicators using multi-criteria scoring based on their perceived scientific value and 
applicability. Finally, quality indicators were selected by consensus during a general discussion in a 
face-to-face meeting. 
 
The identification of potential quality indicators was based on effective interventions and programme 
components identified in recent reviews of the literature, quality indicators as proposed in 
national/international guidelines and standards, as well as ABS/BAPCOC (The Belgian Antibiotic 
Policy Coordination Committee) questionnaires used in Austria and Belgium for auditing the quality 
of antibiotic stewardship programmes [8–16]. 
 
Multi-criteria decision analysis was used to score and rank the quality indicators based on scientific 
value and applicability. Multi-criteria decision analysis is a procedure aimed at supporting decision 
makers who need to assess a number of options against potentially conflicting criteria, combining 
those evaluations into an overall evaluation of relative value through a transparent and traceable 
process. It provides a clear audit trail for reporting the decision-making process. 
 
The methodology for scoring and ranking the potential quality indicators was adapted from the 
procedure described by Schouten et al. [17]. After discussion in the consensus group, two sets of 
criteria were agreed upon; a first set of four criteria was used for ranking the potential value of 
all proposed indicators and a second set of two criteria was scored to assess the assumed applicability 
across health care centres in Europe. 
 
For both sets of criteria, a scoring scale of 0 (lowest value) to 5 (maximum value) was used for scoring 
by each of the 13 team members to remotely and independently assess each proposed quality 
indicator; the sum of rates for each criterion provided the final mean score (maximum of 20 for value 
ranking) for each quality indicator. This ranking score was used to prioritise the options in descending 
order within the structure indicators. The applicability score was used during a group discussion to 
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decide upon suitability for inclusion in the field validation phase. Scoring criteria for ranking score 
was based on clinical relevance, ecological relevance, economic relevance and scientific 
validity (Table 1). 
Table 1.  Scoring criteria for ranking and applicability score 
Scoring criteria for ranking 
Clinical relevance: Is the quality indicator likely to predict a health benefit for the patient and if 
so, how big a benefit to expect? 
Ecological 
relevance:  
Is the quality indicator likely to predict an effect on reducing/minimising the 
development of antibiotic resistance, and if so how big a benefit to expect? 
Economic relevance:  Is the quality indicator likely to predict more efficient use of hospital care 
resources, including drug acquisition, delivery and monitoring costs? 
Scientific validity: What is the strength and volume of scientific evidence from published 
studies linking the quality indicator to either a health benefit or ecological 
benefit for reducing resistance or improved cost-effectiveness of care? 
Criteria for applicability score 
Generalisability: How widely applicable is the quality indicator across hospitals and 
healthcare systems? 
Assumed feasibility:
  
How easy will be the data collection for measuring the quality indicator 
from routinely available administrative and clinical records?  
 
Previous systematic reviews, evidence-based guidelines and meta-analyses were used as the main 
sources for ranking this dimension. Scoring criteria for calculating the applicability score were 
generalisability and assumed feasibility based on the expert experience (Table 1). Finally, a consensus 
meeting was organised to discuss the ranking results and select the quality indicators. Additionally, 
based on the highest score for ranking and applicability, the top ten indicators were identified as the 
minimal set of key structure indicators. 
 
Structured questionnaire survey 
To pilot the feasibility and validate the discriminatory power of the selected indicators, a structured 
questionnaire survey comprising hospital information [hospital affiliation, number of beds, number of 
intensive care unit (ICU) beds] and questions to score indicators was developed. The survey was 
administered by email (April 2008) to the director of the antimicrobial stewardship programme in 11 
volunteer acute care hospitals participating in the ABS project: five in Austria, two in Belgium, one in 
the Czech Republic, two in Germany and one in Slovenia. The respondents could send back the filled 
in questionnaire by email or post to a central data manager. For further analysis, the yes/no answers 
for the indicators were transformed into numbers in order to calculate the total scores for each 
dimension of structure. One point was given in the case of a “yes” answer and zero points in the case 
of a “no” answer. This calculation was made for both the extensive list of structure indicators and the 
top-ten key indicators 
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Results 
 
Development of indicators 
A list of 74 potential quality indicators was identified based on a literature review and national quality 
indicators implemented in the countries participating in the project. Each indicator was scored, 
resulting in a ranking and applicability score. The scores were used during the consensus meeting to 
select and clarify the final indicators. 
 
Based on the initial list of 74 structure indicators, and after screening for redundancy, a final list of 58 
indicators were selected and categorised in the following topics: antimicrobial stewardship services 
(n=12), tools (n=16), human resources and mandate (n=6), health care personnel development (n=4), 
basic diagnostic capabilities (n=6), microbiological rapid tests (n=2), evaluation of 
microbiological data on antibiotic resistance (n=3), antibiotic consumption control (n=5) and drug use 
monitoring (n=4) (Table 2). The top-ten structure indicators with the highest score for ranking and 
applicability are identified with an asterisk (*) and were considered to be key elements of an effective 
antibiotic stewardship programme. 
 
Validation survey 
Eleven hospitals, including seven university and four general hospitals, participated in the pilot study. 
The size of the hospitals ranged from 280 to 2,392 beds, with the number of ICU beds ranging from 9 
to 132. 
 
As shown in Table 3, the total score of individual hospitals ranged from 32 to 50 points. The 
maximum possible score of 58 was not reached by any hospital. When only the ten indicators of key 
elements of an effective antibiotic stewardship programme were listed for the hospitals, the score 
ranged from 5 to 10 points (maximum possible score=10). 
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Discussion 
An extensive list of 58 potential structure quality indicators was selected as being useful for the 
assessment of the comprehensiveness and resource-intensity of antibiotic stewardship programmes. 
The extensive list offers hospitals a tool to characterise and evaluate the activities and resources of 
the local programme. As we were aware that indicators ought to be few and simple to be used in 
practice, we have identified a set of ten key indicators as recommended for monitoring the effective 
deployment of antimicrobial stewardship programmes in acute care hospitals. The top-ten key 
structure indicators focus on the availability of an antibiotic formulary and guidelines for the provision 
of a formal mandate for a multi-disciplinary AMT which would be able to deliver bedside antibiotic 
advice, educate prescribers and audit compliance with local clinical guidelines. To strengthen 
the AMT decisions, one of the team members should also be present on the drugs and therapeutics 
committee. 
 
One can presume that the selected indicators seem to be already implemented in most hospitals, but 
the literature shows the opposite. A survey in 32 European hospitals showed that 52 % of the hospitals 
had no antibiotic committee and 23 % had no antibiotic formulary [18]. A survey of infectious 
diseases physician members of the Infectious Diseases Society of America Emerging Infections 
Network (IDSA EIN) revealed that 27 % of respondents reported that their institutions did not have or 
were not planning an antibiotic stewardship programme. Lack of funding and lack of personnel were 
reported as major barriers to implement a programme. A recent Policy Statement on 
Antimicrobial Stewardship by the Society for Healthcare Epidemiology of America (SHEA), the 
IDSA and the Pediatric Infectious Diseases Society (PIDS) outlines recommendations for 
the mandatory implementation of antimicrobial stewardship throughout health care, suggests process 
and outcome measures to monitor these interventions, and addresses deficiencies in education [19]. 
Another survey in Belgium demonstrated a well-developed structure of AMTs in hospitals and a broad 
range of services provided [16]. The Belgian experience showed that the mandatory implementation of 
antimicrobial stewardship programmes in hospitals and the yearly mandatory review of structure 
indicators was the key to the extensive implementation of antimicrobial stewardship programmes 
across the national hospital care system. Also, the Scottish Antimicrobial Prescribing Group (SAPG) 
has demonstrated that the implementation of regularly reviewed national prescribing indicators, 
acceptable to clinicians, implemented through regular systematic measurement, can drive 
improvement in the quality of antibiotic use in key clinical areas [20]. 
 
In this article, we describe the development of structure indicators for assessing antimicrobial 
stewardship programmes. The project “Implementing antibiotic strategies (ABS) for appropriate use of 
antibiotics in hospitals in member states of the European Union—ABS International” validated also 
process indicators for evaluating surgical antibiotic prophylaxis (indication, drug choice, timing 
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and duration of administration) and process indicators for antibiotic therapy: (1) management of 
community-acquired pneumonia (blood culture and Legionella antigen tests and drug choice for 
empirical treatment); (2) management of Staphylococcus aureus bacteraemia (echocardiography, 
IV catheter removal and duration of effective therapy) and (3) IV-PO switch for treatment with fully 
bio-available antibiotics [4, 21, 22]. 
 
Less focus was given on outcome indicators which were perceived to fall outside the scope of the 
validation in the ABS feasibility study. Nathwani et al. noted that “measurement for improvement is 
not focussed on judging whether data meet a compliance threshold or target but rather is a means of 
determining whether the changes we make to improve are effective and to what degree” 
[20]. Outcome indicators are, indeed, necessary to measure this. Recently, McGowan Jr et al. stated 
that antimicrobial stewardship programmes are associated with desirable outcomes for clinical care 
and cost reduction, but that less evidence exists for reduction in antibiotic resistance as a result 
of antimicrobial stewardship programmes and for their costeffectiveness [23]. They also focussed on 
the methodological problems in assessing outcomes, which are barriers in developing evidence-based 
outcome indicators. 
 
Since the performance of the ABS study, other studies on indicators for assessing antimicrobial 
stewardship programmes have been published. The SAPG has developed prescribing indicators for 
hospital and primary care [24]. Improvement in compliance with the indicators has been demonstrated 
with resultant reductions in Clostridium difficile infection rates. In 2007, New South Wales 
Therapeutic Advisory Group (NSWTAG) developed a set of process indicators to measure the quality 
use of medicines (QUM) in Australian hospitals in collaboration with the NSW Clinical 
Excellence Commission (CEC) [25]. As part of the European Commission concerted action Antibiotic 
Resistance Prevention and Control (ARPAC) Project, data on antibiotic stewardship were collected 
and relationships investigated by antibiotic consumption in European hospitals using antibiotic 
stewardship indicators with focus on the structure, design and content of written hospital antibiotic 
policies and formularies [18]. Policies and practices relating to antibiotic stewardship 
varied considerably across European hospitals. A ten-member expert panel from Canada and the 
United States defined five quality metrics for antimicrobial stewardship programmes with focus on 
process and outcome indicators from three domains including antimicrobial consumption, 
antimicrobial resistance and clinical effectiveness [26]. 
 
Participants of the pilot validation survey had developed a local antibiotic stewardship programme 
with dedicated resources and provided a wide range of education, evaluation and regulation tools for 
local prescribers. In particular, 10 out of the 11 centres had local multi-disciplinary practice guidelines 
for antibiotic prophylaxis and therapy, and seven centres had already performed clinical audit of these 
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guidelines. There was significant heterogeneity among participating centres with regard to their 
scoring for structural components of effective antibiotic stewardship, which ranged from 32 to 50 out 
of the maximum score of 58. Hospitals with a lower score for the complete set of indicators also 
performed poorly for the top-ten key indicators. These findings confirm the results of the 
previously mentioned surveys in Europe and United States revealing heterogeneity among 
participating hospitals when considering the implementation of antimicrobial stewardship programmes 
[18, 27]. 
 
Our study has several limitations. The selected indicators were developed by consensus of a multi-
disciplinary team of professionals (infectious disease specialists, clinical microbiologists, hospital 
pharmacists, and quality and health care scientists) from four countries. Although this 
composition reflects the range of expertise considered to be optimal for the composition of an 
antibiotic policy group for hospital care, no attempt was made to extend its composition beyond the 
ABS project group to represent all stakeholders (e.g. government authorities, policy makers, patient 
platforms) in the field due to the timelines of the project. Therefore, it only reflects the subjective 
opinion and knowledge of a selfselected group of experts. Here we can also mention that no indicator 
in the dimension of microbiological rapid test has achieved high ranking which could be explained by 
the low number of microbiologist participating to the study and the lack of evidence in literature.  A 
second limitation was the methodology used for scoring the scientific validity of quality indicators 
based on the secondary literature and personal knowledge of the primary literature of the ABS 
quality indicator team members. A third limitation could be the use of multi-criteria decision analysis 
to score and rank the quality indicators. Although this methodology was recently also used by Rello et 
al. for the development of a European care bundle for the prevention of ventilator-associated 
pneumonia, most studies developing indicators in human medicine used a modified Delphi method 
[26, 28]. Nevertheless, we can conclude that the different stages are more or less the same comparing 
the multi-criteria decision analysis and the modified Delphi method like for instance used by Morris et 
al . Each expert scored each indicator in regard to the chosen items (taken from the literature) and the 
next stage was to send the individual ranking scores to all experts. Everybody scored the indicators 
again and, afterwards, there was discussion in the experts’ consensus group. 
 
Benchmarking by comparisons between hospitals can be an important stimulus to quality 
improvement [18, 29]. Variations may reflect real and important variations in actual health care 
quality, e.g. inappropriate antibiotic use, that merit further investigation and action, but some 
apparent variation may also arise because of other misleading factors. such as the lack of adjustment 
for case-mix differences. 
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We suggest that a selection among the potential structure indicators examined in this study, with focus 
on the top-ten indicators proposed by the ABS International group, could be used for regular 
assessment of the extent and strength of hospital antimicrobial stewardship programmes. This can 
be done by administering questionnaire surveys on a national or international basis. These 
organisational elements should be seen as part of the hospital patient safety and quality of care system. 
In order to operate, they should be adequately supported and empowered and funded by health 
authorities and hospital management. Verification of the actual implementation of these structure 
indicators may be considered by national or regional health authorities responsible for 
hospital accreditation. 
 
Conclusion 
An international multi-disciplinary team developed and tested 58 potential structure indicators for 
feasibility across health care settings, of which a minimal set of ten key structure indicators were 
selected, that may be used for antibiotic stewardship programme monitoring and comparing efforts by 
health institutions to improve antimicrobial prescribing quality. In this pilot survey in five 
European countries, there was significant heterogeneity with both the extensive and key indicator 
results among participating centres. 
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Abstract  
 
Extended and continuous infusions with betalactam antibiotics have been suggested as a means of 
pharmacokinetic and pharmacodynamic optimisation of antimicrobial therapy. Vancomycin is also 
frequently administered in continuous infusion, although more for practical reasons.  
 
A survey was undertaken to investigate the recommendations by the local antibiotic management 
teams (AMTs) in Belgian acute hospitals concerning the administration (intermittent, extended or 
continuous infusion) and therapeutic drug monitoring of four beta-lactam antibiotics (ceftazidime, 
cefepime, piperacillin–tazobactam, meropenem) and vancomycin for adult patients with a normal 
kidney function.  
 
A structured questionnaire survey comprising three domains was developed and approved by the 
members of the Belgian Antibiotic Policy Coordination Committee (BAPCOC). The questionnaire 
was sent by e-mail to the official AMT correspondents of 105 Belgian hospitals, followed by two 
reminders.  
 
The response rate was 32 %, with 94 %, 59 %, 100 %, 100 % and 100 % of the participating Belgian 
hospitals using ceftazidime, cefepime, piperacillin tazobactam, meropenem and vancomycin, 
respectively. Comparing intensive care unit (ICU) with non-ICU wards showed a higher 
implementation of extended or continuous infusions for ceftazidime (81 % vs. 41 %), cefepime (35 % 
vs. 10 %), piperacillin–tazobactam (38 % vs. 12 %), meropenem (68 % vs. 35 %) and vancomycin (79 
% vs. 44 %) on the ICU wards. A majority of the hospitals recommended a loading dose prior to the 
first dose. For vancomycin, the loading dose and the trough target concentration were too low based 
on the current literature. 
 
This survey shows that extended and continuous infusions with beta-lactams and vancomycin are 
widely implemented in Belgian hospitals. 
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Introduction 
Beta-lactam antibiotics and vancomycin are commonly used to treat severe infections. Beta-lactams 
exhibit timedependent killing, with minimal or no persistent effects. The  time during which the free 
concentration remains above the minimum inhibitory concentration (MIC) (fT >MIC) is their main 
pharmacokinetic/pharmacodynamic (PK/PD) index of efficacy. Vancomycin also has timedependent 
killing, but shows moderate to prolonged persistent effects, which makes the area under the 
concentration– time curve (AUC)/MIC ratio its main PK/PD index for efficacy [1]. 
 
Time-dependent killing antibiotics would, theoretically, benefit from continuous administration, and 
animal as well as in vitro studies have shown improved efficacy when using extended or continuous 
infusions [1]. A systematic review concluded that the continuous administration of beta-lactam 
antibiotics is not  associated with an improvement in clinical cure or in decreased mortality, but the 
authors pointed out that the wide confidence intervals observed in this analysis did not allow 
excluding true differences between both forms of administration [2]. A systematic review focusing on 
continuous versus intermittent infusion of vancomycin showed that continuous infusion is not 
associated with differences in mortality but with a significantly lesser risk of nephrotoxicity [3]. 
Wysocki et al. also found that target concentrations were reached faster with continuous infusion and 
that there was lesser variability in the AUC24h values [4]. 
 
In this context, a survey was undertaken in Belgium to gain knowledge about which recommendations 
were made by the local Antibiotic Management Teams (AMTs) regarding dosing strategy 
(intermittent, extended or continuous infusion) and therapeutic drug monitoring of four betalactam 
antibiotics (ceftazidime, cefepime, piperacillin–tazobactam, meropenem) and vancomycin in adult 
patients with a normal kidney function. 
 
Methods 
A structured questionnaire survey covering three domains was developed: (1) hospital and contact 
information; (2) a form for each antibiotic about the dosing regimen, indications, use of therapeutic 
drug monitoring (TDM), type of administration (roller clamp, volumetric pump, syringe pump) and 
volume of infusion; (3) literature references or other information on which these regimens were based. 
The respondents could enter the AMT’s recommendations for each antibiotic’s (intermittent, extended 
or continuous infusion) unit doses (for intermittent administration) and loading (if applicable) and 
maintenance doses (for extended and continuous infusion); type of patients involved (all patients, 
intensive care patients, patients with a specific pathogen); therapeutic drug monitoring and the 
corresponding target concentration(s). 
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The study questionnaire was revised through pilot testing and was approved by the Belgian Antibiotic 
Policy Coordination Committee (BAPCOC) [5]. The questionnaire was sent by email to the official 
AMT correspondent of each involved Belgian hospital (n=105) on March 25th 2011, with reminders 
on April 21st and May 9th 2011. The respondents could send back the questionnaire by e-mail or post.  
 
Results 
Thirty-four (32 %) responses were received, of which 27 (79 %) were from general and 7 (21 %) were 
from university hospitals. Ten (29 %) hospitals indicated to have less than 300 beds, 13 (38 %) had 
between 300 and 600, and 11 (32 %) had more than 600. The numbers of intensive care unit (ICU) 
beds ranged from 6 to 96. The questionnaires were completed by medical specialists in infectiology, 
pneumology or intensive care medicine (n=16), in clinical microbiology (n=10) or by clinical 
pharmacists (n=11) on behalf of the AMT. 
 
The recommendations for the administration of betalactams and vancomycin are shown in Table 1. 
Ceftazidime, piperacillin–tazobactam, meropenem and vancomycin were used in almost all hospitals.  
 
Table 1.  Recommendations for administration of four betalactam antibiotics and vancomycin: 
ICU versus non-ICU 
   Non  ICU ICU 
  Intermittent 
infusions 
Prolonged infusions Combination Intermittent 
infusions 
Prolonged 
infusions 
Combination 
  N II (%) EC (%) CI (%) II/CI (%) II (%) EC (%) CI (%) II/CI (%) 
ceftazidime 32 19 (59) 0 (0) 13 (41) 0 (0) 6 (19) 0 (0) 26 (81) 0 (0) 
cefepime 20 18 (90) 1 (5) 1 (5) 0 (0) 13 (65) 5 (25) 2 (10) 0 (0) 
piperacillin-
tazobactam  
34 30 (88) 4 (12) 0 (0) 0 (0) 21 (62) 12 (35) 1 (3) 0 (0) 
meropenem 34 22 (65) 11 (32) 1 (3) 0 (0) 11 (32) 22 (65) 1 (3) 0 (0) 
vancomycin 34 19 (56) 0 (0) 12 (35) 3 (9) 7 (20) 0 (0) 24 (71) 3 (9) 
II: intermittent infusion; EC: extended infusion; CI: continuous infusion 
 
Considering the non-ICU wards, the main recommendations were: (i) for ceftazidime: almost equal 
distribution between intermittent administration or continuous infusion (no hospital used extended 
infusion); (ii) for piperacillin–tazobactam and meropenem: mainly by intermittent infusion and, if not, 
by extended infusion only (meropenem was used by continuous infusion in one hospital only); (iii) for 
cefepime: mainly by intermittent infusion and, if not, by continuous infusion only; (iv) for 
vancomycin: about two-thirds by intermittent infusion and one-third by continuous infusion. Moving 
now to ICU wards, we see that: (i) continuous infusion was the predominant mode of administration 
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for ceftazidime and vancomycin; (ii) extended infusion was most often recommended for meropenem 
(four hospitals mentioning that it was for infections with multidrug-resistant pathogens; one hospital 
recommended continuous infusion); (iii) intermittent administration remained predominant for 
cefepime and piperacillin–tazobactam, with extended infusion being the next most popular 
recommendation (continuous infusion was also recommended by several hospitals for cefepime, but 
by only one hospital for piperacillin–tazobactam). 
 
The recommended dosing regimens for each mode of administration of each antibiotic are shown in 
Table 2.  
 
Table 2. Recommended dosing regimens for intermittent, prolonged and continuous infusions.  
 Intermittent Prolonged Continuous 
ceftazidime 2 g q8h/30 min 
 
 2 g/30min loading dose + 6 g q24h/24h 
cefepime 1 g q8h/30 min 
2 g q8h/30 min 
 
2 g q8h/3h 
 
2 g/30min loading dose + 2 g q8/8h 
2 g/30min loading dose + 6 g q24/24h 
piperacilline 
tazobactam 
4/0.5 g q8h/30 min 
4/0.5 g q6h/30 min 
 
4/0.5 g q6h/3h 
4 g/0.5g /30min loading dose 
+ 4/0.5 g q6h/3h 
16g/2g q24h/24h 
meropenem 0.5 q6h/30min 
1 g q8h/30 min 
1 g/30 min loading dose + 0.5 
g q4h/30 min 
2 g q8h/30 min 
1 g q8h/3h 
1 g/30 min loading dose + 1 g 
q8h/3h 
2 g/30 min loading dose + 1 g 
q8h/3h 
2 g q8h/3h 
2 g/30 min loading dose  + 2 g 
q8h/3h 
1 g/30 min loading dose + 1 g q6h/6h 
vancomycin 15 mg/kg q12h/1h 
20 mg/kg q12h/1h 
 15 mg/kg /2h loading dose + 30 mg/kg 
q24h/24h  
20 mg/kg /2h loading dose + 30 mg/kg 
q24h/24h  
 
For the intermittent administration of beta-lactams, the most recommended daily doses were rather 
fixed for ceftazidime (6 g) and piperacillin–tazobactam (12–16 g), but variable for cefepime (3 to 6 g) 
and meropenem (2 to 6 g). For prolonged infusion (always limited to 3 h), similar daily doses as in the 
intermittent mode of administration were recommended for cefepime, piperacillin–tazobactam and 
meropenem, with a loading dose recommended only for the latter two antibiotics. For continuous 
infusion, a loading dose (usually corresponding to the normal unit dose of an intermittent 
administration) was recommended for ceftazidime, cefepime and meropenem, but not for piperacillin–
tazobactam, while the maintenance dose corresponded, essentially, to the total daily dose of the 
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intermittent administration mode. For vancomycin, the dose recommended was 15 to 20 mg/kg for its 
intermittent mode of administration and 30 mg/kg over 24 h preceded by a loading dose corresponding 
to what was recommended for intermittent administration for its continuous administration. 
 
With respect to practical aspects of continuous infusion administration of cefepime and meropenem, 
one hospital prepared syringes with 2 g of cefepime to be administered over an 8-h period, but another 
hospital prepared syringes with 6 g cefepime for use over 24 h, whereas meropenem was usually 
prepared in a syringe containing 1 g of antibiotic to be administered over 6 h. 
 
Concerning monitoring, all hospitals assayed vancomycin, recommending trough serum levels 
between 5 and 20 mg/L for intermittent administration and stable serum levels between 15 and 25 
mg/L (two hospitals) and 20–30 mg/L (19 hospitals) for continuous infusion. One hospital was 
measuring the serum concentrations of meropenem. 
Most of the participants did not provide data concerning the devices used for administration or 
infusion volumes. One hospital, however, mentioned a switch from an extended to an intermittent 
(loading dose of 1 g followed by 500 mg q6h) meropenem infusion after the observation of 40 % loss 
of the antibiotic dose due to line dead space [6, 7]. 
 
The hospitals based their recommendations on the scientific literature (65%), an opinion leader        
(59%), information from a university hospital (53%), the “Sanford guide to antimicrobial therapy”  
(35%) or summaries of product characteristics (SmPCs) (4%) [8–10].  
 
Discussion 
To our knowledge, this survey represents the first attempt to describe the implementation of extended 
and continuous infusions in hospitals at a national level in Europe. The adoption of continuous and 
extended infusion regimens for beta-lactams was variable and largely depended on the antibiotic, but it 
is remarkable that the implementation of these modes of administration was between 10 % and 44 % 
for the non-ICU wards and between 35 % and 81 % for the ICU wards. These modes of administration 
can, therefore, no longer be ignored. Actually, continuous infusion is included as an accepted mode of 
administration for both ceftazidime and vancomycin in the SmPCs of the corresponding branded 
products in Belgium (Glazidim® and Vancocin®), as well as in the Belgian edition of the “Sanford 
guide to antimicrobial therapy” [8–10]. The higher level of adoption in ICUs is consistent with the 
literature, suggesting that prolonged beta-lactam infusions are advantageous for infections with more 
resistant pathogens, in critically ill and immunocompromised patients, and in patients with unreliable 
pharmacokinetics [11]. 
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A loading dose prior to the initiation of the extended or continuous infusion is essential to shorten the 
time needed for obtaining a steady-state concentration at the targeted level [12, 13]. This was not 
always recommended for betalactams, which is most unfortunate, because a simple but effective 
approach is simply to use the normal initial dose recommended for intermittent dosing. Studies have 
stressed the importance of using a sufficiently large loading dose of vancomycin when using 
continuous infusion to avoid insufficiënt drug concentrations in the early phase of therapy [14–16]. 
Even for the intermittent mode of administration, the Infectious Diseases Society of America (IDSA) 
consensus recommendations suggest a loading dose of 25–30 mg/ kg in order to rapidly reach the 
desired target serum concentration [17]. Of note, this loading dose should be administered over at least 
1 h (or even 2 h if the dose is 2 g) to avoid a “red man” syndrome. This was taken into account by all 
hospitals recommending continuous infusion, but not by those recommending intermittent 
administration. 
 
Serum concentrations for beta-lactam antibiotics were not measured (except in one hospital). A recent 
study shows that standard dosing regimens for piperacillin–tazobactam, ceftazidime and cefepime may 
lead to serum concentrations insufficient to cover less susceptible pathogens in the early phase of 
severe sepsis and septic shock [18]. But optimal targets for beta-lactam therapy remain controversial 
[19]. Low trough drug concentrations in critically ill patients seem to be associated with increased 
renal clearance, suggesting that TDM could be useful for this type of patient [20]. For vancomycin, the 
trough serum levels (5–20 mg/L) recommended by the participating hospitals are too low to achieve 
an AUC/MIC ratio of ≥400 in most patients if the MIC of vancomycin for the target organism is ≥1 
mg/L [17]. For continuous infusion, optimal serum levels are less clearly defined, with targets of 15–
20, 20–25 and 25–30 mg/L mentioned in the literature [4, 17, 21, 22]. These should cover organisms 
with a vancomycin MIC up to 1 and 2 mg/ L for the lowest and largest targets, respectively. Should 
organisms with a vancomycin MIC > 2 mg/L become frequent [these organisms should be reported as 
resistant according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
interpretative criteria], we may face a severe limitation in our therapeutic approach with this antibiotic, 
because stable concentrations > 28 mg/L (needed to obtain a satisfactory AUC/MIC ratio) have been 
associated with a significant increase in renal toxicity [23]. Nevertheless, a meta-analysis shows that 
continuous vancomycin infusion is associated with a significantly lower risk of drug-related 
nephrotoxicity compared with intermittent infusions with the same daily dose [3]. As there is a 
tendency to use higher vancomycin dosages, it is important to determine their impact on drug-related 
toxicity [24, 25]. 
 
Antibiotic stability and incompatibility with other drugs are important considerations in the 
implementation of prolonged infusions. Piperacillin–tazobactam, ceftazidime and vancomycin are 
stable for at least 24 h at 25 °C, but  concentrated solutions of cefepime quickly change in colour [26] 
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and meropenem is unstable [27, 28]. Several drugs incompatibilities have been described [9]. 
Vancomycin is incompatible with all beta-lactams, and both beta-lactams and vancomycin are 
incompatible with propofol [9]. In ICU wards, the problem can  easily be avoided, as most patients 
have multiple-lumen catheters, but this may not be the case in non-ICU wards, where most patients 
have single-lumen catheters. 
 
A first limitation of the study is the low response rate (32 %), which questions the generalisability of 
our conclusions. However, all hospital types, based on the number of beds and academic profile, were 
represented. A second limitation is that no valid information was obtained on the mode of 
administration or infusion volume. Implementing prolonged infusions can have important practical 
implications, such as the availability of syringe pumps, multi-lumen catheters (to avoid direct drug 
interferences) and appropriate control of the amount of antibiotic effectively delivered.   
 
It is clear that the Belgian AMTs are in favour of prolonged infusions. However, there is much 
variation in the recommended dosing regimens, especially for meropenem, which reflects the 
variability in the literature data (Table 2). It is important to emphasise that AMTs have the 
responsibilities to support their recommendations for continuous and/or extended infusions of 
antibiotics with  clear guidelines for appropriate administration (doses, schedules, stability, 
incompatibility) to allow their safe and easy implementation by physicians, nurses and clinical 
pharmacists. 
 
Conclusion 
This survey showed that extended and continuous infusion of ceftazidime, cefepime,  piperacillin–
tazobactam, meropenem and vancomycin are widely implemented in Belgian hospitals. For intensive 
care unit (ICU) wards, a majority of the hospitals recommended ceftazidime and vancomycin in 
continuous and meropenem in prolonged infusions. For non-ICU wards, ceftazidime, meropenem and 
vancomycin were frequently used in continuous and/or prolonged infusions, despite the lack of 
evidence of clinical advantage for non-critical patients. Conversely, cefepime and piperacillin–
tazobactam are mostly used as intermittent administration. A majority of the hospitals recommended a 
loading dose prior to the first dose. For vancomycin, the recommended loading dose and trough target 
serum concentrations were too low if considering the current literature data.  
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Abstract 
 
Background 
The time to first antibiotic dose (TFAD) defined as the time in hours from arrival of the patient at the 
emergency department (ED) to the administration of the first antibiotic dose is described in the 
literature as a quality indicator for the treatment of infections. This indicator was evaluated in our 
institution followed by educational interventions in order to optimize TFAD. 
 
Methods 
In this retrospective observational single hospital study, the TFAD for adult patients with a diagnosis 
of an infection in the ED for which an antibiotic treatment was prescribed and who stayed for at least 2 
days in hospital were compared before and after the implementation of corrective interventions (period 
A versus B) .  
A multivariate model was set up to detect key factors associated with TFAD. The following factors 
were entered in the model: age, gender, LOS, CRP, APACHE II score, place of first administration, 
type of infection. 
 
Results 
Sixty-five patients were included in period A and 114 patients in period B. In period A, 46 (71%) 
patients received the first dose in the ED, versus 91 (80%) patients in group B (p=0.200). The other 
patients received the first dose after transfer to the ward.  
The univariate analysis showed that the median TFAD in period A was 2.44 hours ( IQR 1.78-4.19) 
versus 3.30 hours (IQR 2.40-4.50) in period B (p=0.034). The median TFAD when the first dose was 
administered in the ED was 2.14 hours in period A versus 3.2 hours in period B (p<0.001). When the 
first dose was administered on the ward the TFAD was 4.56 hours in period A and 4.26 hours in 
period B (p=0.535) 
The multivariate analysis showed no difference for TFAD between period A and B but showed that 
the place of the first antibiotic dose and type of infection were significantly associated with TFAD.  
  
Conclusion  
In conclusion we demonstrated significant persistent room for improvement for TFAD in infections in 
patients admitted to the ED, in spite of a targeted intervention.    
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Introduction 
For critically ill patients with septic shock and meningitis data suggest that early administration of 
antibiotics is associated with higher survival rates (1, 2, 3). Community acquired pneumonia (CAP), 
usually is less rapidly progressive compared to  septic shock and meningitis. There has been a debate 
over the use of the time to first antibiotic dose (TFAD) as a performance measure.  
 
For severe sepsis (acute organ dysfunction secondary to documented or suspected infection) and septic 
shock (severe sepsis plus hypotension not reversed with fluid resuscitation) administration of broad-
spectrum antimicrobials therapy within 1 hour of recognition is recommended (4). For bacterial 
meningitis, administration of antimicrobial therapy should be initiated as soon as possible after the 
diagnosis of bacterial meningitis is suspected or proven. This may include administration prior to 
hospital admission if the patient initially presents outside the hospital (5).  
For pneumonia data are not so straightforwarded. Recently a cross-sectional analysis of 95,704 adult 
ED admissions with a diagnosis of pneumonia in 530 hospitals in the USA showed no association 
between the publicly reported TFAD quality measure performance and pneumonia inpatient mortality 
(6). However in a study of 529 patients with community-acquired pneumonia admitted to the intensive 
care unit in 33 hospitals, early oxygenation assessment was associated with more rapid antibiotic 
delivery and better intensive care unit survival reflecting the importance of prompt management, 
including antibiotic delivery (7).  
 
For CAP the Joint Commission on Accreditation of Healthcare Organizations (Joint Commission or 
JC) has instituted in 2002, a quality of care standard that evaluates whether pneumonia patients receive 
their first dose of antibiotics within four hours of hospital arrival (8). In 2006, it became part of a 
measure set linked to additional payments under several pilot pay-for performance programs in USA 
hospitals. This standard has been criticized as a quality standard because it put pressure on clinicians 
to rapidly administer antibiotics despite diagnostic uncertainty at the time of patients’ initial 
presentation. In 2007, the allowed time window was extended to 6 hours in response to this criticism 
(8). 
 
In 2005 the local Antibiotic Management Group of the Ghent University Hospital evaluated in 
cooperation with the emergency department (ED) theTFAD for patients with suspected or proven 
infections admitted to the ED and transferred to a ward for further treatment. Following this 
evaluation, organizational interventions were implemented to improve timely drug administration. A 
didactic presentation was once provided in 2006 by an ED physician towards ED physicians and ED 
nurses, during a regular staff meeting, to emphasize the importance of timely antibiotic administration. 
Pharmacy collaborators were also educated (once in 2006, 2008 and 2010) by a pharmacist with focus 
on the clinical impact of delays in pharmacy logistics. This topic is part of a hospital wide training 
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program on antibiotic skills towards nurses which is provided twice a year by an infectious disease 
physician and a clinical pharmacist. Another measure consisted of the extension of the ED stock of 
some frequently prescribed antibiotics as lack of immediate availability of these antibiotics could 
result in a delayed administration. In 2008-2009 a second study was performed to re-evaluate the 
TFAD and to analyse the factors that could explain variation in TFAD. In this study we report the 
retrospective evaluation of this process. 
 
Methods 
In this retrospective observational single hospital study, all medical records of patients admitted to the 
ED between February 28, 2005 and March 22, 2005 (period A) and between December 1, 2008 and 
January 31, 2009 (period B) were screened. Adult patients (>18 years old) with a diagnosis of an 
infection on the ED for which an antibiotic treatment was prescribed and who stayed for at least 2 days 
in hospital were included. Patients who had received antibiotics within 24h before ED arrival were 
excluded.  
 
TFAD was defined as the time  from arrival of the patient at the ED to the administration of the first 
antibiotic dose. Medical and pharmaceutical charts were reviewed and the data were extracted using a 
standardized case record paper form (CRF). The following data were collected: gender, type of 
infection, type of antibiotic, length of stay (LOS), age, APACHE II score, C-reactive protein, place of 
first antibiotic dose (ED versus ward) and hour of admission on ED.  
The APACHE (Acute Physiology And Chronic Health Evaluation) II score or modified APACHE II 
score (in those patients were not all data were available) were calculated based on clinical parameters.  
For period B also the availability of the prescribed antibiotic on ED and the workload on ED was 
collected. The workload was defined as the number of patients on ED, 4 hours before each admission. 
 
On the ED, antibiotics are stocked in an electronic automated dispensing system (Pyxis Medsystem® 
station) which allows to register the exact time when the nurse or physician takes out the medication.  
The time of taking out the antibiotic was used as time point of administration, as the nurse normally 
administers immediately the antibiotic after removal from  the electronic automated dispensing 
system.  
An emergency physician reviewed all medical charts of patients in period B with a TFAD of 6 hours 
or more in order to assess the reason for the delay.      
Data analysis was performed using the Statistical Package for Social Science (SPSS version 20.0 Inc., 
Chicago, IL, USA). Variables were compared between period A and period B. The categorical 
variables were compared using the Chi-square test, continuous variables with the Mann–Whitney U-
test. The significance level was set at p < 0.05.  
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A multivariate model was set up to detect key factors associated with TFAD. The following factors 
were entered in the model: age, gender, LOS, CRP, APACHE II score, place of first administration, 
and type of infection. 
 
The protocol was approved (approval number: B67020095783) by the Ethical Committee of Ghent 
University Hospital.  
 
Results 
Sixty-five patients were included in period A and 114 patients in period B. The patient characteristics 
for the two study periods were similar except for the APACHE II score (Table 1). 
In period A, 46 (71%) patients received the first dose in the ED, versus 91 (80%) patients in group B 
(p=0.20).  
 
Table 1. Patients characteristics 
 
Period  A 
(n=65) 
Period B 
(n=114) 
P-value 
Age, years (median, IQR) 66 (54-74) 66 (52-76) .842 
Sex (male), N (%) 32 (49%) 61 (54%) .642 
Type of infection    
Pulmonary infection, N (%) 45 (69%) 71 (62%) 
.069 
Skin infection and others, N (%) 7 (11%) 9 (8%) 
Intra-abdominal infections, N (%) 10 (15%) 13 (12%) 
Urinary tract infections, N (%) 3 (5%) 21 (18%) 
LOS 8 (5-13) 8 (6-12) .269 
First antibiotic administration on the ER, N (%) 46 (71%) 91 (80%) ,200 
CRP mg/dL on admission (median, IQR)  11 (4-23) 9 (3-17) .435 
APACHE II score (median, IQR) 12 (8-17) 11 (7-13)a .038 
a: 19 missing data 
The univariate analysis showed that the median TFAD in period A was 2.44 hours (IQR 1.78-4.19) 
versus 3.30 hours (IQR 2.40-4.50) in period B (p=0.034) (Table 2). The TFAD 95-percentile was in 
period A respectively 12.76 hours versus 8.25 hours in period B. 
The median TFAD when the first dose was administered in the ED was 2.14 hours (IQR 1.41-2.56)  in 
period A versus 3.20 hours (IQR 2.36-4.33) in period B (p<0.001). When the first dose was 
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administered on the ward the TFAD was 4.56 hours (IQR 4.18-9.39) in period A and 4.26 (IQR 2.60-
7.35) hours in period B (p=0.535) 
 
Table 2. Time to first antibiotic dose comparing period A en period B (univariate analysis) 
Median TFAD (in hours) Period A Period B p value 
Overall  
(median, IQR) 
n=65 
2.44 (1.78-4.19)  
n=114 
3.30 (2.40-4.50) 
0.034 
first dose in the ED 
(median, IQR)  
n=46 
2.14 (1.41-2.56) 
n=91 
3.20 (2.36-4.33) 
<0.001 
first dose on the  ward  
(median, IQR)  
n=19 
4.56 (4.18-9.39) 
n=23 
4.26 (2.60-7.35) 
0.535 
 
After adjustment for age, gender, LOS, CRP, APACHE II score, type of infection and place of first 
antibiotic administration and period of evaluation, two factors were identified as being associated with 
TFAD (Table 3). Patients receiving the first antibiotic dose on the ED had a lower TFAD compared 
with those who received the first dose on a ward. Patients with a pulmonary infection had a lower 
TFAD compared with patients with an abdominal infection. TFAD was not  associated with the period 
of registration (A and B) and with parameters reflecting the severity of illness (APACHE II score, 
CRP and LOS). R squared of this multivariable model was 0.276. 
 
In period B, the median workload, expressed as the number of patients on ED 4 hours before each 
admission, was 6.0 patients (range 0 - 15) which was not statistically correlated with TFAD in an 
univariate analysis. This variable was not assessed in period A.  
 
For patients receiving the first dose in the ED in period B (n=91), median TFAD was 3.5 hours (range 
0.41-7.6 hours ) when the antibiotic was available in the ED (n=82) compared to 3.0 hours (range 1.6-
5.4 hours) when the antibiotic was not available in the ED (n=9). There was no statistical difference 
between these two subgroups (p=0.386). 
 
For the patients receiving the first dose on the ward in period B, in 11 (47.8%) patients the antibiotic 
was available in the ward stock with 4.9 hours as median TFAD (range 2.08-10.9 hours). For 12 
(53.3%) patients the antibiotic was not available on the ward with 8.12 hours as median TFAD (range 
0.26- 16.75 hours). There was no statistically significant difference between these two subgroups 
(p=0.193). 
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For the majority (85%) of the patients in period B the first antibiotic dose was prescribed to be 
administered intravenously. Amoxicillin/clavulanic acid IV (53.2%), piperacillin/tazobactam IV 
(10.3%), moxifloxacin PO (8.7%), levofloxacin IV (7.9%), ciprofloxacin PO (6.3%) and moxifloxacin 
IV (5.5%) were the most frequently prescribed antibiotics.    
 
Thirteen medical charts of patients in period B with a TFAD exceeding 6 hours were reviewed by an 
emergency physician. In two patients the higher TFAD was linked to diagnostic complexity. In 
another two patients the initial diagnosis was not clear and antibiotics were only administered after a 
final diagnosis on the ward. In one patient a referring physician did not order antibiotics in the ED 
although the patient had a urinary tract infection with a history of sepsis . For 2 patients a written order 
was found to give the first dose on the ward. For 6 patients, it was not possible to evaluate 
retrospectively the reason for a higher TFAD.            
 
Table 3. Linear regression modela for TFAD 
  Estimate 95% CI lower bound 95% CI upper bound P 
Intercept 7.958 5.895 10.002 .000 
Period A -.309 -1.260 .642 .521 
Period B 0 b . . . 
First dose on ER -3.252 -4.267 -2.236 .000 
First dose on ward 0 b    
Sex, male -.219 -1.115 .677 .630 
Sex, female 0 b . . . 
Infection type 
    
Pulmonary infection -1.401 -2.798 -.005 .049 
Skin infection and 
others 
-.976 -3.147 1.194 .375 
Intra-abdominal 0 b . . . 
Urinary tract -1.607 -3.359 .145 .072 
Age .005 -.021 .032 .699 
LOS .020 -.046 .086 .559 
CRP .016 -.023 .055 .413 
APACHE II score -.087 -.184 .011 .080 
a
 R squared = .276 
b
 this parameter is set to zero because it is redundant 
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Discussion 
 
In this retrospective observational study, the TFAD for adult patients with a diagnosis of an infection 
in the ED for which an antibiotic treatment was prescribed and who stayed for at least 2 days in 
hospital were compared before and after the implementation of  interventions (period A versus B) . 
 
The study showed that 75% of the patients received their first antibiotic dose within 4.19 hours in 
period A and within 4.50 hours in period B after admission on the ED. In  5 % of the patients TFAD 
exceeded 12.7 hours in period A and 8.25 hours in period B which is unacceptable.  
 
Although the univariate analysis suggested that the TFAD was higher in period B versus period A for 
patients receiving this first dose on the ED, the multivariate analysis showed no difference between the 
two periods. We can conclude that the interventions in our study did not result in any long term  
improvement.   
 
In a similar study performed in a Dutch hospital the TFAD was 5.0 h before and 3.2 h after an 
intervention including the development of guidelines, educational programs (lectures to the medical 
and nursing staff)  and improvement of the availability of antibiotics in the ED in a readily accessible 
place (9). In another study in the USA, evaluating the TFAD for 2.076 patients with pneumonia 
admitted in the ED, 78.6% of the patients received antibiotic therapy within 4 hours which is 
comparable with our results (10). 
 
Even after a teaching intervention, which resulted in a modest increase of antibiotics being delivered 
in the ED, still one fifth of the patients received the first antibiotic dose only after transfer to a ward in 
period B. This was not related to the workload in the ED. This is in contradiction with two 
retrospective studies performed in the USA. In one study including 334 patients, the emergency 
department occupancy rate was associated with increased time to antibiotic treatment for patients 
admitted with pneumonia (11).  In another retrospective study of 694 patients with pneumonia treated 
in an ED crowding on ED resulted in more frequent and longer delays in delivering antibiotics (12). 
The lack of association between workload and TFAD in our study could be the result of the limited 
number of patients. Unfortunately the workload on the ED was not measured in period A.  
 
The longer TFAD for patients receiving the first dose on the ward can be the result of a combination 
of factors. One of the reasons for this delay could be the time needed to transfer the patient from the 
ED to the ward, but this was not measured in this study. In general  nurses administer medication  at 
scheduled times. When the physician not emphasized to administer the first antibiotic dose sooner, 
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then this could lead to a higher TFAD. A Dutch study showed that more than half of the patients 
received indeed their first dose at scheduled times (13). 
 
Although there was no significant correlation between TFAD and availability of the prescribed 
antibiotic on the ward, the TFAD is considerably longer for those patients for whom the antibiotic was 
not in stock on the ward. One of the reasons for this delay could be the delivery time from the 
pharmacy to the ward. To limit this delay physicians and nurses were asked to mention the targeted 
time of administration on the prescription form which allows the pharmacy to give priority to these 
shipments. Dee et al showed indeed that the main reason for delay in antibiotic administration was 
failure to label antibiotic orders as first dose (14). 
 
For the patients receiving the first dose in the ED, the availability of the antibiotic in the ED was not 
linked to a lower TFAD. We can presume that in those cases where the antibiotic was not available in 
the ED there was a good communication between ED and pharmacy about the emergency for delivery.  
 
The multivariate analysis showed that TFAD was considerably longer for intra-abdominal compared 
to pulmonary infections. This could be explained by more complex and time consuming diagnostic 
procedures (i.e. CT scan). The same multivariate analysis did not demonstrate shorter TFAD with 
higher severity of illness, although this may have been due to the limited sample size. 
 
All frequently prescribed antibiotics, except for piperacillin/tazobactam IV and ciprofloxacin PO, were 
available in the electronic automated dispensing system  on the ED. After the discussion of the results 
of period B piperacillin/tazobactam IV was also stocked on the ED. Ciprofloxacin PO was not added 
because levofloxacin PO, being a valid alternative, was already available.  
 
The experience in the USA with a public quality indicator for TFAD of 4 hours in CAP resulted in too 
rapid administration of antibiotics despite diagnostic uncertainty which illustrates the unintended 
consequences of the introduction of an indicator linked to accreditation programs. Although the link 
between early TFAD and clinical outcome is not clear for all type of infections, we agree with Bordon 
et al that early TFAD should be considered as an important marker of optimal care of patients rather 
than as a factor predicting outcomes for patients (15). 
 
The results of this study show that further corrective actions are necessary to optimise the number of 
patients that receive the first antibiotic dose on the ED. This is also recommended in the Infectious 
Diseases Society of America/American Thoracic Society consensus CAP guideline (16). This was also 
supported by a Dutch study where the administration of antibiotics in the ED was strongly associated 
with antibiotic administration within 4 h (17). We emphasize here that the first antibiotic should be 
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given in the ED as several properties of the ED environment like manpower, the presence of 
physicians and the availability of antibiotics ensure timely administration. 
    
In order to enhance the number of patients that receive the first antibiotic dose on the ED, we will 
continue to provide education to nurses, physicians and pharmacy collaborators. For physicians it is 
important to communicate clearly the time frame of administration of antimicrobials towards (with) 
the nurses. Performing a structured interview with the key players on the ED could provide 
information on the barriers to administer timely the first antibiotic dose. 
The most frequently used antimicrobial agents on ED are available in the electronic automated 
dispensing system on the ED. In case other antimicrobial agents are necessary outside the opening 
hours of the pharmacy (10 pm – 8 am), all antimicrobial agents are available in an emergency cabinet 
which is 24h/24h accessible for all nurses and physicians. Furthermore the implementation of the 
computerized physician order entry (CPOE) system will probably optimise the TFAD as there will be 
no delay in forwarding the antibiotic prescription to the pharmacy. The effect of this intervention 
could not be assessed in our study due to the limited number of wards that were already using the 
CPOE system during the study period in our hospital.  Actually CPOE is implemented for 90% of the 
wards which allows the pharmacist to check the hour of administration of each antimicrobial agent 
prescribed and to give priority for shipment to the ward.  
 
The first limitation of this study is the retrospective design. The hours of administering the antibiotics 
are based on the time the nurse took the antibiotic out of the Pyxis Medstation which allows us to 
register the time at the level of minutes. We presume here that this time correlates with the 
administration of the antibiotic. On the wards we used the nursing file where a cross is placed in an 
hour time table which is likely to result in a margin error.  In this study the delays in diagnostic testing 
and in consultant advice were not evaluated which is a second limitation for this study. Thirdly it was 
not possible to evaluate the time between the arrival of the prescription in the pharmacy and the 
delivery of the antibiotic on the ward which could be one of the reasons for a high TFAD on the 
wards. The review of the patient files by the emergency physician showed that for 50 % of the patients 
it was not possible to detect retrospectively reasons for a long TFAD which suggest to perform such 
evaluations in the future prospectively in order to identify causes for delays. Fourthly most  
confounders used in the multivariate analysis were linked to the outcome of the patient (age, LOS, 
CRP, APACHE II score, place of first administration, and type of infection). Ideally also the factor 
working hours/night was included as Natsch et al showed that the TFAD was significantly shorter in 
patients admitted at night than in patients admitted during office hours (3.7 vs. 6.0 h) (13). 
Fifthly the evaluation of the appropriateness of the antibiotic administration according the guidelines 
should have been helpful to interpret the relevance of a shorter TFAD. Sixthly in this study we only 
evaluated the long term improvement. Ideally we performed also a short term evaluation. 
81 
 
 
 
In the future we should asses TFAD in a bundle approach including other process indicators like 
timely oxygenation, obtaining of blood and sputum samples and choice of empiric systemic 
antimicrobial therapy according local guidelines (17,18). 
 
Conclusion 
Seventy five percent of the patients received their first antibiotic dose within 4.19 hours in period A 
and within 4.50 hours in period B after admission on the ED. Even after a teaching intervention, still 
20% of the patients received the first dose only after transfer to a ward. This underscores the need for 
further interventions aiming at long term improvement. 
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Abstract 
 
Objective 
This study measured the impact of three interventions for physicians, in order to implement guidelines 
for sequential therapy (intravenous to oral conversion) with fluoroquinolones. 
 
Setting 
A Belgian university hospital with 1.065 beds. 
 
Method 
The first intervention consisted of the hospital-wide publication of guidelines in the local drug letter 
towards all prescribers. The consumption of fluoroquinolones was measured by means of an 
interrupted time-series (ITS) analysis 21 months before (period A) and 24 months after publication 
(period B). The second intervention was an educational interactive session, by infectious disease 
specialists, to the medical staff of orthopaedics and endocrinology. The third intervention comprised a 
proactive conversion programme on the abdominal surgery, gastro-enterology and plastic surgery 
wards, where pharmacists attached a pre-printed note with a suggestion to switch to an oral treatment 
every time a patient met the criteria for switching. The second and third intervention took place 6 
months after the first intervention. Fluoroquinolone treatments were evaluated during a 2 month period 
before (group 1) and after the introduction of the second (group 2) and third (group 3) intervention. 
 
Main outcome measure  
The monthly ratio of intravenous versus total fluoroquinolone consumption (daily defined doses per 
1,000 bed days) was measured to assess the impact of the first intervention. The impact of the second 
and third intervention was measured in relation to the number of days that intravenous therapy 
continued beyond the day that the patient fulfilled the criteria for sequential therapy and the antibiotic 
cost. 
 
Results 
The ITS demonstrated a reduction of 3.3% in the ratio of intravenous versus total consumption after 
the publication of the guidelines (P = 0.011). In group 1, patients were treated intravenously for 4.1 
days longer than necessary. This parameter decreased in group 2 to 3.5 days and in group 3 to 1.0 day 
(P = 0.006). The mean additional cost for longer intravenous treatment decreased from 188.0€ in 
group 1, to 103.0€ in group 2 and 44.0€ in group 3 (P = 0.037) 
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Conclusion 
This study demonstrated that active implementation of guidelines is necessary. A proactive conversion 
programme by a pharmacist resulted in a reduction in the duration of the intravenous treatment, and 
the treatment cost. 
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Introduction 
Efficient treatment of infection involves selecting the most appropriate drug at its optimal dosage and 
duration in order to eradicate the infection while minimizing side effects and selection of resistant 
strains [1]. In addition, the route of administration of the drug is an important factor. ‘‘Intravenous 
(IV) to oral’’ switch or sequential therapy is considered as a method to achieve a more efficient 
utilisation of antibiotics. Sequential therapy is defined as conversion from intravenous to oral 
formulation of the same medication while maintaining equivalent potency [2]. Several advantages 
have been associated with this strategy: less preparation time, easier drug administration, patient 
comfort, lower risk of bacteraemia and thrombophlebitis, savings in antibiotic costs and potential 
shortening of the length of hospital stay [2–14]. Several clinical trials have demonstrated the efficacy 
of sequential therapy [11–14]. 
 
The main obstacle to sequential therapy is the perception by physicians that IV antibiotics are better 
than oral. One erroneous concept is that all patients with an infectious disease need IV treatment. Anti-
infective treatment should be evaluated regardless of route of administration. If orally administered 
medications are well absorbed and provide blood and tissue levels that are the same as those attained 
by IV administration, then the therapeutic outcome is comparable [15]. 
 
Antibiotic costs represent a significant proportion of a hospital’s budget. In the Ghent University 
Hospital, a Belgian tertiary hospital with 1065 beds, the antibiotics for systemic use represent 12% of 
yearly drug budget for hospitalised patients, and fluoroquinolones (FQ) are responsible for 16% of this 
total. 
 
Most FQ show excellent bioavailability, which makes them ideal for intravenous-to-oral antibiotic 
switches in hospitalised patients. They are also characterised by excellent penetration into most tissues 
and body fluids. Studies showed that FQ, like aminoglycosides but in contrast to b-lactams, work 
mainly in a concentration-dependent manner and exert a marked post-antibiotic effect [16]. 
 
Considering the impact on the drug budget and the excellent bioavailability of FQ and the evidence for 
sequential therapy for this antibiotic group found in the literature, a programme to implement 
sequential therapy was started. 
 
Considering these figures and the excellent bioavailability of FQ and the evidence for sequential 
therapy for this antibiotic group found in the literature, a programme to implement sequential therapy 
was started. 
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Aim of the study 
 
The objective of this study was to assess the impact of three  professional interventions for physicians, 
in order to implement sequential therapy for FQ; namely: publication and dissemination of guidelines 
in the local drug letter, educational interactive sessions by an infectious disease specialist to the 
medical staff of orthopaedics and endocrinology and a proactive conversion programme by 
a pharmacist on the abdominal surgery, gastro-enterology, and plastic surgery ward. 
 
The monthly ratio of intravenous versus total fluoroquinolone consumption, in daily defined doses per 
1,000 bed days, was measured to assess the impact of the first intervention. The impact of the second 
and third intervention was measured in relation to the number of days that intravenous therapy 
continued beyond the day that the patient fulfilled the criteria for sequential therapy and the antibiotic 
cost. 
 
Method 
 
Interventions 
The local Antibiotic Work Group, composed of infectious disease specialists, microbiologists, 
intensive care physicians and pharmacists, developed guidelines for sequential therapy based on 
literature data [3, 7, 14].  
The guidelines were approved by the Pharmacotherapeutic Committee. The activities of the Antibiotic 
Work Group and Pharmacotherapeutic Committee are explicitly defined in Belgian legislation and the 
development of guidelines for rational drug use is mentioned as one of their key activities [17]. The 
criteria proposed for sequential therapy were: body temperature <38°C for 24 h, decreasing or normal 
leukocyte count, no unexplained tachycardia, patient tolerance of oral dosing or feeding, no 
malabsorption (vomiting, diarrhoea), no planned surgery within 24 h [7] (Table 1).  
 
Table 1 Criteria for sequential therapy with fluoroquinolones 
 
The first intervention consisted of the publication and dissemination of guidelines in the local drug 
letter [period A (before intervention) versus B (after intervention)] in October 2003. The drug letter is 
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the official letter of the Pharmacotherapeutic Committee, where new recommendations are published 
and disseminated. This intervention was oriented towards all physicians (approximately 650) in the 
hospital. The sequence of the interventions is illustrated in Fig. 1.  
 
Figure 1. Sequence of the interventions 
 
 
 
The wards where the second and third intervention took place were orthopaedics, endocrinology, 
abdominal surgery, gastro-enterology, and plastic surgery, which were selected based on their high 
fluoroquinolone consumption. Orthopaedics and endocrinology were randomly assigned to the second 
intervention and abdominal surgery, gastroenterology, and plastic surgery to the third intervention. 
 
The second intervention consisted of an educational interactive session given by two infectious disease 
specialists to the medical staff of orthopaedics and endocrinology at the end of March 2004. The 
rationale and advantages of implementing sequential therapy were presented and discussed with the 
participating physicians (approximately 15 physicians at each meeting). The main focus of this 
intervention was to convince the physicians that orally administered fluoroquinolones are as effective 
as those given intravenously if the patient’s clinical status complies with the criteria for sequential 
therapy. 
91 
 
 
During the third intervention, clinical pharmacists reinforced the guidelines every time a patient 
treated with intravenously fluoroquinolones met the criteria for sequential therapy. Infectious disease 
specialists were consulted by the clinical pharmacists in cases where there was doubt about patient’s 
clinical status. A pre-printed note for the prescriber was attached to the patient’s chart by the clinical 
pharmacist, with a suggestion to switch to an oral treatment and a short summary of the advantages. 
The prescriber was also asked to explain the reason if the advice was not taken. The third 
intervention took place on the abdominal surgery, gastro-enterology, and plastic surgery wards 
between 1 April 2004 and 31 May 2004.  
 
This study was approved by the Ethics Committee of Ghent University Hospital. 
 
Interrupted time-series (ITS) analysis. 
 
The impact of the interventions was measured at two levels, macro and micro. 
At the macro level the hospital consumption of FQ (ofloxacin, ciprofloxacin, levofloxacin, 
moxifloxacin) was used to evaluate the long term impact of the publication of the guidelines by 
performing an interrupted time-series (ITS) analysis [18, 19]. This study design is characterized by 
a series of measurements over time in order to detect spontaneous evolution and discriminate from the 
effect of an intervention, thus avoiding possible bias. Consumption data were expressed in daily 
defined doses (DDD) using the Anatomical Therapeutic Chemical (ATC) classification rates were 
expressed in DDD/1,000 bed days. The monthly oral and IV FQ consumption and the ratio of IV 
versus total FQ usage were counted, starting 21 months before until 24 months after the publication of 
the guidelines. 
 
Pre- and post- prospective study 
At a micro level, a pre- and post-prospective study was performed in order to assess the impact of the 
educational sessions and the proactive conversion programme. All patients treated with intravenous 
FQ were included for a period covering 2 months before until after the intervention. For every patient 
the following variables were collected: age, type of infection, co-morbidity, leukocyte level, heart rate, 
antibiotics used, concomitant drugs, administration route of antibiotics. In the baseline period (group 
1) data were collected on the orthopaedics, endocrinology, abdominal and plastic surgery and 
gastroenterology wards. The impact of the educational sessions was assessed on the orthopaedics and 
endocrinology wards (group 2). The impact of the proactive conversion programme was assessed on 
the abdominal, plastic surgery and gastro-enterology wards (group 3). The data were collected by a 
hospital pharmacist. The severity of the underlying illness was defined for each patient by counting the 
case mix index [20]. The case mix index is calculated using diagnosis-related groups (DRG’s), a 
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measure that is nowadays routinely obtained in various countries as a basis for hospital 
reimbursement. DRG’s developed as an instrument to relate the case mix of a hospital to the 
costs, classify patients depending on their diagnosis, treatments, age and other information into 
mutually exclusive, clinically and financially homogeneous categories [21]. 
 
A panel of one hospital pharmacist and two infectious disease specialists evaluated the treatment of 
each patient and identified the moment the patient fulfilled the criteria to switch to oral therapy after 
starting intravenous treatment. The number of days that intravenous therapy continued beyond this day 
enables measurement of the impact of the intervention. To calculate the potential financial impact, 
the cost of continuing intravenous therapy when oral FQ could have been used was determined for 
each treatment and compared with the cost of an oral treatment. Indirect costs for preparing and 
administering the FQ were not considered. 
 
At the end of the study the results were presented to all participating prescribers. 
 
Statistical analysis 
Statistical analysis was performed using R (a language and environment for statistical computing) 
[22]. The categorical variables were compared using the Chisquare test, continuous variables with the 
Mann–Whitney U-test and Kruskal–Wallis test. Segmented regression analysis was used for the two 
time periods. The significance level was set at a = 0.05, two-tailed. 
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Results 
 
Impact publication of guidelines  
An interrupted time-series analysis demonstrates a decreasing IV versus total (IV + PO)FQ 
consumption since the publication of the guidelines (Fig. 2). The mean ratio of IV versus total (IV + 
PO) FQ usage was in the 21 months before the intervention 44.5% and decreased to 41.2% in the 
following 24 months (P = 0.011). 
 
Impact of educational sessions and pro-active intervention 
Eighty-one patients were included, 36 in group 1, 21 in-group 2 and 24 in group 3 (Table 2). The 
number of type of infections was significantly different for skin and soft tissue infections and 
prosthetic material infections. There was no difference for urinary tract infections, 
gastrointestinal infections, pneumonia and osteomyelitis. The case mix index, mean age and gender 
ratio were similar. The case-mix index was not available for two patients in group 1 and five patients 
in group 2 and 3. The mean time to reach the criteria for sequential therapy was 5.2 days in group 1, 
5.8 days in group 2 and 5.0 days in group 3 (P = 0,934). 
 
Table 2 Comparison of patient characteristics in group 1 (baseline), group 2 (educational 
sessions by infectious disease specialist) and group 3 (proactive conversion-programme by a 
pharmacist) 
 
In group 1, patients were treated for a further 4.1 days after they fulfilled the criteria (Table 3). This 
parameter decreased in group 2 to 3.5 days and in group 3 to 1.0 day (P = 0.006). The pharmacist’s 
advice in group 3 was accepted 22 times (91.7%). In two cases (8.3%) the physicians did not follow 
this advice because the patient had started vomiting. 
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Table 3 Comparison patient outcome group 1 (baseline), group 2 (educational sessions by 
infectious disease specialist) and group 3 (proactive conversion-programme by a pharmacist) 
 
The economical impact was demonstrated by counting the difference in cost of antibiotics between an 
intravenous and oral treatment (difference extra IV treatment and similar oral PO treatment for an 
individual patient). The mean extra cost per patient by longer IV treatment decreased significantly 
from 188.0€ in group 1, to 103.0€ in group 2 and 44.0€ in group 3 (P = 0.037). 
 
Figure 2. Evolution of the ratio of IV versus total (IV/ PO) FQ usage, expressed in daily defined 
doses per 1,000 bed days, starting 21 months before until 24 months after the publication of the 
guidelines in the drug letter 
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Discussion 
The results of this pilot study demonstrate that the delay in switching to oral FQ therapy once the 
criteria for sequential therapy were met was significantly shorter during the intervention where the 
pharmacist provided immediate feedback to the prescriber about a specific patient. There was a limited 
impact of the educational interactive sessions. The long-term impact of the publication of 
the guidelines for all physicians, based on consumption figures, shows a small decrease in usage of 
intravenous FQ. 
 
Six months after publication of the guidelines the IV/PO ratio was increasing (Fig. 2). This illustrates 
that such an intervention has a gradual rather than an instant effect (learning effect) which may decline 
over time (decay effect). The IV/PO ratio may be an indicator for implementing sequential therapy but 
could be biased by confounding factors. An example of a possible confounding factor is the length of 
stay of the patients. Patients who are switched to an oral therapy could be discharged earlier as the oral 
therapy can easily be continued at home. In this case the IV/PO ratio will increase as we only look at 
the consumption in the hospital. 
 
In the pre and post prospective study, the mean time to reach the criteria for sequential therapy was 
approximately 5.0 days for the three evaluated groups. In comparable studies, this varies between 2.4 
and 3.6 days [6, 13, 14]. The high figure in our study could be explained by the case mix index of the 
included patients. 
 
The most important outcome was the extra IV treatment after reaching the criteria for sequential 
therapy. In the baseline period, patients were treated for an additional 4.1 days. This was reduced by 
0.6 days after the education sessions and by 3.1 days during the proactive intervention. Studies 
measuring the impact of proactive interventions describe a reduction of 1.5–4.0 days [4, 13]. 
 
The impact of a once-only educational session is clear but not significant. It was remarkable during 
these sessions that the majority of the physicians were not aware of the bio-equivalence of intravenous 
and oral FQ and the difference in costs between the oral and intravenous preparations. The limited 
reduction in extra IV days after the educative session can possibly be explained by the fact 
that physicians, although being aware of the guidelines, were reluctant to initiate oral therapy in daily 
practice. 
 
The impact of the pro-active programme by a pharmacist was significant. The physicians mostly 
accepted the advice of the pharmacist. This intervention was not considered as interference by the 
physicians, something that became clear during the oral presentation at the end of this study where the 
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results were discussed with the prescribers. The advice was well founded and difficult cases 
were discussed in advance with an infectious disease specialist. When the pharmacist suggested 
switching to an oral therapy, possible food-drug and drug–drug interactions were also taken into 
account. In this case the pharmacist suggested administering the interacting drug 2 h after 
the administration of the FQ to avoid reduced absorption of the FQ antibiotic. Physicians and nurses 
considered this important as they were not always aware of these potential pitfalls during oral FQ 
treatment. 
 
The relation between the case mix index and the duration of an intravenous treatment is not clear. A 
shorter IV treatment with FQ was not associated with a shorter length of stay. Studies with more 
statistical power are necessary to evaluate this relationship. 
 
The pre and post prospective study has limitations. First the small number of patients limited the 
statistical power of the study. More inclusions should have been possible if the study was conducted 
over a longer period than 2 months before and after the study. Second, a control group was 
not included after the second and third intervention. That’s the reason why this study is not considered 
as a controlled before and after study but a pre-and post study. The limitation with this type of study is 
that, without reference to a control group, it cannot answer whether the improvement or decline would 
have occurred anyway, even without the intervention. The results of this study however confirms 
the conclusions of similar publications [13, 14]. Third, the first evaluation of patients’ charts (group 1) 
took place 4 months after the publication of the guidelines and started 2 months before the educational 
sessions by the infectious disease specialist. Ideally, the same evaluation should have been done 2 
months before and after the publication of the guidelines in order to evaluate the impact of this 
intervention based on clinical data. 
 
It is clear that an early switch to oral treatment is linked to lower costs. In this study only the cost of 
the antibiotics was considered. The advantages are in reality higher, taking into account supplies for 
administration, labour in drug preparation and administration, and avoiding 
infusionrelated complications. In addition, the length of stay may be shortened if patients are able to 
complete their course of therapy outside the hospital. In a pharmaco-economic study evaluating a 
pharmacist-managed programme for automatically converting levofloxacin route from IV to oral, 
the total cost per patient decreased from 121 $ to 82 $. The length of stay decreased from 9.5 to 6.0 
days [5]. 
 
This study will be the start of an extensive poster campaign in our hospital. The campaign will focus 
not only on FQ but also on clindamycin, linezolid, fluconazole and metronidazole, which are also 
equally bioavailable. Most educational initiatives are planned at the beginning of the medical year in 
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order to promote early development of optimal prescribing habits for new residents in a 
teaching hospital. Pro-active interventions can be integrated into an electronic prescribing programme. 
This will give the opportunity to develop computer-generated reminders based on an algorithm, to 
indicate when a patient can be treated orally instead of IV. 
 
Conclusion 
This study demonstrated that an active implementation of guidelines for sequential therapy is 
necessary. Several methods of implementation were compared: publication of guidelines, educative 
sessions by an infectious disease specialist and a pro-active intervention by a clinical pharmacist. The 
results show that a pro-active intervention results in a significant reduction of the duration of 
the intravenous treatment, and a reduction in the treatment cost. 
 
Acknowledgements 
The authors acknowledge prof. dr. E. Baert for making available the case-mix index, pharmacist N. 
Beck for the support in collecting the patient data and Mrs T. James for editing the text. 
 
Conflict of interest 
None.  
 
Funding 
None.  
 
References 
1. Fishman N. Antimicrobial stewardship. Am J Med. 2006; 119:S53–61. 
2. Nathawani D, Tillotson G, Davey P. Sequential antimicrobial therapy the role of quinolones. J 
Antimicrob Chemother. 1997;39:441–6. 
3. Dellit TH, Owens RC, McGowan JE, et al. Infectious diseases society of America and the society 
for healthcare epidemiology of America guidelines for developing an institutional program to enhance 
antimicrobial stewardship. Clin Infect Dis. 2007;44: 159–77. 
4. Sevinc  ¸ F, Prins J, Koopmans R, Langendijk P, Bossuyt P, Dankert J, et al. Early switch from 
intravenous to oral antibiotics: guidelines and implementation in a large teaching hospital. J 
Antimicrob Chemother. 1999;43:601–6. 
5. Kuti J, Le T, Nightindale C, Nicolau D, Quintiliani R. Pharmacoeconomics of a pharmacist-
managed program for automatically converting levofloxacin route from IV to oral. Am J Health 
Syst Pharm. 2002;59:2209–15. 
6. Jensen K, Paladino J. Cost-effectiveness of abbreviating the duration of intravenous antibacterial 
therapy with oral fluoroquinolones. Pharmacoeconomics. 1997;11:64–74. 
98 
 
7. Vogel F. Intravenous/oral sequential therapy in patients hospitalised with community-acquired 
pneumonia. Drugs. 2002;62: 309–17. 
8. Conort O, Gabardi S, Didier M, Hazebroucq G, Cariou A. Intravenous to oral conversion of 
fluoroquinolones; knowledge versus clinical practice patterns. Pharm World Sci. 2002;24: 67–70. 
9. Beringer A, Nguyen K, Razeghi J. Implementing a program for switching from I.V. to oral 
antimicrobial therapy. Am J Health Syst Pharm. 2001;58:1146–9. 
10. Ramirez J, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with 
bacteremic communityacquired Streptococcus pneumoniae pneumonia. Arch Intern Med. 
2001;161:848–50. 
11. Martinez M, Freire A, Castro I, Inaraja M, Ortega A, Del Campo V, et al. Clinical and economic 
impact of a pharmacist-intervention to promote sequential intravenous to oral clindamycin conversion. 
Pharm World Sci. 2000;22:53–8. 
12. Laing R, Mackenzie A, Shaw H, Gould I, Douglas J. The effect of intravenous-to-oral switch 
guidelines on the use of parenteral antimicrobials in medical wards. J Antimicrob 
Chemother. 1998;42:107–11. 
13. Zamin M, Pitre M, Conly J. Development of an intravenous-tooral route conversion program for 
antimicrobial therapy at a Canadian tertiary care health facility. Ann Pharmacother. 1997; 31:564–70. 
14. Von Gunten V, Amos V, Sidler A, Beney J, Troillet N, Reymond J. Hospital pharmacists’ 
reinforcement of guidelines for switching from parenteral to oral antibiotics: a pilot study. Pharm 
World Sci. 2003;25(2):52–5. 
15. Wetzstein G. Intravenous to oral (iv:po) anti-infective conversion therapy. Cancer Control. 
2000;7:170–6. 
16. Van Bambeke F, Michot J, Van Eldere J, Tulkens P. Quinolones in 2005: an update. Clin 
Microbiol Infect. 2005;11:256–80. 
17. Royal Decree of February 12, 2008 laying down the standards which a hospital pharmacy must 
meet in order to be approved. Brussels: Belgian Gazette; 12 Feb 2008. 
http://www.ejustice.just. fgov.be/doc/rech_n.htm. Accessed 14 Mar 2008. 
18. Ansari F, Gray K, Nathwani D, Phillips G, Ogston S, Ramsay C, et al. Outcomes of an 
intervention to improve hospital antibiotic prescribing: interrupted time series with segmented 
regression analysis. JAC. 2003;52:842–8. 
19. Matowe L, Leister C, Crivera C, Korth-Bradley J. Interrupted time series analysis in clinical 
research. Ann Pharmacother. 2003;37:1110–6. 
20. The WHO Collaborating Centre for Drug Statistics Methodology. ATC index with DDD’s. Oslo, 
Norway; 2003. http://www.whocc. no/atcddd/. Accessed 3 Apr 2006. 
21. Kuster S, Ruef C, Bollinger A, Ledergerber B, Hintermann A, Deplazes C, et al. Correlation 
between case mix index and antibiotic use in hospitals. JAC. 2008;62:837–42. 
99 
 
22. R Development Core Team. R: a language and environment for statistical computing. Vienna, 
Austria: R Foundation for Statistical Computing; 2007. ISBN 3-900051-07-0. http://www. R-
project.org. Accessed 2 Jan 2007.  
  
100 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 7: IMPLEMENTATION OF A MULTIDISCIPLINARY 
INFECTIOUS DISEASES TEAM IN A TERTIARY HOSPITAL 
WITHIN AN ANTIMICROBIAL STEWARDSHIP PROGRAM 
  
101 
 
 Implementation of a multidisciplinary infectious diseases team in a tertiary hospital within an 
Antimicrobial Stewardship Program 
 
 
F.M. Buyle, M. Wallaert, N. Beck, J. Boelens, S. Callens, G. Claeys, S. Deryckere, E. Haegeman, I. 
Leroux-Roels, E. Sermijn, E. Steel, H. Robays, L. Vandekerckhove, K. Vermis, D. Vogelaers 
 
 
Acta Clin Belg 2014;69:320-6  
102 
 
Abstract 
 
Background  
In January 2011, as part of an antimicrobial stewardship program the Antimicrobial Management 
Team (AMT) at the Ghent University Hospital initiated a multidisciplinary Infectious Diseases Team 
(MIT) consisting of infectious diseases physicians, clinical microbiologists and clinical pharmacists. 
The aim of this study is to describe the type and acceptance rate of recommendations provided by the 
MIT.   
 
Methods  
Prospective, observational study in a tertiary care, university teaching hospital with 1062 beds in non 
consecutive hospitalized adult patients, excluding intensive care units and pediatrics.  
 
Results 
The MIT communicated 432 recommendations in 87 days observed. Of the 293 patients for whom a 
recommendation was made, the median age was 57 years (range 16–91 years) and 169 (57.7%) were 
male. Skin or soft tissue infections (14%),  respiratory tract infections (13%), infections without 
known focus (11%), abdominal infections (11%) and bone infections (8%) were most common. 
Recommendations were made to perform additional clinical investigation(s) [N = 137 (27%)], to 
adjust the dose of an antimicrobial drug [N = 42 (8%)], to stop an antimicrobial drug [N = 104 (21%)], 
to switch from a parenteral to an oral drug [N = 39 (8%)] or to initiate an antimicrobial drug [N = 178 
(36%)] with an acceptance  rate of 73.0%, 83.3%, 81.7%, 76.9% and 84.0% respectively. 
 
Conclusions 
The MIT formulated about 5 recommendations a day primarily focusing on pharmacotherapy but also 
on clinical investigations. In both fields a high acceptance rate was observed. 
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Background 
Antimicrobial stewardship refers to coordinated interventions designed to improve and measure the 
appropriate use of antimicrobial agents by promoting the selection of the optimal antimicrobial drug 
regimen including dosing, duration of therapy and route of administration [1]. The major objectives 
are to optimize the clinical outcomes related to antimicrobial use while minimizing toxicity and other 
adverse events and limiting the selective pressure on bacterial populations that drives the emergence of 
antimicrobial-resistant strains. 
 
Infections caused by multidrug-resistant bacteria are associated with higher mortality, prolonged 
hospital stay and increased costs [2]. The emergence of multidrug-resistant organisms limits 
therapeutic choices in hospital-acquired infections.  
Reducing and preventing antimicrobial resistance by enhancing the appropriate use of antimicrobials 
is one of the cornerstones of the European Union policy against antimicrobial resistance [3].  
Antibiotic stewardship programs are proposed as a tool to optimize the prescribing of antibiotics [4].  
Antimicrobial stewardship may also reduce excessive costs attributable to suboptimal antimicrobial 
use [1]. A recent study has shown that 38% of the antibiotic usage in European hospitals was not 
compliant to guidelines which need to be promoted through an antimicrobial stewardship program [5]. 
 
To influence the antimicrobial prescribing behaviour, a multidisciplinary approach which involves 
opinion leaders and senior clinicians is preferable. Ideally such a multidisciplinary antimicrobial 
stewardship team should bring different competences together, including infectious diseases (ID) 
physicians, clinical microbiologists and clinical pharmacists. 
Since 2002, the Belgian Antibiotic Policy Coordination Committee (BAPCOC) was able to secure 
federal funding, provide technical guidance and offer advanced specialist training for the formal 
establishment and follow-up of Antimicrobial Management Teams (AMTs) in Belgian hospitals [6]. 
The minimal composition, mandate and tasks of hospital AMTs have been consolidated in legislation 
(Royal Decree of 12 February 2008) on the norms for AMTs as dedicated subgroups of the hospital 
Drugs and Therapeutic Committee [6].  
 
The AMT of the Ghent University hospital provides national (The Sanford Guide To Antimicrobial 
Therapy - Belgian/Luxembourg Edition) and local antimicrobial guidelines to the prescribers [7]. The 
electronic medical record allows physicians to consult the microbiological results of the clinical 
laboratory, including identification and susceptibility of pathogens. Eighty percent of the wards use a 
computerised physician order entry (CPOE) system in which dosing regimens are incorporated in 
medication order sets and where current and past antimicrobial therapies can be consulted. Wards 
where CPOE is not yet implemented can prescribe restricted antimicrobials (voriconazol, caspofungin, 
anidulafungin, liposomal amphotericin B, meropenem, piperacillin/tazobactam, linezolid, tigecycline, 
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vancomycin, teicoplanin, colimycin, ceftazidim, levofloxacin, moxifloxacin, ciprofloxacin) with a 
specific antibiotic prescription form. 
 
The AMT at our hospital initiated a multidisciplinary infectious diseases team (MIT) in January 2011, 
as part of an antimicrobial stewardship program, which is directed by ID physicians and also consists 
of clinical microbiologists and clinical pharmacists. Once a week, a haematologist joins the team. 
Figure 1 gives a schematic representation of the activities of the MIT. The MIT meets daily to discuss 
(a) requests for ID consultations reviewed by ID physicians, (b) positive blood cultures and cultures 
with resistant strains or with organisms requiring special attention, reviewed by microbiologists (c) 
presumed inappropriate therapies identified by pharmacists. The pharmacists review therapies with 
antifungals, meropenem, piperacillin/tazobactam, linezolid, tigecycline, vancomycin and teicoplanin, 
blood concentrations of antimicrobials requiring monitoring (vancomycin and teicoplanin, 
aminoglycosides,voriconazole) and antimicrobials with high bioavailability that may be switched from 
parenteral to oral administration based on the electronic medical patient record. The MIT 
communicates its recommendations to the physicians by phone and by notes in the electronic patient 
file where a specific MIT section is available. The MIT limits its interventions to adult patients 
hospitalized in non-critical care departments. Critical care patients are discussed weekly in a separate 
meeting with clinical microbiologists and intensive care physicians. The pediatric department has a 
dedicated pediatric ID physician. 
 
The aim of this pilot study is to describe the type and acceptance rate of interventions provided by the 
MIT. 
 
Methods 
A prospective, observational study was performed in a tertiary care, teaching hospital with 1062 beds. 
The MIT pharmacists registered every recommendation communicated by the MIT during 87 non-
consecutive days between October 2011 and May 2012.  
The following data were registered in a standardised case record form: date of MIT recommendation, 
hospitalisation ward, type of infection and current antimicrobial treatment. Five types of 
recommendations can be distinguished: (a) initiating or changing an antimicrobial regimen; (b)  
additional clinical investigations; (c) dosing adjustments;(d) switching from parenteral to oral 
formulations (5) discontinuing antimicrobials. The rationale for the recommendations and the specific 
antimicrobials involved were registered. 
Recommendations were scored as accepted when a physician implemented the recommendation(s) 
within 3 days after the communication. The acceptance rate was classified as “not documented” in 
those cases where it was not possible to document this retrospectively (e.g. patient discharged or 
transferred to another health care facility).  
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The study was approved by the local Ethics Committee. 
 
Results 
The MIT communicated 432 recommendations during 87 non-consecutive days in  293 patients  The 
median age was 57 years (range 16–91 years) and 169 (57.7%) were male. 
Skin or soft tissue infections (14%), respiratory tract infections (13%), infections without known focus 
(11%), abdominal infections (11%) and bone and joint infections, including prosthetic infections (8%) 
were most frequently involved . 
 
In 277 (64.1%) of the recommendations the MIT proposed a modification in therapy or further clinical 
investigations which were accepted. In 84 (19.4%) of the recommendations the MIT suggested to 
continue the actual therapy which was implemented. This resulted in a total acceptance rate of 83.5%. 
For the other recommendations, 57 (13.2%) were not implemented and for 14 (3.2%) implementation 
could not be documented.  
 
MIT recommendations  originated from new electronically requested ID consultations (61%), current 
antimicrobial therapies provided by pharmacists (18%), follow up of earlier requested ID consultations 
(12%), microbiological information  provided by microbiologists (4%), current therapies provided by 
ID physicians (3%) and haematologists (2%). The electronical ID consultations were ordered by 30 
medical disciplines, ranging from 1 to 24 (median 7.5) requests per discipline. 
 
The majority of the recommendations were made for patients on the following wards: abdominal 
surgery (16.2%), gastroenterology (9.3%), thoracovascular surgery (7.9%), rehabilitation medicine 
(5.8%) and orthopaedics (5.0%). 
Some of the 432 recommendations consisted of multiple types of recommendations, which were taken 
into account individually in table 1. This resulted in 500 individual recommendations.  
 
Recommendations were made to perform additional clinical investigation(s) [N = 137 (27%)], to 
adjust a dose of an antimicrobial drug [N = 42 (8%)], to stop an antimicrobial drug [N = 104 (21%)], 
to switch from a parenteral to an oral drug [N = 39 (8%)] and to initiate an antimicrobial drug [N = 
178 (36%)] with an acceptation rate of respectively 73.0%, 83.3%, 81.7%, 76.9% and 84.0% (Table 
1). Of the 178 initiated antimicrobials 113 (63%) were a replacement of and 26 (15%) an addition to 
the current therapy. 
 
Within the accepted recommendations, vancomycin, piperacillin/tazobactam and meropenem 
treatments were more frequently stopped versus initiated (respectively 31 vs. 5 , 21 vs. 7  and 20 vs. 
14).  Considering the administration route, parenteral therapies were more frequently stopped than 
106 
 
initiated (148 versus 97). In general, treatments were more frequently discontinued instead of initiated 
(184 versus 152) after a MIT recommendation. This is not a likelihood but a frequency distribution as 
recommendations to continue treatments were more likely to be implemented. 
 
Table 1. Classification of the recommendations provided by the MIT with acceptance rates. 
 
Discussion 
This study shows that an average of five recommendations per day were provided by the MIT, of 
which 83% were accepted This acceptance rate is comparable with numbers in similar studies 
performed in the USA, Brazil, Singapore and Australia, showing acceptance rates ranging from 64% 
to 80% [8-12].  
 
Remarkably, the number of recommendations seems slightly higher in our study. This could be the 
result of the inclusion of pharmacotherapeutic as well as diagnostic recommendations, in contrast to 
the previously published reports. In the other studies the AMT program was performed by ID 
physicians together with clinical pharmacists whereas only in one study there was also participation of 
a clinical microbiologist [9]. The numbers of beds ranged from 60 to 1596 [8-12].   
 
Our recommendations cover a wide range of infection types, with a majority of skin or soft tissue 
infections, respiratory tract infections, infections without known focus and abdominal infections. 
Classification of recommendation 
Number of 
recommendations  
N (%) 
Accepted   
 N (%) 
Acceptance not 
documented 
N(%) 
Not accepted 
N(%) 
Additional clinical investigation 137 (27%) 100 (73%) 5 (4%) 32 (2%) 
Dosing adjustment 42 (8%) 35 (83%) 3 (7%) 4 (10%) 
Reason Subtherapeutic or toxic serum  
concentration 
15 (36%) 12 (80%) 0 (0%) 3 (20%) 
Evidence-based guidelines 15 (36%) 12 (80%) 2 (13%) 1 (7%) 
Other* 8 (19%) 7 (88%) 1 (13%) 0 (0%) 
Compromised renal function 4 (10%) 4 (100%) 0 (0%) 0 (0%) 
Type of 
adjustment 
Increase 22 (52%) 16 (73%) 2 (9%) 4 (18%) 
Reduction 11 (26%) 11 (100%) 0 (0%) 0 (0%) 
Same daily dose, other dosing 
regimen 
9 (21%) 8 (89%) 1 (11%) 0 (0%) 
Stop antimicrobial therapy 104 (21%) 85 (82%) 4 (4%) 15 (14%) 
Reason No indication to proceed 70 (67%) 57 (81%) 4 (6%) 9 (13%) 
Prolonged therapy 25 (24%) 22 (88%) 0 (0%) 3 (12%) 
Tentative 9 (9%) 6 (67%) 0 (0%) 3 (33%) 
Switch parenteral to  oral therapy 39 (8%) 30 (77%) 1 (3%) 8 (21%) 
Initiation antimicrobial therapy 178 (36%) 150 (84%) 11 (6%) 17 (10%) 
Reason  Replacement 113 (63%) 94 (83%) 7 (6%) 12 (11%) 
Untreated indication 35 (20%) 30 (86%) 1(3%) 4(11%) 
Addition 26 (15%) 23 (88%) 1 (4%) 2 (8%) 
Restart 2 (1%) 1 (50%) 0 (0%) 1 (50%) 
Reason unknown 2 (1%) 2 (100%) 0 (0%) 0 (0%) 
* different length of administration, increase of dose to reach the sternum, increase of dose because of intermediate sensitivity of bacterial 
strain, increase of dose because of infection of vascular prosthesis, different dosing regimen because of parenteral administration in home 
setting, increase of dose because of high body weight, tentative. 
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Some of these infections can be complicated and complex, requiring a long duration of therapy, a 
setting in which the advice of the MIT can be important.  
 
The majority (61%) of the recommendations originate from ID consultations. This may reflect the 
embedment of this clinical service within the hospital. A significant number (18%) of 
recommendations originate from therapies reviewed by clinical pharmacists. Pharmacists  spend 
approximately 2 hours per day in analysing treatments with antifungals (with the exception of 
fluconazole), meropenem, piperacillin/tazobactam, linezolid, tigecycline, vancomycin, teicoplanin and 
antimicrobials with a high bioavailability that may be switched from parenteral to oral administration. 
Because this represents a significant workload each type of antimicrobial agent is reviewed only once 
a week. Data-mining software able to generate automated reports based on pharmaceutical, clinical 
and microbiological data could have a time-saving effect [11]. This should allow us to enhance the 
frequency of the actual antimicrobial agents and to evaluate additional antimicrobial agents . 
Furthermore, computer decision support systems could support physicians upon the initiation of a 
therapy [13,14]. Such a system is already applied on the intensive care unit of our hospital [14].  
However, this was outside the scope of the current study.  
 
The number of recommendations originating from positive microbiological cultures provided by 
clinical microbiologists is small, because during the time period of the study, most of the positive 
cultures were directly discussed by the clinical microbiologists with the treating physicians outside the 
framework of the MIT. This is a direct consequence of the different organisation of the microbiology 
laboratory, where the results are generated early in the morning, in contrast with the MIT meetings 
which are held in the late afternoon.  
 
The majority (73%) of the recommendations focus on pharmacotherapy. All recommendations to 
reduce the dose of antimicrobials were accepted, while recommendations to increase the dose had a 
lower acceptance rate. Physicians seem to feel more confident with reducing doses considering 
compromised renal function or risk of side effects. They may not yet be fully aware of the concept of 
individualised antimicrobial therapy. This may  require increasing doses e.g. in infections with less 
sensitive strains, in patients with significant pharmaco-kinetic changes such as increased distribution 
volume (burns, cirrhosis) or the phenomenon of augmented renal clearance in critically ill.15 
Recommendations that propose a tentative stop of an antimicrobial therapy and an observation of the 
clinical evolution imply a greater degree of uncertainty for physicians which can explain the low 
acceptance rate in this setting.  
 
The acceptance rate to switch from a parenteral to an oral formulation (IV-PO switch) of the same 
antimicrobial is relatively low. An explanation could be that pharmacists’ only source to consider 
108 
 
possible switches is the electronic medical record where clinical data that could support the medical 
decision to continue parenteral therapy (e.g. severe vomiting, diarrhea, not functional tube) were not 
always documented. The proportion of recommendations proposing an IV-PO switch is small, which 
could be the result of other and earlier initiatives towards physicians. Within the same hospital we 
have reported high compliance with internal guidelines on IV/PO switch [16,17]. These initiatives 
were developed outside the framework of the MIT but were coordinated by the AMT.  
 
Recommendations to initiate an antimicrobial therapy have the highest overall acceptance rate with 
physicians. Most recommendations in this category propose to replace a current antimicrobial by an 
alternative. Most persuasive reasons to initiate an antimicrobial therapy were to enhance effectiveness, 
to narrow spectrum and to allow a switch to oral therapy. The analysis of accepted recommendations 
suggests that the MIT was able to de-escalate therapies, to switch to oral antimicrobials and to 
discontinue antimicrobials when applicable. 
About 17% of the recommendations focus on additional clinical investigations with an acceptance rate 
of 73%, which is lower compared to pharmacotherapy oriented recommendations but comparable with 
a recently published similar study [18]. The lower acceptance rate on diagnostic issues suggests that 
physicians more readily accept recommendations on pharmacotherapy as compared to critical 
reflections on their diagnostic path. This is also shown by the low uptake of performing 
transesophageal echocardiography in patients with Staphylococcus aureus bacteraemia. As a result of 
these data, patients with a Staphylococcus aureus bacteraemia are now prospectively followed during 
their hospital stay to ensure echocardiography screening for latent infective endocarditis [19]. 
 
Establishing a culture of measurement and clinician feedback is an effective stewardship strategy 
[4,20]. The effectiveness can be improved by the Feedback Intervention Theory through providing 
specific, frequent and written suggestions for improvement [21]. This was also applied by the MIT by 
documenting recommendations in the CPOE system and by additional communication by phone. 
Another strength of the MIT is that follow up by the MIT is provided for patients with complex 
infections. This is strongly appreciated by the physicians. The multidisciplinary composition of the 
MIT reflects the recommendations in literature [2,4,22]. The MIT is directed by an infectious disease 
physician who is a respected authority which is a fundamental feature in marketing the MIT concept 
[23]. Initially the pharmacist reviewed only prolonged therapies (>10 days) of the target antimicrobial 
agents which has changed over time to all treatments.  
 
Pre-authorization of restricted antimicrobial agents is not implemented in our hospital and only once a 
week each type of antimicrobial agents is reviewed. The combination of these two factors indicates 
potential for further optimization. This will increase the workload which can be in turn reduced by 
implementing automated reports. One study from a hospital in the USA with 513 beds described that 
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software-generated antimicrobial therapy reports contain information on approximately 60–80 patient 
cases, resulting in about 20 cases daily after evaluation by a pharmacist. These cases are then reviewed 
together with an ID physician. Projecting this method to our hospital, this could generate 36 cases on a 
daily basis to discuss within the MIT [11]. 
 
In order to support physicians during the diagnostic evaluation of the patient, some guidelines are now 
linked to the data of clinical chemistry (e.g. serum concentration levels of glycopeptide and 
aminoglycoside agents are linked to drug therapeutic monitoring guidelines) and microbiology 
(positive  blood cultures with Staphylococcus aureus are linked to the Staphylococcus aureus 
bacteremia guideline).  
 
This pilot study has some limitations. Reasons to decline a recommendation were not assessed. Recent 
literature on antimicrobial stewardship focuses on the behaviour of individual prescribers. This could 
lead to understanding the barriers to and facilitators of behavioural change [24]. This should be taken 
into account for further research.  
 
No statements can be made on the cost-effectiveness, patient safety, impact on morbidity and mortality 
and local resistance patterns. Restricted antibiotics (e.g. vancomycin, piperacillin-tazobactam and 
meropenem) were more frequently stopped than initiated and oral therapies were more frequently 
initiated compared with parenteral therapy. This suggests that the MIT can have a positive impact on 
antimicrobial expenditure. In the past this was shown in our hospital for an IV-PO switch program 
[16]. This is in line with documented positive impact of antimicrobial stewardship programs on 
antimicrobial expenditure and clinical outcome [8-12,25]. 
 
Conclusion 
This prospective observational pilot study showed that the multidisciplinary infectious diseases team, 
as part of an antimicrobial stewardship program, formulated about 5 interventions a day for non-
critically ill adult patients. Recommendations were communicated by phone and by notes in the 
electronic patient file resulting in high acceptance rates. Acceptance rates were higher for 
recommendations on pharmacotherapy as compared to diagnostic issues. 
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Figure 1 Flowchart activities multidisciplinary infectious diseases team. 
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Discussion and general conclusion 
Antimicrobial stewardship stimulates the appropriate selection, dosing, route of administration, and 
duration of antimicrobial therapy. In conjunction with infection prevention it is a key to the prevention 
and control of the emergence of antimicrobial resistance. 
 
In this thesis we describe the development and validation of quality indicators in order to monitor 
antimicrobial stewardship programs in a European context (Chapter 2-3). Furthermore we described 
elements of an antimicrobial stewardship program to optimize antimicrobial prescribing in a hospital 
setting (Chapter 4-5-6-7).  
 
In the following chapter the main findings of each study will be summarized followed by a general 
discussion and directions for future research.   
 
1. Main findings 
1.1. Development of quality indicators for evaluating antimicrobial stewardship programmes 
In the first (Chapter 2) and second study (Chapter 3) we described the development and validation of 
quality indicators for evaluating antimicrobial stewardship programmes in a European context.  
 
In the first study (Chapter 2), a prospective observational study in 5 acute care hospitals in Austria, 
Belgium and Germany, we evaluated the feasibility and clinical relevance of measuring an indicator 
for intravenous to oral switch therapy with highly bioavailable antibiotics. The feasibility of the 
indicator was evaluated by measuring data availability, data collection workload and sensitivity to 
improvement. Data were collected over a 3 month period resulting in 211 patients.  
 
Main findings 
Feasibility of the indicator. 
More than 99% of the required data proved available, which was higher than the pre-set threshold 
value of 80%. On average, the workload required for collecting, reviewing the data and filling the 
CRF was 29 min per assessed case. Significant inter-hospital variation suggests that the efficiency of 
data extraction depends on the quality and accessibility of clinical and pharmacy data sources. 
Opportunities for automated data extraction from computerized patient records should enhance the 
efficiency of monitoring such indicators. 
 
Heterogeneity of the performance gap 
By intention-to-treat analysis, 37.0% (95% CI 30.5-43.9) of treatments were inappropriate, ranging 
from 17.5% to 53.8% across hospitals which revealed a substantial heterogeneity of the performance. 
116 
 
The average proportion of inappropriate iv administration was 20.9% in the hospitals with an 
improvement programme versus 50.0% in the other hospitals (P=0.001). 
After adjusting for type of care and type of infection, absence of an iv-to-po switch programme was 
associated with more inappropriate prescribing (OR 6.78; 95% CI 3.02–15.23; P<0.001). 
 
General conclusion 
The results of this study indicated that the iv-to-po quality indicator is widely applicable in acute care 
hospitals and could be a tool to evaluate compliance with iv-to-po switch guidelines. 
 
 
In the second study (Chapter 3) we developed structure indicators for antimicrobial stewardship and 
antibiotic use in a hospital setting. Furthermore, we performed a validation study based on the selected 
indicators across a pilot sample of European hospitals.  
 
A multidisciplinary panel from four European countries developed structure indicators in three steps: 
identification and listing of indicators, remote ranking of indicators using multi-criteria scoring, 
selection of indicators in a face-to-face consensus meeting. Additionally, the top-ten indicators were 
identified as a minimal set of key indicators. A survey was sent to the directors of antimicrobial 
stewardship programmes in eleven European hospitals. The yes/no answers for the indicators were 
transformed into numbers in order to calculate the total scores. 
 
Main findings 
Development of structure indicators 
A final list of 58 indicators was selected and categorised in the following topics: antimicrobial 
stewardship services (n=12), tools (n=16), human resources and mandate (n=6), health care personnel 
development (n=4), basic diagnostic capabilities (n=6),  microbiological rapid tests (n=2), evaluation 
of microbiological data on antibiotic resistance (n=3), antibiotic consumption control (n=5) and drug 
use monitoring (n=4). The top-ten structure indicators with the highest score for ranking and 
applicability were considered to be key elements of an effective antibiotic stewardship programme in a 
hospital setting (Table 1).  
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Table 1. Top ten indicators considered as key elements of an antimicrobial stewardship 
programme (cfr Chapter 3) 
Item Indicator description 
Services Bedside expert consultant advice regarding antibiotics by 
microbiologist/infectious disease specialist/antibiotic officer on request available 
on the same day 
 Regular ward rounds  by members of AMT (multidisciplinary antibiotic 
management team) performed (at least weekly) 
 Clinical audit of prescribers' compliance with local clinical guidelines/guide 
performed  by AMT/AB Officer 
Tools AB formulary/ list biannually updated 
 Local clinical practice guidelines/guide for microbiologically documented therapy 
updated biannually 
 Local clinical practice guidelines/guide for empirical therapy available 
 Local clinical practice guidelines/guide for surgical antibiotic prophylaxis 
available 
Human resources and mandate Formal mandate for hospital multi-disciplinary antibiotic management team 
(AMT) existing 
 AB officer or AMT member is member of the drugs and therapeutics committee 
Personnel development Prescriber education by personalized interactive methods (like daily ward rounds) 
performed 
 
Validation survey 
There was significant heterogeneity among participating centers with regard to their scoring for 
structural components of effective antibiotic stewardship, which ranged from 32 to 50 out of the 
maximum score of 58. Hospitals with a lower score for the complete set of 58 indicators were also less 
performant on the top-ten key indicators. 
 
General conclusion 
We concluded that a selection among the potential structure indicators examined in this study, with 
focus on the top-ten indicators could be used for regular assessment of the extent and strength of 
hospital antimicrobial stewardship programmes. 
 
 
1.2. Elements of an antimicrobial stewardship program to optimize antimicrobial prescribing 
 
In the third study (Chapter 4) we describe a national Belgian survey investigating the 
recommendations by the local antibiotic management teams (AMTs) in Belgian acute hospitals for the 
administration (intermittent, extended or continuous infusion) and therapeutic drug monitoring of four 
beta-lactam antibiotics (ceftazidime, cefepime, piperacillin–tazobactam, meropenem) and vancomycin 
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for adult patients with a normal kidney function. Thirty-four (32%) of the 105 Belgian hospitals 
participated to the survey. 
 
Main findings 
Dosing strategies in Belgian hospitals 
The implementation of extended/continuous modes of administration was between 10% and 44% for 
non-ICU wards and between 35% and 81% for ICU wards. 
For the non-ICU wards ceftazidime the intermittent administration or continuous infusion method was 
almost equally used. Piperacillin–tazobactam and meropenem were mainly recommended by 
intermittent infusion and, if not, by extended infusion. For cefepime intermittent infusion was most 
recommended and if not, by continuous infusion. For vancomycin about two-thirds of the ICU wards 
recommended intermittent infusions and one-third by continuous infusion. 
For the ICU wards continuous infusion was the predominant mode of administration for ceftazidime 
and vancomycin. Extended infusion was most often recommended for meropenem. Intermittent 
administration remained predominant for cefepime and piperacillin–tazobactam, with extended 
infusion being the next most popular recommendation.  
The higher level of adoption in ICUs is consistent with the literature, suggesting that prolonged beta-
lactam infusions are advantageous for infections with more resistant pathogens, in critically ill and 
immunocompromised patients, and in patients with unreliable pharmacokinetics. 
 
Pitfalls 
For continuous infusion, a loading dose was recommended for ceftazidime, cefepime and meropenem, 
but not for all piperacillin–tazobactam dosing regimens. Compared with the recommendations of 
current literature, the loading dose and the trough target concentration for vancomycin were too low.  
 
General conclusion 
Belgian AMTs adopt recent literature on extended/continuous modes of administration in daily 
practice but more attention should be given to appropriate administration (loading dose, vancomycin 
target concentrations,..  ). 
 
In Chapter 5 and 6 of this thesis we describe 2 interventional studies to optimize antimicrobial 
prescribing with focus on appropriate timing of the initiation of an antimicrobial treatment and on 
parenteral to oral conversion of fluoroquinolone antibiotics. Both interventions are examples of 
persuasive interventions, according to The Cochrane Collaboration which combine audit and feedback. 
 
In the fourth study (Chapter 5) the time to first antibiotic dose (TFAD), defined as the time in hours 
from arrival of the patient at the emergency department (ED) to the administration of the first 
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antibiotic dose, was investigated. This indicator, described in literature as a quality indicator for the 
treatment of infections, was evaluated in the Ghent University Hospital followed by educational 
interventions in order to optimize the TFAD.  
 
In this retrospective observational study, the TFAD for adult patients with a diagnosis of an infection 
in the ED for which an antibiotic treatment was prescribed were compared before and after the 
implementations of an intervention (period A versus B).  
A multivariate model was set up to detect key factors associated with TFAD. The following factors 
were entered in the model: age, gender, LOS, CRP, APACHE II score, place of first administration, 
type of infection. Sixty-five patients were included in period A and 114 patients in period B. 
 
Main findings 
Time to first antibiotic dose 
The study showed that 75% of the patients received their first antibiotic dose within 4,19 hours in 
period A and within 4,50 hours in period B h after admission on the ED.  
The univariate analysis showed that the median TFAD in period A was 2.44 hours ( IQR 1.78-4.19) 
versus 3.30 hours (IQR 2.40-4.50) in period B (p=0.034). The median TFAD when the first dose was 
administered in the ED was 2.14 hours in period A versus 3.2 hours in period B (p<0.001). When the 
first dose was administered on the ward the TFAD was 4.56 hours in period A and 4.26 hours in 
period B (p=0.535). 
Impact of an intervention to optimize the TFAD 
The multivariate analysis showed no difference for TFAD between period A and B but showed that 
the place of the first antibiotic dose and type of infection were significantly associated with TFAD.  
General conclusion 
This study showed that our intervention to improve TFAD did not result in any long time 
improvement. 
 
In the fifth study (Chapter 6) the implementation of guidelines for sequential therapy (intravenous to 
oral conversion) with fluoroquinolones (FQ) in a Belgian hospital are described. In an interventional 
monocentric study three persuasive interventions (hospital-wide publication of guidelines in the local 
drug letter, which is addressed to all physicians; educational interactive session given by infectious 
disease specialists to the medical staff; a proactive conversion programme initiated by a pharmacist) 
were implemented. 
 
A pre- and post-prospective study was performed in order to assess the impact of the educational 
sessions and the proactive conversion programme. All patients treated with intravenous FQ were 
included for a period covering 2 months before and after the intervention. 
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At the macro level the hospital consumption of FQ was used to measure the long term impact of the 
publication of the guidelines by performing an interrupted time-series (ITS) analysis. 
 
Main findings 
Interventions 
In the baseline group patients (group 1) were treated intravenously for 4.1 days longer than necessary. 
This parameter decreased to 3.5 days for the patients on wards where an educational interactive 
session (group 2) was performed and to 1.0 day (P = 0.006) on wards were a proactive conversion 
programme (group 3) was implemented by a clinical pharmacist.  
 
Impact on the antibiotic treatment and consumption 
The mean additional cost for a longer intravenous treatment decreased from 188.0€ in group 1, to 
103.0€ in group 2 and 44.0€ in group 3 (P = 0.037).  
The mean ratio of IV versus total (IV+ PO) FQ usage was in the 21 months before the intervention 
44.5% and decreased to 41.2% in the following 24 months (P = 0.011). 
Six months after publication of the guidelines, the IV/PO ratio was increasing. This illustrates that 
such an intervention has a gradual rather than an instant effect (learning effect) which may decline 
over time (decay effect). 
 
General conclusion 
This study demonstrated that an active implementation of guidelines for sequential therapy is 
necessary. Several methods of implementation were compared: publication of guidelines, educational 
sessions by an infectious disease specialist and a pro-active intervention by a clinical pharmacist. The 
results show that a pro-active intervention results in a significant reduction of the duration of 
the intravenous treatment, and a reduction in the treatment cost. 
 
The sixth study (Chapter 7) describes the type and acceptance rate of interventions provided by a 
multidisciplinary infectious diseases team (MIT) in a tertiary hospital. This intervention is an example 
of educational outreach intervention (another form of persuasive intervention) and can be considered 
as a core antimicrobial stewardship strategy.  
A prospective, observational study in a tertiary care, university teaching hospital with 1062 beds in 
non-consecutive hospitalized adult patients, excluding intensive care units and pediatrics was 
performed.  
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Main findings 
Recommendations made by a multidisciplinary infection team  
The MIT communicated 432 recommendations in 87 days. Recommendations were made to perform 
additional clinical investigation(s) [N = 137 (27%)], to adjust the dose of an antimicrobial drug [N = 
42 (8%)], to stop an antimicrobial drug [N = 104 (21%)], to switch from a parenteral to an oral drug 
[N = 39 (8%)] or to initiate an antimicrobial drug [N = 178 (36%)].  
 
Acceptance rate of the recommendations 
The acceptance rate of these recommendations were 73.0% for performing additional clinical 
investigation, 83.3% to adjust the dose of an antimicrobial drug, 81.7% to stop an antimicrobial drug, 
76.9% to switch from a parenteral to an oral drug and 84.0% to initiate an antimicrobial drug 
respectively. 
Restricted antibiotics (e.g. vancomycin, piperacillin-tazobactam and meropenem) were more 
frequently stopped than initiated and oral therapies were more frequently initiated compared with 
parenteral therapy. This suggests that the MIT can have a positive impact on antimicrobial 
expenditure. 
 
General conclusion 
This prospective observational pilot study showed that the multidisciplinary infectious diseases team, 
as part of an antimicrobial stewardship program. Acceptance rates were higher for recommendations 
on pharmacotherapy as compared to diagnostic issues. 
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2. Discussion  
 
2.1. Global perspective 
In a global perspective antimicrobial resistance has become a major issue. Increasing resistance may 
compromise acquisitions in health care and hence affects everybody in the world (1), as infections 
may increasingly become more difficult to treat. Emergence and spread of new resistance mechanisms 
seems to outpace the development of new antimicrobials, especially in the field of Gram negative 
pathogen. The causes of antimicrobial resistance are complex. Some mechanisms involve human 
behaviour at many levels of society. These include antimicrobial prescription by caregivers both in the 
community and in hospital settings but also cultural attitudes and expectations within society itself and 
awareness of potential problems due to irrational use of antimicrobials. The future of antimicrobials 
and safeguarding their contribution to health improvement will hence depend on the commitment of 
many stakeholders, including government authorities, policy makers, university teachers, 
pharmaceutical companies, health-care workers and consumers. 
 
Prevention of infection is superior to treatment of established infection. From a resistance perspective, 
prevention reduces antimicrobial use and the spread of resistant bacteria. At the community level, 
improvement of sanitation, access to clean water, poverty reduction, and vaccination will have a huge 
effect on infectious disease incidence and transfer of multidrug-resistant organisms (1).  
 
When irrational use of antimicrobials is common among the public and health professionals, it 
becomes the norm. To break this pattern, antimicrobial stewardship programmes should focus not only 
on appropriate use, but also on ensuring sustainability of behavioural change and reorientation of 
societal norms. This is comparable with the attitude towards the relation between climate changing 
and pollution during the last decades around the world and, as such, implies major changes in 
awareness of the problem and of the shared responsibility to tackle this issue.  
 
The lack of new antimicrobials is a threat for future treatment of infectious diseases. This empty or at 
the most trickling pipeline can be explained by three reasons: scientific challenges; regulatory 
requirements, such as the requirement of superiority or noninferiority trials; and market failure (i.e., 
absence of appropriate incentives to develop medicines for which use is predefined to be restricted). 
The Office of Health Economics has estimated that, with restrictions, the net present value of a new 
antimicrobial to a drug company is minus $50 million, whereas a new musculoskeletal drug, without 
restrictions, is worth $1 billion (1). Ten years ago antimicrobials accounted for up to 20% of the 
hospital pharmacy budget. Today this contribution has decreased to 5%, as drugs like antitumoral, 
biological and orphan drugs have moved into a leading role. Society should consider how to 
reintroduce or to rekindle incentives to develop relevant new antimicrobials. These could include 
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package deals between civil authorities and pharmaceutical industry ensuring availability and 
development of these niche antimicrobials in combination with guaranteed market introduction of new 
drugs in other pharmaceutical classes or in tender systems. Programs such as the 10 by 20 initiative in 
the United States calling in 2010 for the development and introduction of 10 new antimicrobials by 
2020 could offer such frameworks. These should be firmly based on a long term agreement and 
contract between major stakeholders and, as such, not remain limited to a call or a political wish (2).  
 
2.2. European perspective 
On a European level a common strategy is necessary as resistant organisms are not constrained by 
national borders. Agreement on principles and key components of antimicrobial stewardship programs 
are necessary to support the EU member states in developing national programs. In Chapter 2 and 3 of 
this thesis we described two studies that were a part of the project ABS international. ABS 
International was one the first EU funded initiative focusing on antimicrobials stewardship programs. 
These studies aimed at the development of relevant indicators, of which the implementation should 
further be promoted by health organisations.  
 
The Transatlantic Task Force on Antimicrobial Resistance (TATFAR) which is a cooperation between 
CDC and ECDC, fosters cooperation between US and EU on the issue of antimicrobial resistance. The 
first TATFAR recommendation refers to appropriate use of antimicrobials in human medicine through 
hospital antimicrobial stewardship programs and specifically, to the development of common structure 
and process indicators of antimicrobial stewardship programs (ASP). These consensus set of indicators 
is expected to be published in 2015. Hopefully this will result in further political steps in European 
member states to create a framework for implementing ASP. It remains to be assessed whether the 
Belgian model of a compulsory legal framework for antimicrobial management teams will be more 
widely applied throughout Europe.  
 
2.3. Belgian perspective  
On a Belgian level the BAPCOC structure mirrors the complexity of antimicrobial resistance by 
focusing on the different fields of community, hospital and veterinary medicine. In this thesis we 
focused on antimicrobial stewardship programs (ASP) in the hospital setting. These ASP are to be 
viewed as complementary to hospital hygiene. Both are core elements in tackling the problem of 
antimicrobial resistance and hence should strongly interact around the hospitalised patient. 
 
In general, antimicrobial stewardship programs are strongly favoured and facilitated by a strong 
mandate by the hospital board. In the Belgian context there is a legal framework requiring the 
implementation of  antibiotic management teams in all hospitals, with specific funding in the hospital 
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budget (3). However, hospital financing mechanisms in Belgium are very complex and it is not always 
clear if and to what extent this budget is truly allocated to the antimicrobial management team.  
 
Undoubtedly, the human resources (both in availability and in quality of interactive communication) 
are key and more essential than structures in itself in achieving targets of antimicrobial stewardship. 
Core activities in antimicrobial stewardship programs are education, audit and feedback, surveillance 
of antimicrobial use and surveillance of microbial resistance and most of these areas require excellent 
communication skills. 
 
2.4.  Availability of guidelines 
The availability of guidelines for empirical and documented infections and surgical prophylaxis is 
essential to support health collaborators in treating infectious diseases (4, Chapter 2-3-6). Although the 
availability of printed national guidelines (such as the BAPCOC guide for ambulatory use of 
antimicrobials and the Belgian-Luxembourg edition of the Sanford guide on Antimicrobial Therapy), 
antibiotic management teams spend a lot of time in developing local guidelines. It should be 
questioned to what degree this is efficient use of resources and whether standardized consensus 
approaches could not be generalized and where a balance between general and local guidelines should 
lie. Our third study showed that practices for extended and continuous antibiotic administration can 
differ substantially between hospitals in Belgium (Chapter 4). Certainly in this issue more 
standardisation is strongly recommended.   
    
This objective of a set of national guidelines should ideally take the form of an electronically available 
and updatable tool. Such a tool should be user friendly to physicians and clinical pharmacists with no 
infectious disease background. BAPCOC and the Belgian Society for Infectiology and Clinical 
Microbiology have agreed to be key players and partners to develop and provide such guidelines. Also 
clinical pharmacists should be strongly involved in this process especially when pharmaceutical 
aspects are important such as in the administration of extended and continuous antibiotics (Chapter 4) 
and in screening for interactions (drug-drug, drug-food) etc.  
 
The availability of centrally published practical guidelines should give the opportunity to the 
institution-based Belgian antibiotic management teams to focus more on the implementation of the 
guidelines and surveillance of antibiotic use than on the local development of guidelines themselves.    
 
The guidelines of the Dutch Working Party on Antibiotic Policy  are an example of  guidelines for the 
use of antibiotics in hospitalized adult patients that have been developed at a national level and are 
available online (5)  
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2.5 Implementation of guidelines        
The second step is to implement those guidelines in daily practice.  First it is essential that the 
guidelines are easily accessible at the moment the physician prescribes antimicrobial therapies. 
 
In this thesis we used persuasive interventions to implement guidelines. The delivery of printed 
educational materials, which is also a passive dissemination strategy, slightly improves healthcare 
professionals’ practice (4). The publication of a drug letter in our fifth study showed a limited impact 
on the ratio of intravenous versus total fluoroquinolone consumption (Chapter 6).  Also the impact of 
educational meetings which we used in two studies was limited when we measured the short term 
impact or even absent when we studied the long term impact (Chapter 4 and 5). This confirms earlier 
literature on the limited impact of these types of interventions and warrants an investment into proven 
effective strategies, such as bedside outreaching activities (4). 
 
This “online” educational outreach however is the most labour-intensive persuasive intervention 
within an ASP. It combines individual patient assessment, leading to a practical recommendation, 
supported by motivation,  to the prescriber during patient therapy (Chapter 6 and 7). Considering that 
the median antibiotic consumption in Belgian hospitals is 548 DDD per 1000 patient days, it is clear 
that it is time- consuming for ASP to identify all patients in whom antimicrobial treatment is 
inappropriate. It is not feasible that the whole bulk of these prescriptions can be reviewed with the 
limited manpower involved in AMT. Hence it needs to be assessed to what extent targeted 
interventions, either through limitation of the scope or restriction in time, would prove to be 
sufficiently effective to reach preset targets of improvement in relevant antimicrobial prescription 
indicators and have lasting teaching effects. 
 
In our fifth study the proactive role of the clinical pharmacist in identifying possible IV-PO switches 
and in advising physicians could be clearly demonstrated (Chapter 6). This allowed us to empower 
clinical pharmacists to change antimicrobial prescriptions within a predefined and agreed institution-
specific protocol, validated by the Antibiotic Management Team and the Medical Pharmaceutical 
Committee. Active participation of the clinical pharmacist in this process could be further supported 
by the elaboration of a legal framework defining the different validated activities of the clinical 
pharmacists. Such a framework, which is currently lacking, could settle the issue of liability in case of 
mistake and result in more legal responsibilities for clinical pharmacists in advising physicians and 
nurses. This framework could be similar to the legal description of autonomous or delegated nurse 
activities in Belgium (6).  Both a general legal framework and internal institution specific protocols 
are especially appropriate for interventions such as IV-PO switch, dose adjustments based on the 
kidney functions and plasma concentrations levels.  
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The treatment of infectious diseases is already a significant part of the 3-year curriculum of hospital 
pharmacists in Belgium. In the future, a subspecialisation in infectious diseases for clinical 
pharmacists could be considered resulting in an infectious disease residency program comparable with 
that in the USA where residency graduates are equipped to participate as integral members of 
interdisciplinary teams caring for patients with infectious diseases, assuming responsibility for their 
pharmaceutical care (7). However laudable, this official recognition could be difficult to achieve in 
Belgium, taking into account that even clinical infectious diseases and medical microbiology have not 
been officially recognized as competencies or specialties in Belgium, in spite of an obvious need.           
  
In our sixth study we described the activities of a local multidisciplinary infectious diseases team 
(MIT) (Chapter 7). In this MIT, ID consultation and the prescription of different types of antimicrobial 
agents is reviewed on a daily basis. A number of key antimicrobial classes (antifungals, carbapenems, 
piperacillin/tazobactam) are reviewed only once a week according the available time and resources. 
Each advice is motivated and hence rendered transparent and obvious to patient care. From this 
perspective a regular teaching effect can be assumed through this type of consultation, as antimicrobial 
prescriptions can be influenced. Certain aspects, such as screening of items such as IV/oral switch or 
of insufficient dosing of antimicrobials, such as glycopeptides, through screening of therapeutic drug 
monitoring (TDM) results could be facilitated through increased IT support. With this MIT structure 
we adapt 3 of the top ten indicators considered as key elements of an antimicrobial stewardship 
programme (Chapter 3). First of all we provide bedside expert consultant advice regarding 
antimicrobials on request, which is rendered available on the same day. Secondly we perform on daily 
basis a clinical audit of prescribers' compliance with local clinical guidelines. Thirdly we educate the 
prescribers by a personalized interactive method. Other items within the top ten listing of indicators 
are more generic and are developed within the AMT, of which the MIT somewhat serves as an 
operational arm. 
 
More efficient identification of inappropriate antimicrobials is possible through electronic alerts which 
are an example of a structural intervention. Electronic alerts can notify the ASP members or directly 
the treating physician. Potential electronic alerts include: drug dosing (according kidney function, 
weight, drug plasma concentrations), dosing regimens (extended and continuous infusions), choice of 
antibiotic according antibiogram (de-escalation,…) duration of therapy, interactions (drug-drug, drug 
food), choice of administration route (IV-PO switch), allergy status, positive hemoculture 
(Candidemia, Staphylococcus aureus bacteraemia), etc. One of the barriers to implement such 
electronic alerts consists of potential “alert fatigue”. Nevertheless in the future it can be a useful tool 
for ASP to identify targets for intervention or education and can possibly also provide prescribers with 
reports and evaluations of their prescribing habits (8,9).  
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In this thesis no restrictive interventions such as the implementation of a compulsory order form, were 
assessed. Nevertheless, such compulsory order forms, in which the prescriber has to complete a 
number of steps with essential clinical information, such as diagnosis and expected pathogens, has 
proven effectiveness in improving the adequacy of empiric antimicrobial choices and may be part of 
an antimicrobial stewardship “navigator” integrated in an electronic medical record (8 - 14).  
 
2.6. Barriers to implement guidelines 
It is important to recognize that implementing guidelines is a complex process requiring skills beyond 
those that can be offered by the health professionals (15).    
A recent study suggested that ASPs may have more success in implementing their stewardship 
strategies if they focus on promoting a non-confrontational image (i.e., not a policing image), and in a 
face-to-face manner when possible (16).  
An Australian study showed following barriers: gaps in antimicrobial prescribing knowledge 
(especially among interns), a lack of awareness about which antimicrobials were restricted and a 
reliance on senior colleagues to make antimicrobial prescribing decisions. (17). This study confirms 
that behaviour of physicians should be shaped starting at the undergraduate training and running 
through their entire professional training as juniors start to copy the behaviour of their supervisors 
within the first weeks in the hospital (18). Especially on the moment when new (trainee) physicians 
start in the hospital, clinical pharmacists should be available to make them aware of the existing 
guidelines and protocols.     
 
Although medical microbiology and infectious diseases specialties are dedicated to the treatment of 
infections, in reality health care professionals across all specialties are required to be able to promptly 
diagnose and treat infections. Incentives to change behaviours in prescribing may be to acknowledge 
local hierarchies and include opinion leaders within different medical specialties in setting up policies 
and guidelines in prescribing.  
 
In general, physicians also remain concerned about the reliability of an ASP recommendation 
especially when the patient had neither been seen nor examined by the ASP team stressing the 
importance of physical outreaching. This could probably explain partly the relative high acceptance 
rate of the recommendations proposed by the multidisciplinary infection team like mentioned in our 
sixth study (Chapter 7).          
 
2.7. Outcome of ASP interventions 
Measuring the relationship of ASPs interventions on antimicrobial resistance is complex. The time lag 
and relationship of changes in hospital antibiotic use to resistance patterns are inconsistent and not 
suited to reliably evaluate ASP interventions. There are, however, other markers of ASP success. 
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Measurement of antimicrobial use along with other patient-focused outcomes is critical to demonstrate 
impact of ASPs and should be considered (8,9). 
 
Defining quantitative targets for evaluating antibiotic use in hospitals is difficult. The Scientific 
Institute of Public Health provides consumption data which allow to benchmark the Belgian hospitals. 
Interpretation of these data is not easy. More specific data are available on a pathology level including 
the severity index. But due the significant delay these data provide no clinical relevant data for the 
AMTs to take action. 
 
Recent data published by the European Centre for Disease Prevention and Control (ECDC) show that 
the consumption of antibiotics and antimycotics in the Belgian community setting is high compared to 
other European countries (19). Actions need to be taken as reduction in ambulatory consumption can 
decrease resistance in community population and reduce import in the hospital setting. A recent study 
from the Belgian Scientific Institute of Public Health demonstrated the existence of a risk for acquired 
antimicrobial resistance in major bacterial pathogens, directly related to the consumption of 
antimicrobial agents at the individual patient level. When prescribing these agents, clinicians should 
consider that antimicrobial consumption also inherently bears an individual risk for their own patient, 
besides the resistance induction at the population level that has been known for a long time (20).     
 
Actually the health care system evolves, at least partially, from a pay for service system to a pay for 
quality system. In order to implement this, quality indicators are necessary. In Chapter 2 and 3 we 
demonstrated a methodology to test the feasibility of implementing structure indicators and one 
process indicator in order to evaluate antimicrobial stewardship programs. In 2013, the BAPCOC 
organized a non- mandatory audit of 3 process indicators in antimicrobial prophylaxis in surgery. In 
the future other subjects for audit could be urinary tract infections, sepsis, CAP, IV PO switch, 
Staphylococcus aureus bacteremia. For the three last topics, indicators were developed and validated 
in the ABS international study (Chapter 2). Making these audits mandatory and defining targets could 
be a next step. We must however take into account that the performance level can vary by 
hospital according to previous or ongoing local quality intervention programmes. This was also shown 
in our second study where performance on IV-PO switch was higher for those hospitals with local 
improvement programs on this topic (Chapter 2).  
 
The point prevalence study performed by the Scottish Antimicrobial Prescribing Group (SAPG) 
showed that the regular review of national prescribing indicators can drive improvement in quality of 
antibiotic use in key clinical areas (21). This intervention has been included in a recently developed 
policy statement of the Belgian Workgroup “Hospital Medicine” of the BAPCOC (22). A target of 
90% is set for the indicator that evaluates the traceability of an indication for antimicrobials in the 
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medical file of an individual patient. Recent meta-analyses indeed suggested that the effectiveness of 
audit and feedback is enhanced by setting a target or behavioural goal (23,24). For sustainable clinical 
engagement it is important that national prescribing indicators are seen as drivers for improving 
clinical outcomes as opposed to being viewed as either punitive or restrictive measures (18). This is 
important as the experience with the TFAD indicator in the USA has led to an irrational use of 
antimicrobials caused by the pressure on prescribers to perform well according hospital accreditation 
programs linked to financial punishment.   
 
Feedback may be more effective when baseline performance is low, the source is a supervisor or 
colleague, it is provided more than once, it is delivered in both verbal and written formats, and when it 
includes both explicit targets and an action plan (25). 
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3. Future research  
Future research on the promotion and implementation of antimicrobial stewardship programs should 
focus on the evaluation of best practices to implement interventions and outcome research.  
 
In view of the wide range of practices aimed at PK/PD optimization, the optimal choices of achieving 
this through standardization should be further assessed (indications, resistance levels of causative 
pathogens, modalities of drug administration). Clear guidelines for appropriate administration (doses, 
schedules, stability, and incompatibility) to allow safe and easy implementation by physicians, nurses 
and clinical pharmacists are here necessary. 
 
Considering the risk of acquiring nosocomial infections and the likely increase of patients requiring 
long term antimicrobial therapy for infections with multidrug resistant microorganisms without oral 
alternatives, the active development of an outpatient parenteral antimicrobial therapy program (OPAT) 
should be considered. Although already developed under different formats in the USA and the UK, the 
practice with OPAT in Belgium remains limited and hampered by the absence of a framework for 
transmural distribution and follow-up. This should be ideally organized through the hospital 
pharmacy, in coordination with an ID service. Research on this topic should focus on the development 
of practical guidelines in collaboration with the infectious disease physician, hospital pharmacist, 
social worker, general practitioner, public pharmacist and home nurse. Clinical outcome and adverse 
events should be studied. Collaboration with Belgian government is necessary to create a legal 
framework.            
 
It is necessary to understand the impact of antimicrobial stewardship interventions on resistance rates 
in hospitals but also in community. We should evaluate which interventions are most effective and 
cost-efficient to implement clinical guidelines in daily practice with focus on the treatment of highly 
prevalent infections (CAP, urinary tract infections,..), infections resulting in a high mortality figures 
(Staphylococcus aureus bacteremia, sepsis, candidemia,..) and surgical prophylaxis. In order to 
evaluate this, evidence based indicators should be further developed and validated by multidisciplinary 
panels using Delphi technique methodologies. These indicators should be oriented towards 
pharmacotherapy but also on diagnostic approaches (e.g. in pneumonia timely oxygenation, obtaining 
of blood and sputum samples).  
 
Indicators can be used on different levels. Local AMT’s can incorporate them in a checklist to review 
the appropriateness of antimicrobial treatments on a frequent basis. This could be used by clinical 
pharmacists to identify inappropriate therapies. Furthermore they can be incorporated in information 
technology programs to alert prescribers or AMT’s when there is an opportunity to optimize therapies. 
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Here the implementation of structural interventions like clinical decision support tools and mobile 
health systems should be studied.  
 
Finally, guidelines get poorly translated into real practice. Hence, the impact of inclusion of behavior 
change theory into the development and implementation of interventions should be studied, as this 
may prove crucial in order to achieve true change and improvement.   
 
4. Policy recommendations 
International and local authorities have a high responsibility in dealing with the problem of 
antimicrobial resistance threats. We list in this chapter policy recommendations based on the findings 
of this thesis oriented towards Belgian authorities. 
 
1. Guidelines for antimicrobial therapy 
The Belgian government should provide structural funding for the development and maintenance of 
national guidelines for empirical, documented and prophylactic antimicrobial therapy in a hospital 
setting. 
Not only data on indications and dosages (inclusive in case of reduced kidney function) should be 
provided but also practical information on the administration (e.g. continuous infusion, 
incompatibility, stability,..) to allow safe and easy use  by physicians, nurses and clinical pharmacists.  
This information should be made electronically available to all health care workers with the possibility 
to incorporate them in the local CPOE systems. All key players like the BVIKM and VZA should be 
involved. 
These guidelines should be used in the basic and graduated education of physicians and pharmacists to 
make them familiar with this format in preparation of their professional career.  
 
2. Pay for service system 
As the health care system will evolve from a pay for service system to a pay for quality system the 
government should progress in monitoring and steering the quality of antimicrobial stewardship 
programs based on predefined indicators.  Here we should move from the “soft” structure indicators to 
the process and outcome indicators which could be measured by performing mandatory audits and 
defined targets. 
The government should provide consumption data on a pathology level which allows benchmarking 
the Belgian hospitals.  
 
Not only the hospital setting but also the ambulatory setting should evolve in the direction of a pay for 
service system in order to have impact on antimicrobial prescribing by general practioners.   
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3. Information technology 
Information technology has potential for facilitating antimicrobial stewardship efforts. Here the 
government should support the cooperation between hospitals in the development/purchasing of new 
information technology systems as an encompassing project.   
 
4. Awareness campaigns about the threat on antimicrobial resistance 
Not only healthcare workers but all Belgian civilians should be aware of the threat on antimicrobial 
resistance. We need here the same attitude as towards the relation between climate changing and 
pollution. Here education should start beginning at the primary school. 
 
5. Legal framework for healthcare workers.   
As clinical pharmacists increasingly participate in clinical advice towards physicians and nurses a 
legal framework defining the different validated activities of the clinical pharmacists should be 
developed. The recognition of the function of clinical infectiology in the hospital organisation is 
urgently needed. 
 
6. OPAT 
Belgian government should create a framework for ambulatory parenteral antimicrobial treatment. All 
key players from the hospital and ambulatory setting should been involved 
 
5. Conclusion 
Antimicrobial stewardship programs can play a major role in the prudent use of antimicrobials in an 
environment with increasing endemicity of resistance. There is a clear need to better identify the most 
effective strategies to be developed by antimicrobial management teams and the mechanisms that 
underlie barriers to implementation. Antimicrobial stewardship is likely to be most effective through a 
collaborative effort, evolving away from a stand-alone function, to a part of an institution’s quality- 
and safety-enhancing infrastructure (26). It is evident that a successful program requires a structured 
and systematic interaction of key players within the hospital, including clinical pharmacy, clinical 
infectiology, medical microbiology and hospital hygiene, not only in formal meetings but foremost in 
daily practice around the patient as well as a mandate from the institution itself. These activities need 
to be measurable through appropriate and approved indicators. 
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SUMMARY 
Health care is challenged by the emergence of antibiotic resistance and the slow pipeline of new 
antibiotics, especially against Gram negative multi-resistant bacteria. The most important cause of 
emergence and spread of antimicrobial resistance has been a massive overuse of antibiotics worldwide 
across all ecosystems over the past decades, including humans, animals, aquaculture, and agriculture. 
Antimicrobial resistance may lead to more difficult to treat infections and may hence be associated 
with increased patient mortality, longer hospital stays, and increased healthcare costs. Up to 30% of 
antimicrobial regimens in hospitals are considered inappropriate. An effective approach to improving 
antimicrobial use in hospitals is an organised antimicrobial stewardship program. 
 
In this thesis we tried to develop and validate quality indicators in order to monitor antimicrobial 
stewardship programs in a hospital setting. Furthermore we evaluated key components of an 
antimicrobial stewardship program to optimize antimicrobial prescribing. 
 
With a multidisciplinary panel from four European countries we developed 57 structure indicators 
from which ten indicators were identified as a minimal set of key indicators. A validation survey in 
eleven European hospitals showed a significant heterogeneity with regard to their scoring for 
structural components of effective antibiotic stewardship. We concluded that potential structure 
indicators examined in this study, with focus on the top-ten indicators, could be used for regular 
assessment of the extent and strength of hospital antimicrobial stewardship programs.  
 
The feasibility and clinical relevance of measuring a process indicator for appropriate iv use of highly 
bioavailable antimicrobial drugs, allowing early IV to oral switch, was evaluated revealing a 
substantial heterogeneity of the performance gap. Absence of an iv-to-po switch programme was 
associated with more inappropriate prescribing. The results of this study indicated that the iv-to-po 
quality indicator is widely applicable and could be a tool to evaluate compliance with iv-to-po switch 
guidelines. 
 
Optimizing antibiotic dosing regimens is a core activity within an antimicrobial stewardship program. 
Extended and continuous infusions with betalactam antibiotics have been suggested as a means of 
pharmacokinetic and pharmacodynamic optimisation of antimicrobial therapy. A survey was 
undertaken to investigate the recommendations on extended and continuous infusions of ceftazidime, 
cefepime,  piperacillin–tazobactam, meropenem and vancomycin by the local antibiotic management 
teams (AMTs) in Belgian acute hospitals. This survey showed that extended and continuous infusions 
are widely implemented in Belgian hospitals but revealed significant variation in the recommended 
dosing regimens. 
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Two interventional studies were performed to optimize antimicrobial prescribing. These focused on 
appropriate timing of the initiation of an antimicrobial treatment for presumed infections in the 
emergency ward and on parenteral to oral conversion of fluoroquinolone antibiotics. We showed that 
the implementation of merely persuasive interventions such as hospital-wide publication of guidelines 
in the local drug letter and educational interactive sessions towards nurses and physicians only resulted 
in limited improvement. However, a pro-active intervention by a clinical pharmacist to stimulate 
parenteral to oral conversion resulted in a significant reduction of the duration of the intravenous 
treatment, as well as in treatment cost. 
 
Finally we assessed the functioning of a multidisciplinary infectious diseases team (MIT), which is an 
example of educational outreach intervention. The MIT formulated a daily average of 5 interventions 
for non-critically ill adult patients in a teaching hospital. Following bedside assessment by junior staff, 
diagnostic and therapeutic recommendations were communicated by phone and by notes towards 
prescribers in the electronic patient file resulting in high acceptance rates, in particular for therapeutic 
recommendations.  
 
In general this thesis provides indicators to the AMT’s to evaluate their antimicrobial stewardship 
activities. Proactive interventions on an individual patient level are needed to optimize antimicrobial 
prescribing.    
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SAMENVATTTING 
Antibiotica-resistentie en de beperkte introductie van nieuwe antibiotica, vooral tegen Gram- 
negatieve multiresistente bacteriën, vormen een bedreiging voor de gezondheidszorg. De belangrijkste 
oorzaak van ontstaan en verspreiding van antibiotica-resistentie ligt in het overgebruik van antibiotica 
zowel in de humane-, veterinaire- als landbouwsector. Antibiotica resistentie geeft aanleiding tot 
potentieel moeilijker te behandelen infecties en kan daarom gepaard gaan met een verhoogde 
mortaliteit, langere hospitalisatie duur voor de patiënt en toegenomen kosten voor de gezondheidszorg. 
Er wordt geschat dat meer dan 30% van het antibiotica gebruik in ziekenhuizen als onoordeelkundig 
ingeschat kan worden. ‘Antimicrobial stewardship’ programma’s worden als een effectief instrument 
gezien om het antibiotica gebruik in ziekenhuizen te verbeteren. 
 
In dit proefschrift hebben we kwaliteitsindicatoren ontwikkeld en gevalideerd die toelaten 
antimicrobial stewardship programma’s te monitoren in het ziekenhuis. Verder hebben we elementen 
van een antimicrobial stewardship programma geëvalueerd met het oog op een optimalisatie van het 
antibioticagebruik.  
 
In een eerste studie werden met een multidisciplinair panel afkomstig uit 4 Europese landen 57 
structuur indicatoren ontwikkeld. Hiervan werden er 10 geïdentificeerd als een minimale set van 
indicatoren. Een validatie studie in 11 Europese ziekenhuizen toonde aan dat deze indicatoren kunnen 
worden gebruikt om de performantie van antimicrobial stewardship programma’s in ziekenhuizen te 
evalueren. 
      
In een tweede studie werd in 4 ziekenhuizen een proces indicator getest die toelaat de mogelijkheid tot 
omschakeling van intraveneuze naar perorale antimicrobiële geneesmiddelen met een hoge 
biologische beschikbaarheid te evalueren. De afwezigheid van IV-PO switch richtlijnen ging gepaard 
met minder performant voorschrijven. Deze studie toonde aan dat ziekenhuizen deze indicator kunnen 
gebruiken om de compliantie aan IV-PO richtlijnen te evalueren. . 
 
Het optimaliseren van antibiotica doseringsschema’s is een onderdeel van een antimicrobial 
stewardship programma. Het toedienen van beta-lactam antibiotica in verlengde of continue infusie is 
gebaseerd op farmacokinetische en farmacodynamische principes om antimicrobiële therapieën te 
optimaliseren. Met een vragenlijst gericht aan de Antibioticabeleidsgroepen van de Belgische 
ziekenhuizen werd gepeild naar de doseringschema’s voor ceftazidim, cefepim, piperacillin–
tazobactam, meropenem en vancomycine. We konden aantonen dat verlengde en continue schema’s in 
belangrijke mate toegepast worden maar met uitgesproken variatie in de lokaal aanbevolen schema’s. 
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Twee interventionele studies werden uitgevoerd. De eerste bestudeerde het tijdig opstarten van 
antibiotica bij vermoeden van infectie op de afdeling voor spoedgevallen; de tweede de optimalisatie 
van de overschakeling van intraveneuze naar perorale fluorochinolones. Het louter verspreiden van 
richtlijnen en organiseren van interactieve vorming gericht aan verpleegkundigen en artsen resulteerde 
in een slechts beperkte verbetering. In de tweede studie werd evenwel een duidelijk positief resultaat 
gedocumenteerd: een proactieve interventie door een klinisch apotheker resulteerde in een significante 
reductie van de duur en kost van intraveneuze fluorochinolone antibiotica. 
 
Tenslotte werd het functioneren van een multidisciplinair infectieteam als typisch voorbeeld van een 
“outreach” interventie geëvalueerd. In de bestudeerde periode werden dagelijks gemiddeld 5 
aanbevelingen voor volwassen patiënten op niet kritieke afdelingen in een tertiair ziekenhuis 
geformuleerd. Diagnostische en therapeutische aanbevelingen werden telefonisch en elektronisch via 
het patiëntendossier gecommuniceerd naar de voorschrijvers. Er werd een hoge aanvaardingsgraad 
gedocumenteerd, in het bijzonder voor therapieadviezen. 
 
Samengevat worden met deze thesis indicatoren ter beschikking gesteld voor het evalueren van 
antimicrobial stewardship programma’s in ziekenhuizen. Proactieve interventies gericht op de 
individuele patiënt zijn noodzakelijk om het antibioticagebruik te optimaliseren.  
   
139 
 
CURRICULUM VITAE  
Name     Franky M.A. Buyle 
Date and place to birth   April 27th 1973, Wetteren 
Married to    Ruth Piers 
Children    Matteo, Noor, Arthur 
Contact     franky.buyle@uzgent.be 
 
Education 
• Latin-Sciences, St.-Franciscus College, Wetteren, 1991 
• Pharmaceutical Sciences, Ghent University, 1996 
• Specialisation hospital pharmacy, Ghent University, 1997 
 
Certificates 
• Aspirant Management Development Program, Ghent University Hospital, 2011-2012 
• Basics of pharmacokinetics and pharmacodynamics of anti-infective agents. ICAAC 2009, 
San Francisco, USA 
• Summer School: Clinical pharmacology. 2008, Ghent 
• Management for hospital pharmacists. Vlerick course. 2006-2007 
• 2 week trainee-ship Clinical pharmacy, Hartford Hospital, Hartford, Connecticut, VS (March 
2006) 
• ESCMID post-graduate education course "Measuring, auditing and improving antimicrobial 
prescribing" 2004, Czech Republic  
• BAPCOC Opleiding Antibioticabeleid-deskundige Truncus communis 2002-2003    
 
Present post 
• 1997- today: Hospital pharmacist, Ghent University Hospital, De Pintelaan 185, 9000,Ghent 
 
Awards 
• Amgen Scientific award 2004 for hospital pharmacists”: poster “Buyle F, Vogelaers D, 
Peleman R, Schelstraete P, Verschraegen G, Claeys G, Van Hooreweghe M, Robays H. A 
multidisciplinary prospective interventional program to enhance appropriate prescribing of 
restricted anti-infectives in the Ghent University hospital”. (March 2004, Middelkerke)  
• Amgen Scientific award 2012 for hospital pharmacists”: poster “Buyle F, Delobel C., Van 
Marcke A., Berkvens R., Verduyn A., Vermeir I., Robays H. Development and 
implementation of an e-learning module "Medical calculations for healthcare workers" 
(February 2012 ,Schelle)  
140 
 
 
Scientific membership 
• Flemish Association of Hospital Pharmacists (board member –secretary) 
• Belgian Association of Hospital Pharmacists 
• European Association of  Hospital Pharmacists 
• European Society of Clinical Pharmacy 
 
Internal and external services 
• Member VZA “Antibiotic Workgroup” (2014-)  
• Member Expert Committtee “The Transatlantic Task Force on Antimicrobial Resistance 
(TATFAR)” Development of structure and process indicators of antimicrobial stewardship 
programs (2014) 
• Review board Farmaceutisch Tijdschrift voor België (2013-) 
• Member Scientific Committee ESCP International Workshop ‘Patients, Infections and the 
Clinical Pharmacist’workshop”  30/05/2012 -1/06/2012; Leuven Belgium 
• Member Multidisciplinary Infection Team (MIT), Ghent University Hospital (2011-)  
• Member Belgian Antibiotic Policy Coordinating Committee workgroup hospital medicine 
(2006-) 
• Board member Vlaamse Vereniging Ziekenhuisapothekers (VZA) (2005-) 
• Secretary Antibiotic Policy Group Ghent University Hospital (2002-) 
 
Publications 
• Bauters T, Buyle F, Blot S, Robays H, Vogelaers D, Van Landuyt K, Vanhove W, Claeys G. 
Prophylactic use of levofloxacin during medicinal leech therapy. Int J Clin Pharm. 
2014;36:995-999 
• Buyle FM, Wallaert M, Beck N, Boelens J, Callens S, Claeys G, Deryckere S, Haegeman E, 
Leroux-Roels I, Sermijn E, Steel E, Robays H, Vandekerckhove L, Vermis K, Vogelaers D. 
Implementation of a multidisciplinary infectious diseases team in a tertiary hospital within an 
Antimicrobial Stewardship Program. Acta Clin Belg. 2014;69:320-6 
• Buyle FM, Metz-Gercek S, Mechtler R, Kern WV, Robays H, Vogelaers D, Struelens MJ; on 
behalf of members of the Antibiotic Strategy International (ABS) Quality Indicators Team. 
Development and validation of potential structure indicators for evaluating antimicrobial 
stewardship programmes in European hospitals. Eur J Clin Microbiol Infect Dis. 2013 Mar 23.  
• Buyle FM, Decruyenaere J, De Waele J, Tulkens PM, Van Audenrode T, Depuydt P, Claeys 
G, Robays H, Vogelaers D. A survey of beta-lactam antibiotics and vancomycin dosing 
141 
 
strategies in intensive care units and general wards in Belgian hospitals. Eur J Clin Microbiol 
Infect Dis. 2013;32:763-8.  
• Buyle FM , Metz-Gercek S, Mechtler R, Kern W V, Robays H, Vogelaers D , Struelens MJ. 
Prospective multicentre feasibility study of a quality of care indicator for intravenous to oral 
switch therapy with highly bioavailable antibiotics. JAC 2012;67: 2043-2046 
• Claus B, Buyle F, Robays H, Vogelaers D. Importance of infusion volume and pump 
characteristics in extended administration of ß-lactam antibiotics. Antimicrob Agents 
Chemother. 2010;54:4950. Epub 2010 Sep 7. 
• Buyle F,  Vogelaers D, Peleman R, Maele G,  Robays H. Implementation of guidelines for 
sequential therapy with fluoroquinolones in a Belgian hospital. Pharm World Sci. 
2010;32:404-410   
• Buyle F, Robays H. Evaluation of Belgian hospital drug formularies based on quality 
indicators. EJHP 2009;15:32-37 
• Reynvoet E, Vandijck DM, Blot SI, Dhondt AW, De Waele JJ, Claus S, Buyle FM, Vanholder 
RC, Hoste EA. Epidemiology of infection in critically ill patients with acute renal failure. Crit 
Care Med. 2009;37:2203-9. 
• Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, Oeyen S, 
Colpaert KE, Peleman RP, Blot SI, Decruyenaere JM.Daily cost of antimicrobial therapy in 
patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection.Int J 
Antimicrob Agents. 2008;31:161-5 
• Vandijck DM, Oeyen SG, Buyle FM, Claus BO, Blot SI, Decruyenaere JM. Hyperglycaemia 
upon onset of ICU-acquired bloodstream infection is associated with adverse outcome in a 
mixed ICU population.Anaesth Intensive Care. 2008;36:25-9 
• Vandijck DM, Depaemelaere M, Labeau SO, Depuydt PO, Annemans L, Buyle FM, Oeyen S, 
Colpaert KE, Peleman RP, Blot SI, Decruyenaere JM.Daily cost of antimicrobial therapy in 
patients with Intensive Care Unit-acquired, laboratory-confirmed bloodstream infection.Int J 
Antimicrob Agents. 2008;31:161-5 
• Bauters TG, Buyle FM, Verschraegen G, Vermis K, Vogelaers D, Claeys G, Robays 
H.Infection risk related to the use of medicinal leeches.Pharm World Sci. 2007;29:122-5.  
• Blot S, Janssens R, Claeys G, Hoste E, Buyle F, De Waele JJ, Peleman R, Vogelaers D, 
Vandewoude K.Effect of fluconazole consumption on long-term trends in candidal ecology.J 
Antimicrob Chemother. 2006;58:474-7 
• Bauters TG, Nguyen BT, Buyle F, Schelstraete P, De Cock P, De Jaeger A, Verrijckt A, 
Robays H. Clinical pharmacy and pediatrics: why focus on antibiotics?Pharm World Sci. 
2006;28:3-5 
142 
 
• Bauters TG, Buyle FM, Peleman R, Robays H.Antifungal drugs and rational use of 
antifungals in treating invasive aspergillosis: the role of the hospital pharmacist.Pharm World 
Sci. 2005;27:31-4 
 
Poster presentations 
• F. Buyle , A. Capiau, J. De Keulenaer, A. Somers, J. Boelens,  S. Callens, D. Vogelaers, S. 
Commeyne. Evaluation of the treatment of Candidemia in the Ghent University hospital .  
Yearly symposium Flemish Association hospital pharmacists. February 3th 2015 Schelle, 
België.  
• Boelens J, Leroux-Roels I, Callens S, Buyle F, Vogelaers D on behalf of the Multidisciplinary 
Infection Team of the Ghent University Hospital. Results of a stewardship program for the 
management of S. aureus bacteremia. 24ste ECCMID 2014, Barcelona, Spanje, 2014. 
• M. Wallaert, F. Buyle, D. Vogelaers, S. Deryckere, K. Vermis, E. Haegeman, N. Beck, L. 
Vandekerckhove, S. Callens, E. Sermijn, F. Moerman, G. Claeys, I. Leroux-Roels, J. Boelens, 
A. Somers, H. Robays. Evaluation of the recommendations of an multidisciplinary infection 
team in the Ghent University hospital. Yearly symposium Flemish Association hospital 
pharmacists. February 5th 2013, Belgium 
• Buyle F, Vogelaers D, Claeys G, Robays H. Evaluation of the treatment of Staphylococcus 
aureus bacteremia based on three quality indicators in a University Hospital’. ESCP 
International Workshop ‘Patients, Infections and the Clinical Pharmacist’workshop”  
30/05/2012 -1/06/2012; Leuven België 
• Buyle F, Delobel C., Van Marcke A., Berkvens R., Verduyn A., Vermeir I., Robays H. 
Ontwikkeling en implementatie van een e-learning module "Medisch Rekenen" voor 
gezondheidsmedewerkers in het UZ Gent. Dag van de ziekenhuisapotheker 7 februari 2012, 
Schelle   
• Buyle F, Delobel C., Van Marcke A., Berkvens R., Verduyn A., Vermeir I., Robays H. 
Ontwikkeling en implementatie van een e-learning module "Medisch Rekenen" voor 
gezondheidsmedewerkers in het UZ Gent. 5de Symposium Kwaliteit en patiëntveiligheid. 
Brussel 28 november 2011  
• F. Buyle, D. Vogelaers, G. Claeys, J. De Jonghe, H. Robays. Staphylococcus aureus 
bacteriëmie (SAB): evaluatie behandeling en ontwikkeling richtlijnen. Dag van de 
ziekenhuisapotheker. 22 februari 2011   
• F. Buyle, M. Besset, J. Decruyenaere, H. Robays, J. De Waele. Evaluation of the 
pharmacokinetic effect of the interaction between valproate and meropenem in critically ill 
patients. EAHP March 23 2010, Nice, France  
143 
 
• F. Buyle, S. Metz-Gercek,  M.  Struelens and the ABS team. Feasibility Testing of an 
Indicator  for Intravenous to Oral Switch with Highly Bio-available Antibiotics. ICAAC 
September 15th 2009, San Francisco, USA (oral presentation)  
• W. Kern, S. Metz-Gercek, F. Buyle, V. Jindrak, A. Lechner, H. Mittermayer, H. Seifert, A. 
Wechsler-Fördös, C. Wenisch, T. Zupanc-Leijko, R. Mechtler, M. Struelens and the ABS QI 
Team .Staphylococcus aureus bloodstream infection management indicators as quality 
indicators for hospital antibiotic stewardship: feasibility study by the ABS International 
Quality Indicators (ABS QI) team. ECCMID meeting, Helsinki from  May 2009 
• M. Struelens, S. Metz-Gercek, R. Mechtler, F. Buyle, A. Lechner, H. Mittermayer, F. 
Allerberger, W. Kern and the ABS QI Team & Feasibility Study Participants. Validation of 
quality indicators for hospital antibiotic use by the ABS International – Quality Indicators (QI) 
Project ECCMID meeting, Helsinki from  May 2009 
• F. Buyle, T. Verdonck, D. Vogelaers, J. Decruyenaere, L. Vandekerckhove, T. Fiers, A. 
Dhondt,  H. Robays. Evaluation of antibiotic dosages in patients with a reduced kidney 
function. ESCP November 2008. Dubrovnik, Croatia 
• Deryckere S, Buyle F, Van Hooreweghe M, Robays H. Maatregelen ter promotie van oraal 
gebruik van paracetamol in UZ Gent. Annual meeting Flemish Hospital Pharmacists, Gent, 
Ghent March 1st2008 
• F. Buyle, S. Deryckere, A. Clerens, D. Vogelaers, J. De Waele, J. Decruyenaere, L. 
Vandekerckhove, T. Fiers,  H. Robays. Evaluation of  administration of glycopeptide 
antibiotics. Annual meeting Flemish Hospital Pharmacists. Ghent March 1st2008 
• F. Buyle, S. Deryckere, A. Clerens, D. Vogelaers, J. De Waele, J. Decruyenaere, L. 
Vandekerckhove, T. Fiers,  H. Robays. Guideline and algoritm for administration and 
monitoring of glycopeptide antibiotics. Annual meeting Flemish Hospital Pharmacists. Ghent  
March 1st 2008 
• Vandijck DM, Blot SI, Depaemelaere M, Oeyen S, Colpaert KE, Annemans L, Vandewoude 
KH, Peleman RP, Buyle FM, Labeau SO, Decruyenaere JM. Candidemia in the Critically Ill: 
An Economic Analysis of Daily Antimicrobial Therapy Related Costs. 20th Annual Congress 
of the European Society of Intensive Care Medicine (ESICM), Berlin, Sept 24-27, 2007. 
Intensive Care Med 2007; 33, S159: 616. 
• Vandijck DM, Blot SI, Depaemelaere M, Oeyen S, Colpaert KE, Annemans L, Peleman RP, 
Buyle FM, Labeau SO, Decruyenaere JM. Daily Cost of Antimicrobial Therapy in Critically 
Ill Patients with Nosocomial Sepsis. 20th Annual Congress of the European Society of 
Intensive Care Medicine (ESICM), Berlin, Sept 24-27, 2007. Intensive Care Med 2007; 33, 
S206, 798. 
144 
 
• F. Buyle, V. Bostoen, D. Vogelaers, W. Buylaert, P. De Paepe, J. Decruyenaere, H. Robays. 
Evaluation of the initialisation of appropriate antibiotics in patients admitted through the 
emergency department with suspected serious infections. December 2005, Las Vegas, VS 
(oral presentation) 
• F. Buyle, M. Bogaert, T. Bauters, B. Claus, E. Kestens, A. Somers, M. Van Hooreweghe, H. 
Robays. “Evaluation of Belgian hospital drug formularies based on quality indicators” during 
5th Spring conference European Symposium on Clinical Pharmacy. (25 May oktober 2005, 
Stockholm, Sweden) 
• F. Buyle, N. Beck, T. Bauters, R. Peleman, D. Vogelaers, M. Van Hooreweghe, H. Robays. 
“Evaluation of the implementation of sequential therapy for fluoroquinolones”   tijdens 39th 
Midyear meeting American Society of Health-System Pharmacists (7 december 2004, 
Orlando, VS) 
• Buyle F, Vogelaers D, Peleman R, Schelstraete P, Verschraegen G, Claeys G, Van 
Hooreweghe M, Robays H. A multidisciplinary prospective interventional program to enhance 
appropriate prescribing of restricted anti-infectives in the Ghent University hospital. Abstract 
en poster tijdens 32th European Symposium on Clinical Pharmacy (30 oktober 2003, 
Valencia, Spain) 
• Somers A, Buyle F, Robays H, Colardyn F, Verschraegen G. Evolution of antibiotic 
consumption and resistance patterns in the intensive care unit. Abstract en poster tijdens 
BESPE-symposium (23 november 2002, Gent) 
• Buyle F, Vogelaers D, De Cloet J, Somers A, Kestens E, Van Hooreweghe M, Robays H. 
“Drug Use Evaluation of fluoroquinolones and piperacilline/tazobactam in the surgical 
intensive care unit of a university hospital”. Abstract en poster tijdens BESPE-symposium (23 
november 2002, Gent) 
• Buyle F, Somers A, Van Hooreweghe M, Vander Stichele B,  Bogaert M, Robays H. Quality 
Indicators for Pharmacotherapy and Pharmaceutical Care in Hospitals: development and 
feasibility”. Abstract en poster tijdens BESPE-symposium (23 november 2002, Gent) 
• Buyle F, Vogelaers D, De Cloet J, Somers A, Kestens E, Van Hooreweghe M, Robays H. 
“Drug Use Evaluation of fluoroquinolones and piperacilline/tazobactam in the surgical 
intensive care unit of a university hospital. Abstract en poster tijdens 33th European 
Symposium on Clinical Pharmacy (30 oktober 2002, Florence, Italy) 
• F. Buyle, A. Somers, M. Van Hooreweghe, H. Robays. Drug use evaluation of glycopeptide 
antibiotics. Poster ESCP Congress (oktober 1999, Berlijn)  
145 
 
ACKNOWLEDGEMENTS - DANKWOORD    
 
Met veel plezier heb ik aan dit onderzoek gewerkt en ik hoop dat ik hiermee een steentje heb kunnen  
bijdragen aan het antibioticabeleid in het ziekenhuis. Zonder de hulp van velen was dit evenwel niet 
mogelijk geweest.  
 
In de eerste plaats gaat mijn dank uit naar mijn promotor prof. dr. D. Vogelaers en co-promotor prof. 
apr H. Robays.  
 
Prof. Vogelaers, reeds voor er sprake was van deze thesis stond u steeds open voor de klinische rol van 
de ziekenhuisapotheker in het antibioticabeleid. U opende vele deuren in dit ziekenhuis wanneer ik 
terug met een protocol voor een project aan uw deur klopte. Ondanks uw drukke klinische agenda 
maakte u steeds ruimte vrij om mij met raad en daad bij te staan bij het schrijven van deze thesis.        
 
Hugo, bedankt voor de kansen die u mij heeft aangeboden om mij te ontplooien in de wereld van de 
ziekenhuisfarmacie. Daarnaast bedankt om voor mij de deur te openen naar BAPCOC en VZA die mij 
veel nieuwe inzichten hebben bijgebracht. 
 
Prof. dr. J. Decruyenaere en prof. dr. P. Tulkens wil ik bedanken als leden van de 
begeleidingscommissie. Dank ook voor de feedback en ondersteuning o.a. bij de PK/PD studie.      
 
Prof. dr. M. Streulens, thank you for your stimulating role as scientific coordinator in the “ABS 
international study” project. It was for me an extraordinary experience to participate to this project.    
 
Prof. dr. P. De Paepe en prof.dr. W Buylaert, bedankt voor jullie enthousiasme bij het uitvoeren van de 
studie op de spoedopname.     
 
Ook de leden van de examenjury prof. dr. K. Boussery,  prof. dr. S. Callens, prof. dr. I. Gyssens, prof. 
dr. E. Padalko, prof. dr. W. Peetermans, prof. dr. M. Petrovic en prof. dr. J. Vande Walle wil ik 
bedanken voor de kritische vragen en opmerkingen die verrijkend waren voor dit werk.  Dank ook aan 
dhr. C. Maes voor de logistieke ondersteuning  
 
Dank ook aan de collega’s (inclusief alle gepensioneerde collega’s) van de ziekenhuisapotheek van het 
UZ Gent voor de aanmoedigingen en oprechte interesse.    
 
146 
 
Ook alle leden van de Antibioticabeleidsgroep en van het Multidisciplinair infectieteam wil ik 
bedanken voor de waardevolle input bij de verschillende studies.  
 
Dank ook aan alle diensten binnen het UZGent  en de externe ziekenhuizen die hebben deelgenomen 
aan de studies. 
 
Ik wil ook de leden van de BAPCOC werkgroep ziekenhuisgeneeskunde bedanken voor de  
ondersteuning bij het verspreiden van de vragenlijst omtrent de verlengde en continue infuzen.  
 
Ik wil hier zeker ook alle stagiairs apotheker bedanken voor de hulp bij het collecteren van de data: 
Natalie, Vanessa, Hannelore, Charlotte, Thijs en Matthias. 
     
Mijn ouders wil ik in het bijzonder bedanken voor de onvoorwaardelijke steun die ik steeds heb 
ontvangen en de warme thuis die jullie mij hebben gegeven. Nog steeds staan jullie klaar om mij, Ruth 
en de kindjes bij te staan. Ook mijn schoonouders wil ik bedanken voor de zorg voor onze kinderen en 
voor de hulp bij de “klusjes” die de laatste tijd zijn blijven liggen. 
     
Matteo, Noor en Arthur, papa zijn “boekje” is eindelijk klaar. Jullie drukte in huis zorgde ervoor dat ik 
alles kon blijven relativeren. Deze zomer staan jullie samen met mama centraal. 
 
Liefste Ruthje, ik besef dat het schrijven van deze thesis de laatste jaren veel van mijn vrije tijd heeft 
opgebruikt. Ik beloof je dit de komende tijd goed te maken te beginnen met deze zomervakantie!   
 
 
Franky, 8 juni 2015  
